The development of a clinical trial protocol and functional biomarkers for age-related macular degeneration by McKeague, Claire
 The Development of a Clinical Trial 
Protocol and Functional Biomarkers for 
Age-Related Macular Degeneration 
Claire McKeague 
A thesis submitted to Cardiff University for the degree of Master of 
Philosophy 
 
 
 
 
 
 
 
SCHOOL OF OPTOMETRY AND VISION SCIENCES, CARDIFF UNIVERSITY 
2014 
SUPERVISED BY DR ALISON BINNS & DR TOM MARGRAIN 
 
  
DECLARATION 
 
This work has not previously been accepted in substance for any degree and is not concurrently 
submitted in candidature for any degree. 
 
 
 
 
 
STATEMENT 1 
 
This thesis is being submitted in partial fulfillment of the requirements for the degree of 
…………………………(insert MCh, MD, MPhil, PhD etc, as appropriate) 
 
 
 
 
STATEMENT 2 
 
This thesis is the result of my own independent work/investigation, except where otherwise 
stated. 
Other sources are acknowledged by explicit references.   
 
 
 
 
 
STATEMENT 3 
 
I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter-
library loan, and for the title and summary to be made available to outside organisations. 
 
 
 
 
 
 iii 
Summary 
Age-related macular degeneration (AMD) is the leading cause of blindness amongst 
older adults in the developed world. With the predicted rise in the ageing population 
over the next decades, the prevalence of this debilitating disease will simply continue 
to increase. The only treatments currently available are for advanced neovascular 
AMD.  The retina is already severely compromised by this stage in disease 
development. Therefore, there is a pressing need to evaluate potential novel 
interventions that aim to prevent the development of advanced disease in people with 
early AMD, to prevent sight loss from occurring. Furthermore, it is necessary to 
develop tests that are sensitive to subtle changes in visual function in order to evaluate 
the efficacy of these emerging treatments.  
There is a growing body of evidence to suggest that hypoxia contributes to the 
development of AMD. Hypoxia is most acute at night when the retinal photoreceptors 
are most metabolically active, due to the demands of the rod dark current. Increasing 
the light levels at night will cause the oxygen demand, and hence the hypoxia, to be 
substantially diminished. This leads to the hypothesis that providing low level night 
time light therapy to people with early AMD may slow disease progression by reducing 
hypoxia.  
In order to evaluate the potential effectiveness of such an intervention, it is necessary 
to select appropriate outcome measures. The inherent variability of the standard test of 
visual function, visual acuity, renders it inappropriate for use as a primary outcome 
measure in proof of concept clinical trials. Therefore, the first aim of this thesis was to 
evaluate the diagnostic validity and repeatability of alternative functional tests that may 
be used as biomarkers for early macular disease.  
Dark adaptation was evaluated using three stimuli, a spot of 2o radius and annuli of 7o 
and 12o radii, in 21 healthy adults (on two occasions) and in 11 participants with early 
AMD. All stimuli were found to be highly diagnostic for early AMD. The spot of 2o 
radius provided the best separation between groups with respect to the time constant of 
cone recovery (area under the ROC curve 0.91). The repeatability of chromatic and 
flicker thresholds were also assessed in 30 healthy adults. The coefficient of 
repeatability, expressed as a percentage of the mean threshold, was 17.1% for red-green 
chromatic thresholds, 31.1% for blue-yellow, 53.4% for 14Hz flicker thresholds, and 
ranged between 36.4%-53.3% for parameters of dark adaptation. A small learning 
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effect was found for both chromatic thresholds and the 14-Hz flicker test, indicating 
that a control group is needed in studies of new therapeutic interventions.  
The second aim of this thesis was to develop a protocol for a clinical trial that seeks to 
determine if low level night time light therapy can prevent the progression of early 
AMD. The level of retinal illuminance required to suppress the rod dark current, the 
maximum retinal illuminance which prevents substantial suppression of melatonin 
secretion, and the most appropriate means of delivering the dose of retinal illumination 
were evaluated. The final protocol employed an organic LED illuminated light mask, 
worn during hours of sleep, as the mode of intervention.  
In conclusion, this thesis has confirmed that cone dark adaptation is a sensitive 
functional biomarker for AMD, and that all three functional tests have a good inter-
session repeatability. These biomarkers will be validated in the prospective clinical trial 
of low-level light therapy to confirm their prognostic and predictive capabilities. The 
proposed trial will also evaluate the effectiveness of the low level night time light 
therapy, delivered by means of an illuminated light mask, at slowing the progression of 
early AMD.  
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1. Introduction 
1.1 General Introduction 
Age-related macular degeneration (AMD) is a degenerative disease of the central retina 
that leads to a progressive loss of central vision. Despite being the leading cause of 
blindness among older adults in the developed world (Bunce et al. 2010; Klein et al. 
2011) and the cause of approximately 50% of registrations as sight impaired or severely 
sight impaired in the UK (Bunce et al. 2010), treatments are currently limited. Indeed, 
for the 85% of people suffering from the dry form of the condition, the only ‘treatment’ 
is vitamin supplementation and lifestyle modification. Therefore, there is a pressing 
need to evaluate potential new therapies to prevent the progression of this debilitating 
disease.  
 
The overall objective of this thesis is to investigate the repeatability and diagnostic 
validity of functional biomarkers in AMD, and to develop a protocol for a clinical trial 
investigating the impact of low-level light therapy on disease progression in AMD. The 
introductory chapter of this thesis will comprise the necessary background information 
on the structure of the healthy retina, before providing an overview of the 
epidemiology, pathogenesis and classification of AMD and a detailed review of the 
literature on the role of hypoxia in the progression of AMD. This will be followed by a 
literature review of the current biomarkers used to detect the disease and monitor its 
progression. The next chapters will describe the studies into the repeatability and 
diagnostic validity of three functional biomarkers. Following this, the development of 
a clinical trial protocol investigating the impact of light therapy in AMD will be 
outlined, and a final chapter will summarise the conclusions of the thesis and discuss 
further work. 
1.2 The Healthy Retina 
1.2.1 Overview of the Retina 
The retina is a thin piece of tissue lining the back of the eyeball that is responsible for 
the first stage of image processing: here, light energy is converted to an electrical signal 
by photochemical transduction. This signal then travels to the brain via the optic nerve 
for further processing. Situated between the choroid and the vitreous humour, the retina 
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extends from the optic nerve head to the ora serrata. It is composed of a number of 
distinct layers, including three layers of neuron cell bodies, two synaptic layers and an 
outer, pigmented layer, as depicted in Figure 1 below.  
 
 
 
 
 
 
 
 
 
 
Figure 1. A cross-sectional schematic diagram of a human eye with its various structures (left). 
A small section of retina is magnified (right), outlining its layers. The photoreceptors lie against 
a layer of pigmented cells known as the retinal pigment epithelium (Kolb 2003). 
 
Knowledge of the retinal anatomy is vital for a proper understanding of its function and 
associated pathology. Light is transmitted through the full thickness of the retina to 
activate the rod and cone photoreceptor cells. Following the absorption of a photon of 
light by the visual pigment in the photoreceptors, an electrical signal is generated which 
then stimulates the remaining retinal cells.  A schematic of these major cell types in the 
retina is shown in Figure 2. 
 
 
 
 
 
 
 
 
 
 
Figure 2. The arrangement of the major cells in the retina. In this rendering, light enters the 
eye from bottom to top (Kolb 2003). 
LIGHT 
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The first neurophil area is the outer plexiform layer where the rod and cone cells 
synapse with the vertically orientated bipolar cells, of which there are 11 types, and the 
horizontally running horizontal cells. The second region of neurophil is the inner 
plexiform layer, the site where bipolar cells transfer their information to the 20 different 
types of ganglion cells. Additionally, there are 22 to 30 varieties of amacrine cell 
present in this region, which integrate and modulate the visual information for the 
retinal ganglion cells to transmit along the optic nerve to the brain (Kolb 2003). For 
further information on this subject, the reader is referred to an excellent review by Kolb 
(2003). AMD is a condition affecting the outer retina and associated structures, 
targeting the macular region (Ambati et al. 2003). Therefore, the following sections 
will concentrate on these structures. 
1.2.2 Bruch’s Membrane 
Although Bruch’s membrane (BM) is not considered a part of the retina, it is closely 
attached to it via the basement membrane of the RPE and plays a vital role in normal 
retinal function. According to Hogan’s classification, BM consists of five distinct 
layers: the RPE basement membrane, the inner collagenous layer, the elastin layer, the 
outer collagenous layer and the basement membrane of the choriocapillaris (Hogan 
1961). The inner and outer collagenous layers are composed of striated collagen fibres, 
organised in a multi-layered grid-like structure embedded in a number of biomolecules, 
such as heparin sulphate and chondroitin sulphate (Booij et al. 2010).  
 
In addition to its role in providing physical support for RPE cell adhesion, it also serves 
as a semi-permeable filtration barrier for metabolic exchange between the choroid and 
the retina and a diffusion barrier for cell migration (Booij et al. 2010; Guymer et al. 
1999). The pentalaminar BM undergoes age-related changes throughout life, including 
an overall increase in thickness and a reduced capacity to facilitate macromolecular 
exchange (Moore and Clover 2001) due to a reduction in membrane elasticity, 
increased hydrophobicity and accumulation of cellular debris (Pauleikhoff et al. 1990; 
Bird 1992). In particular, the presence of lipid deposits has been shown to play a small 
but significant role in this decline in the hydraulic conductivity of Bruch’s membrane 
(Sheraidah et al. 1993; Moore and Clover 2001). 
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1.2.3 The Retinal Pigment Epithelium 
The retinal pigment epithelium (RPE), the outermost layer of the retina, forms part of 
the blood-retinal barrier (Bok 1993; Strauss 2005). It is a single layer of pigmented, 
hexagonal cells that are connected by tight junctions. The basement membrane of the 
RPE forms part of Bruch’s membrane. Its apical membrane contains numerous 
microvilli that project towards the neural retina and enclose the photoreceptor outer 
segment tips. An adhesion between the RPE and the retina is provided by a variety of 
factors such as osmotic pressure and water transport (Kita and Marmor 1992), and 
adhesive forces from extracellular material in the sub-retinal space (Hageman et al. 
1995). 
 
The RPE has a number of essential functions, including: 
1) Absorption of Light. The melanin-containing melanosomes in the RPE help to 
prevent light scatter, improving visual acuity (Strauss 2005). 
2) Transport of Metabolites and Ions. The RPE transports ions and water from 
the subretinal space to the blood (Hamann 2002) and so has the structural 
characteristics of an ion transporting epithelium. Gap junctions between cells 
enable the controlled transport of nutrients and ions between photoreceptors and 
choriocapillaris, which also prevents retinal oedema (Steinberg 1985; Miller 
and Steinberg 1977; Hamann 2002). 
3) Blood-retinal Barrier. The zonular adherens and zonular occludens that bind 
adjacent RPE cells together allow the RPE to act as a blood-retinal barrier 
between the choriocapillaris and the neural retina (Steinberg 1985). 
4) Phagocytosis of Photoreceptor Outer Membranes. The RPE diurnally 
regulates the phagocytosis of the tips of the photoreceptor outer segments to 
maintain vision. With increasing age, incomplete digestion of these tips leads 
to an accumulation of lipofuscin in the RPE (Beatty et al. 2000). 
5) Photopigment Regeneration. The RPE is the site of the re-isomerisation of 11-
cis retinal following phototransduction (Lamb and Pugh 2004). 
6) Immune Privilege. The RPE aids immune privilege by the tight barrier 
separating the neural retina from the blood circulation, and by secreting immune 
modulatory factors, such as complement factor H, to activate or disable the 
eye’s immune response (Kim et al. 2009). 
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1.2.4 Photoreceptor cells 
The human retina contains four types of photoreceptor cells, which have been designed 
to absorb photons of light and convert them into nervous impulses i.e. to intitate 
phototransduction. The rod photoreceptors responsible for scotopic vision are sensitive 
to low levels of illumination, whereas cone photoreceptors, which mediate photopic 
vision, optimally function at higher illumination levels. There are three classes of cones, 
each containing a different photopigment: short-wavelength sensitive cones (S-cones) 
contain cyanolabe, middle-wavelength sensitive cones (M-cones) contain chlorolabe 
and long-wavelength sensitive cones (L-cones) contain erythrolabe. Normal colour 
vision is dependent upon these three cone mechanisms (Schwartz 2009). 
 
The relative density of the different classes of photoreceptors varies with retinal 
eccentricity. Cone density peaks at the fovea (199,000 cells/mm) and falls rapidly with 
increasing eccentricity (Figure 3). In contrast, rod photoreceptors are absent from the 
fovea and peak in density (150,000 cells/mm) between 12-18 degrees from fixation. 
However, the total number of rods far exceeds that of cones. Indeed, the average human 
retina contains 92 millions rod photoreceptors, as opposed to only 4.6 million cones 
(Curcio et al. 1990). 
 
A further distinction between these two classes of cells is their physical structure. Cones 
are so-called because of their conical shape, with their inner and outer segments 
pointing towards the retinal pigment epithelium. Rods, on the other hand, have slim 
rod-shaped bodies with thinner outer and inner segments than cones, except at the fovea 
(Anderson and Fisher 1976). Both classes of cell, however, do consist of the same basic 
elements: an outer segment containing stacks of membranous discs in which the 
photopigment is embedded; an inner segment containing mitochondria, a cell body 
containing the nucleus and a synaptic terminal where the cell can transmit information 
to other neurons (Young 1971).  
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Figure 3. Graph 
illustrating the rod and cone densities as a function of retinal eccentricity (Kalloniatis and Luu 
2011a). 
1.2.5 The Macula 
The macula is the central region of the retina that is responsible for high acuity vision. 
It is often called the macula lutea, or yellow spot, due to its high density of yellow 
xanthophylls such as lutein and zeazanthin, which comprise macular pigment 
(Snodderly 1995). Macular pigment peaks in concentration in the central 1-2 degrees 
of the fovea, and rapidly declines to an insignificant level at 5-10 degrees retinal 
eccentricity (Delori et al. 2006). This pigment is thought to protect the macula by 
filtering out short wavelength light and by acting as an antioxidant (Snodderly 1995).  
 
Located in the midst of the vascular arcades, the macula is approximately 6mm in 
diameter, which equates to 15-20 degrees of visual angle (Figure 4) (Hendrickson 
2005). In anatomical terms, it is defined as the retinal area where the retinal ganglion 
cell layer is more than 1 cell thick. The macula can be further organised into four 
anatomical regions, named in relation to the fovea centralis, as depicted in (Polyak 
1941). The foveola, which is the central avascular zone, contains the highest volume of 
cone photoreceptors and midget pathways, and corresponds to the visual axis (Provis 
et al. 2005). The foveola is also devoid of all short-wavelength sensitive cones, rods, 
ganglion cells and inner nuclear layer cells (Neelam et al. 2009). These second and third 
order neurones are displaced to the surrounding macula by the elongated cone axons 
which form the fibres of Henle, and are the principal location of macular pigment 
accumulation. The displaced foveal bipolar cells and retinal ganglion cells result in a 
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thickening of the macula relative to other retinal locations. The surrounding fovea 
represents a transition zone between the cone-dominated fovea and the periphery. The 
perifovea, like the peripheral retina, contain a high density of blood vessels and a 
preponderance of rod photoreceptors (rod: cone ratio approximately 33-130:1); 
whereas the parafovea has little retinal vasculature, a large number of ganglion cells 
and approximately a 4:1 ratio of rods to cones (Provis et al. 2005).  
 
 
 
 
 
 
 
Figure 4. Diagrammatic representation of the human macula showing the anatomical divisions 
centred on the fovea centralis, or foveola (Hendrickson 2005). 
 
1.2.6 Blood Supply to the Retina 
Oxygen is delivered to the retina via two circulatory systems, as shown in Figure 5. The 
central retinal artery provides oxygen to the inner two thirds of the retina, including the 
bipolar and ganglion cell layers, and has lower blood flow with higher oxygen 
extraction ratio than the choroid (Alm and Bill 1973). In contrast to the outer retina, 
inner retinal blood flow is autoregulated by the secretion of vasoactive factors, such as 
nitric oxide and prostaglandins, by the vascular endothelium and retinal tissue 
encapsulating the arteriolar cell wall. This allows a tissue to adjust its blood flow in 
accordance with its metabolic requirements.  
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Figure 5. Histology of the human retina and its assciated blood supply. IS/OS = Inner and outer 
segments; ONL = outer nuclear layer; OPL = outer plexiform layer; INL = inner nuclear layer; 
IPL = inner plexiform layer; GCL = ganglion cell layer; NFL = nerve fibre layer (Lange and 
Bainbridge 2012). 
 
The choroidal vasculature supplies the outer retina, which includes the retinal pigment 
epithelium and photoreceptor layer, and also the avascular macular region 
(Hendrickson 2005). It has a 20-fold greater blood flow than the inner retina and has a 
low oxygen extraction ratio, leading to a low arteriovenous difference and increased 
reserve of oxygen transport (Alm and Bill 1970; Alm and Bill 1972). The choroidal 
circulation shows less evidence of oxygen regulation than the inner retinal vasculature 
(Bosch et al. 2009).  
 
In order for cells to function at their best, a tightly regulated environment is necessary. 
The blood-retinal barrier, with its specialised tissues and extracellular materials, is able 
to rapidly respond to changes in extracellular conditions to maintain homeostasis and 
control transport between retinal structures. The inner blood retinal barrier is mediated 
by the endothelium with its associated pericytes and glial cells. The outer barrier is 
composed of the endothelium of the choriocapillaris, Bruch’s membrane and the RPE 
(Pournaras et al. 2008).   
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1.3 Age-Related Macular Degeneration 
1.3.1 Background 
Age-related macular degeneration (AMD) is a degenerative condition of the macula 
characterized by dysfunction and death of photoreceptors, which can cause progressive 
loss of central vision in one or both eyes. This occurs either due to extensive atrophy 
of the macular area, or because of scarring secondary to a neovascular event. 
 
AMD is the leading cause of visual impairment in the UK. Figures from 2007-2008 
estimate that degeneration of the macula and posterior pole account for 58.6% of severe 
sight impairment (SSI) and 57.2% of sight impairment (SI) certifications in England 
and Wales (Bunce et al. 2010). Whilst certification figures provide an insight into the 
proportion of visual impairment in the UK attributable to AMD, they almost certainly 
underestimate the actual prevalence of the condition since these data exclude those who 
choose not to be registered and those who are deemed ineligible for certification by the 
ophthalmologist. A Bayesian meta-analysis of 31 UK population studies from 2007-
2009 with a total sample of 57,173 estimated the overall prevalence of late AMD in the 
UK to be 2.4% in the population aged over 50 years and 12.2% in those aged over 80 
years. Furthermore, 71,000 new cases of late AMD were estimated to occur per year 
(Owen et al. 2012). Similar trends to this are seen in the rest of the developed world. In 
the United States, AMD has been reported to affect 11.1% of the population over 60 
years (Klein et al. 2011) and is the estimated cause of 22.9% of low vision and 54.4% 
of blindness among white persons (Congdon et al. 2004). 
 
Given the prediction by the Office for National Statistics of a 32% increase in the 
population of pensionable age, with the number aged over 85 more than doubling to 
3.3m by 2033, the prevalence of AMD and its resultant morbidity will continue to 
escalate (Office for National Statistics 2009). Advanced AMD is not only associated 
with visual loss, but also depression, social isolation and falls (Dargent-Molina et al. 
1996; Margrain et al. 2012). Furthermore, it is a significant financial burden on the 
NHS, costing the British economy between £1.2B and £3.7B p.a. (Access Economics 
2009; Cruess et al. 2008). Given this massive socio-economic burden, there is a great 
necessity to evaluate potential new therapeutic interventions to prevent the progression 
of early AMD to the advanced form in which vision is threatened. 
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1.3.2 Clinical Classification 
Practitioners and patients commonly refer to macular degenerative changes as being 
either dry or wet. The former signifies the absence of neovascularisation, and can either 
indicate early AMD or the advanced, atrophic form of the disease known as geographic 
atrophy (GA), as depicted in Figure 6. Wet, or neovascular AMD (nAMD), occurs 
following an ingrowth of new blood vessels from the choriocapillaris, which penetrate 
Bruch’s membrane to proliferate underneath the RPE and/or the retina. The resultant 
haemorrhages, exudates, or RPE detachments lead to a rapid reduction and distortion 
in vision. Neovascular AMD accounts for approximately 10-15% of the total AMD 
population (Bhutto and Lutty 2012). 
 
Figure 6. Diagrammatic representation of early AMD (Left, top), geographic atrophy (Left, 
bottom) and neovascular AMD (Right) (Kanski, 2003). 
 
1.3.3 Clinical features of AMD 
1.3.3.1 Drusen 
Drusen are deposits of extracellular material that accumulate between the RPE and the 
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inner collagenous layer of Bruch’s membrane (Johnson et al. 2003). They vary greatly 
in terms of size, number, shape, elevation and distinctness (Kanski and Bowling 2011). 
Although drusen are the first clinically detectable funduscopic sign of AMD, they can 
also be found in healthy retinas. Those drusen associated with AMD can be divided 
into two main phenotypes, hard and soft (Figure 7). 
 
 
 
 
 
 
 
Figure 7. Drusen. Hard drusen (A), Soft drusen (B). (Kanski 2011). 
 
Hard drusen are small (≤63μm), round, discrete yellow-white deposits associated with 
local RPE dysfunction. Although they are not considered to be indicative of AMD in 
isolation (Bird et al. 1995), large numbers (8 or more) of hard drusen are associated 
with an increased risk of developing both soft drusen and pigmentary abnormalities 
(Klein et al. 2002). Soft drusen are larger with indistinct margins, and may enlarge and 
coalesce to form confluent drusen, a common precursor to the development of advanced 
AMD (Holz et al. 1994). Unlike with hard drusen, the presence of soft drusen alone is 
indicative of AMD (Bird et al. 1995; Davis et al. 2005; Ferris et al. 2005). 
1.3.3.2 Pigmentary abnormalities 
Another characteristic indication of AMD is the presence of focal regions of RPE hypo- 
or hyperpigmentation (AREDS 2001b). Focal hyperpigmentation is an area of pigment 
clumping, due to an increase in melanin concentration in the RPE cells (Bressler et al. 
1994). Focal hypopigmentation may be caused by RPE atrophy, RPE thinning or a 
reduction in melanin concentration in RPE cells. Eyes with these retinal pigmentary 
abnormalities are more at risk of developing advanced AMD over time compared to 
eyes without these lesions (Klein et al. 2002; Ferris et al. 2005). 
1.3.3.3 Geographic Atrophy 
Geographic atrophy is a sharply delineated area of partial or complete depigmentation 
of the RPE of at least 175μm in diameter, often with exposure of the underlying 
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choroidal vasculature (Bird et al. 1995; AREDS 2001b). The atrophy often begins near, 
but not in, the foveal region, thus sparing the central vision. Over time, foveal atrophy 
develops and the patient must take up eccentric fixation to view objects of interest 
(Sarks et al. 1988; Sunness et al. 2008). 
1.3.3.4 Choroidal neovascularisation (CNV) 
Neovascular AMD is caused by choroidal neovascularisation (CNV) originating from 
the choriocapillaris that grows through defects in Bruch’s membrane. The new vessels 
either remain in the sub-RPE space (“occult” CNV) or may extend anteriorly into the 
subretinal space (“classic” CNV) (Roth et al. 2004). This neovascularisation is thought 
to be due to a local imbalance of growth factors such as VEGF-A, which stimulate the 
inward growth of blood vessels from the choroid. If left untreated, it will lead to the 
formation of a fibrous disciform scar at the fovea with permanent loss of central vision 
(Penfold et al. 2001). 
1.3.3.5 Retinal pigment epithelial detachment (PED) 
Pigment epithelial detachments (PED) are clinically detectable as round, sharply 
demarcated elevations of the retina. They occur between the inner collagenous layer of 
Bruch’s membrane and the RPE basal lamina, and are often associated with CNV 
(Murphy et al. 1985). They are either inflammatory, ischaemic, idiopathic or 
degenerative in aetiology, the latter of which is associated with AMD (Zayit-Soudry et 
al. 2007). The three types of PED that occur in AMD (serous, fibrovascular and 
drusenoid) can be distinguished using fluorescein angiography (Pauleikhoff et al. 
2002). Although PEDs may spontaneously resolve, the course is variable and they can 
potentially lead to detachment of the sensory retina, RPE tear formation or geographic 
atrophy (Pauleikhoff et al. 2002). 
1.3.4 Grading scales for severity of AMD 
A number of grading systems have been developed to describe and characterise AMD-
associated lesions in epidemiologic and clinical studies. In 1980, the Framingham Eye 
Study relied solely on ophthalmological opinion and visual acuity to rank disease 
severity (Milton 1979). Later, the ‘Wisconsin Age-Related Maculopathy Grading 
System’ (Klein et al. 1991) was developed as an observer-based, photographic grading 
method for the Beaver Dam study, a large population-based cohort study examining the 
15-year incidence and progression of AMD (Klein et al. 2007). This formed the basis 
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for the standardised ‘International Classification and Grading System’ (Bird et al. 1995) 
and the ‘Age-related Eye Disease Study System’ (AREDS 2001b; Davis et al. 2005; 
Ferris et al. 2005), the two most commonly used grading scales to date. They both 
classify AMD on the basis of fundus appearance alone, as assessed by stereo 
photography. A summary of the diagnostic criteria used in the former is outlined in 
Table 1 below. 
 
AMD Status Diagnostic Criteria 
Early AMD/ ARM Soft drusen (≥63μm) with or without associated 
hyperpigmentation or hypopigmentation of the 
RPE 
Advanced dry AMD  Area of geographic atrophy >175m in diameter 
Advanced wet AMD  At least one of the following: 
 RPE detachment 
 SubRPE/ subretinal neovascular 
membrane 
 Subretinal haemmhorage 
 Hard exudates 
 Disciform scar 
Table 1. AMD Classification according to the International Classification and Grading System 
(Bird et al. 1995). 
 
The AREDS grading scale outlines 9 sub-classifications of increasing overall severity 
of non-advanced AMD, including a 6-step drusen area scale and a 5-step pigmentary 
abnormality scale, based on the risk of developing advanced AMD involving the central 
macula within 5 years (AREDS 2001b; Davis et al. 2005). A more simplified scale was 
later developed for use in clinical practice (Ferris et al. 2005). The scoring system 
assigns to each eye 1 risk factor for the presence of 1 or more large (≥125μm) drusen 
and 1 risk factor for any pigmentary changes. Risk factors are summed across both eyes, 
resulting in a 5-step severity scale (0-4) on which the 5-year risk of developing 
advanced AMD increases progressively: 0 factors, 0.5%; 1 factor, 3%; 2 factors, 12%; 
3 factors, 25%; 4 factors, 50%. Two risk factors are assigned when one has advanced 
AMD one eye. 
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1.3.5 Risk Factors for the Development of AMD 
AMD is a multifactorial condition involving a complex interaction between both 
genetic and environmental risk factors. A summary of the main risk factors associated 
with AMD is presented below. For further information, the reader is referred to 
excellent reviews by Evans 2001 and Chakravarthy et al. 2010. 
1.3.5.1 Age 
Given that it is a disease of the ageing eye, it is not surprising that the predominant risk 
factor for the development and progression of AMD is increasing age (Evans 2001). In 
a 10-year study of the incidence and progression of AMD, persons aged 75 or older 
were 5.2 times more likely to develop early AMD than persons aged 43 to 54 years 
(Klein et al. 2002). 
1.3.5.2 Smoking 
There is strong evidence to suggest a causal relationship between current smoking and 
the progression of AMD (Thornton et al. 2005; Khan et al. 2006; Klein et al. 2008b; 
Cong et al. 2008; Chakravarthy et al. 2010).  Indeed, those who currently smoke have 
up to five times greater chance of developing AMD compared with a non-smoker 
(Smith et al. 1996), which increases with increased consumption of cigarettes and 
number of years of smoking (Khan et al. 2006). It has been calculated that 
approximately one quarter of AMD cases may be attributable to cigarette smoking in 
persons over 69 years of age (Kelly et al. 2004). Several studies have examined the 
reversibility of the damage caused by smoking. A systematic review of 11 studies 
carried out a pooled analysis, and determined that ex-smokers had only a slightly 
increased risk of developing AMD compared with never-smokers, which was greater 
for those who smoked more than 25 cigarettes a day (Thornton et al. 2005). 
 
1.3.5.3 Genetics 
Current research suggests that there may be a strong genetic factor in the pathogenesis 
of AMD. Indeed, people with a family history of AMD are at increased risk of 
developing the disease (Heiba et al. 1994; Smith et al. 1998). It has been estimated that 
siblings of an affected person have an almost 20 times greater risk of developing AMD 
compared to a control sibling (Silvestri et al. 1994). In addition, a US study of 840 
elderly male twins found that genetic factors contributed to between 46% and 71% of 
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the variation in disease severity (Seddon et al. 2005). Studies of twins have shown a 
greater concordance for AMD in monozygotic (identical) than dizygotic (non-identical) 
twins (Hammond et al. 2002).  
 
Genetic factors, mainly in the complement factor H (CFH) gene and on the 10q26 locus 
are now thought to be reliable biomarkers to characterise the risk of AMD onset 
(Leveziel et al. 2011). Certainly, the development of AMD has been linked to 
polymorphisms on chromosome 1 of CFH (Haines et al. 2005), complement 2 (C2) 
(Gold et al. 2006), complement factor B (CFB) (Gold et al. 2006), complement 3 (C3) 
(Maller et al. 2007) and complement factor H-related gene (CFHR1 and CFHR3) 
(Spencer et al. 2008). Additionally, there is thought to be an association between the 
development of wet AMD and polymorphisms on chromosome 10 in the Age-Related 
Maculopathy Susceptibility 2 (ARMS2) and the HTR1A serine peptidase 1 (HTRA1) 
genes (Edwards et al. 2005; DeWan et al. 2006). These genetic factors lead to varying 
degrees of susceptibility to the development of AMD, which is influenced by 
modifiable environmental factors (Seddon 2013).  
1.3.5.4 Race 
A number of studies have demonstrated that white people have a greater risk of 
development and progression of AMD than black people (Klein et al. 2006; Klein 2011; 
Klein et al. 2011).  For example, a population-based study involving 6176 older adults 
determined the prevalence of AMD to be 2.4% in blacks compared with 5.4% in whites 
(Klein et al. 2006). Assuming that the data in these studies are an accurate reflection of 
the wider population, the reasons for these racial differences are not known. It has been 
speculated that the higher melanin concentration in the RPE of people with darker skin 
may act as a barrier to oxidative damage to the RPE, Bruch’s membrane and choroid 
(Jampol and Tielsch 1992). An alternative theory is that different ethnic groups have 
different distributions of protective and deleterious genes such as complement factor 
H, which may increase susceptibility to disease progression in certain races ( Klein et 
al. 2008a; Klein 2011). 
1.3.5.5 Diet 
Throughout life, the photoreceptors in the retina are susceptible to oxidative stress 
caused by long-term light and oxygen exposure. Anti-oxidant vitamin and mineral 
supplements are thought to minimise the cellular damage caused by these 
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environmental influences and, hence, lower the risk of AMD progression (Evans 2008).  
The most robust evidence comes from the Age-Related Eye Disease Study (AREDS), 
a randomised controlled trial which assigned 4757 participants to one of four treatment 
groups, receiving: (i) high dose antioxidants only (vitamin C 500mg, vitamin E 400IU 
and beta-carotene 15mg); (ii) zinc only (zinc oxide 80mg and cupric oxide 2mg); (iii) 
antioxidants plus zinc; (iv) a placebo tablet (AREDS 2001a; Chew et al. 2009). The 
results demonstrated a 25% reduction in the risk of progression to advanced AMD in 
participants with extensive intermediate drusen, large drusen or advanced unilateral 
AMD who were taking the antioxidant plus zinc formulation. Therefore, they suggested 
that AREDS-type supplements should be recommended to patients at a high risk of 
developing advanced AMD. 
 
More recently, the National Institute of Health commissioned the Age-Related Eye 
Disease Study 2 (AREDS2), to determine the effect of lutein, zeaxanthin and the 
omega-3 polyunsaturated fatty acids (docosahexaenoic acid, DHA, and 
eicosapentaenoic acid, EPA) on the risk of developing advanced AMD (AREDS2 
2013). Docosahexaenoic acid (DHA) is a long-chain omega-3 fatty acid present in 
photoreceptor outer segments, and is not synthesised by the human body (Krishnadev 
et al. 2010). EPA may have the potential to affect signalling molecules implicated in 
abnormal retinal neovascularisation (SanGiovanni and Chew 2005). Since DHA and 
other fatty acids are thought to help prevent AMD-related oxidative and inflammatory 
damage, it has been postulated that a deficiency in this nutrient is related to the 
development of AMD (SanGiovanni and Chew 2005). Indeed, in a 10-year longitudinal 
study of 2454 participants, one serving of fish every week was associated with a 
reduction in the risk of developing early AMD (Tan et al. 2009). In a separate study, 
the 12-year incidence of wet AMD in moderate to high risk individuals was found to 
be lowest for those who reported the highest intake of omega-3 fatty acids 
(SanGiovanni et al. 2009). The AREDS 2 trial, however, found that omega-3 fatty acid 
supplementation had no significant effect on disease progression (AREDS2 2013) 
Macular pigment is comprised of the antioxidant carotenoids lutein, zeaxanthin and 
meso-zeaxanthin, which play a critical role in protecting the retina from the harmful 
effects of short wavelength light and are obtained solely from dietary sources such as 
green, leafy vegetables (Ahmed et al. 2005). Indeed, there is evidence to suggest that a 
diet rich in these nutrients may reduce the risk of developing AMD (Tan et al. 2008). 
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The AREDS group tried adding the xanthophylls lutein and zeaxanthin to their original 
formulation as part of the AREDS 2 trial. Despite the primary analysis showing no 
evidence of an improved overall effect, those individuals with the lowest levels of 
serum carotenoids at baseline did show a significant reduction in rate of progression 
when xanthophylls were added to the formula. Another notable finding of the AREDS 
2 study was that the effectiveness of the supplement was not reduced when beta 
carotene was removed, which is important as beta-carotene may increase the risk of 
lung cancer among current smokers (AREDS2 2013). Hence the authors of AREDS 2 
recommend the substitution of beta carotene for lutein and zeaxanthin in the 
supplement.  
 
The AREDS 1 and 2 supplements are the only nutritional supplements which have been 
shown in robust randomized controlled trials to reduce the risk of progression of AMD. 
It should be noted, however, that a systematic review by the Cochrane Collaboration 
indicated that individuals taking vitamin E and beta carotene supplementation may be 
at an increased risk of mortality (Evans and Lawrenson 2012).  
 
Other dietary factors which have been implicated in the increased risk of development 
of AMD include high saturated fat intake (Mares-Perlman et al. 1995) and alcohol 
consumption (Cho et al. 2000; Ritter et al. 1995). However, the evidence is currently 
inconclusive. 
1.3.5.6 General Health 
A recent meta-analysis of the clinical risk factors for AMD found that in case control 
studies the risk of developing late AMD is doubled in individuals with cardiovascular 
disease (OR 2.20; 95% CI 1.48 – 3.26). Other significant risk factors with a lower 
strength of association (OR ≤ 1.5) include BMI, hypertension and plasma fibrinogen 
(Chakravarthy et al. 2010). 
1.3.6 Clinical Assessment of AMD 
In optometric practice, AMD is currently diagnosed and monitored using a variety of 
conventional tests such as visual acuity, ophthalmoscopy, fundus photography and 
Amsler chart evaluation. Increasingly, optical coherence tomography (OCT) is a 
technology that is also found in optometric practice. Ophthalmological investigation of 
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AMD involves more sophisticated imaging technology such as fundus fluorescein 
angiography (FFA) and fundus autofluorescence (FAF), which are better able to detect 
subtle structural changes at the macula before they are evident ophthalmoscopically.  
1.3.6.1 Fundus Photography 
Fundus photography has been widely used to screen for retinal pathological conditions 
such as diabetic retinopathy (Williamson and Keating 1998) and is the primary imaging 
technique used to document the presence and severity of AMD in clinical practice (Jain 
et al. 2006). A recent investigation into the necessity of retinal photography in 
conjunction with OCT in Lucentis clinics claimed that retinal colour photographs were 
indispensable for ophthalmologists making informed retreatment decisions (Hibbs et 
al. 2011). A number of studies have examined the validity of fundus photographs for 
the identification of various features of AMD. For example, the AREDS study reported 
that stereoscopic colour fundus photography had moderate to high inter-rater reliability 
and reproducibility for the identification of features of advanced AMD (AREDS 
2001b). However, the authors acknowledged that using fundus photographs without 
FFA to identify advanced AMD might delay its identification and underestimate its 
incidence. Nevertheless, high-quality, stereoscopic colour fundus photographs have 
been the gold standard in monitoring disease severity and progression in major 
epidemiological studies (AREDS 2001b; AREDS2 2013).  
 
1.3.6.2 Fundus Fluorescein Angiography (FFA) 
Fluorescein angiography is the principal method used to image superficial retinal 
vasculature and identify abnormalities in vascular perfusion, permeability and 
proliferation, as depicted in Figure 8. Despite the growing importance of OCT imaging, 
FFA remains the gold standard technique for diagnosing nAMD, with fluorescein 
leakage being the major sign of neovascular activity (Yannuzzi 2011). The technique 
involves intravenous injection of yellow fluorescein dye followed by sequential 
photographs assessing choroidal and retinal blood flow properties (Lim et al. 2012). 
Hyperfluorescence, i.e. leakage of dye, is an indication of neovascular AMD. This 
leakage can be described by type (classic, occult or mixed) or location (subfoveal, 
juxtafoveal or extrafoveal). Classic choroidal neovascularisation (CNV) lesions break 
through the RPE, whereas occult CNV lesions remain underneath the RPE. For this 
reason, classic lesions cause more sudden and severe vision loss, but respond better to 
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treatment with photodynamic therapy (Lim et al. 2012). 
 
 
 
 
 
 
 
 
 
Figure 8. Fundus photograph (A) and fluorescein angiogram (B) of a 76-year-old patient with 
early age-related macular degeneration, RPE atrophic spots and a central area of prolonged 
choroidal filling phase. There is an increase of the RPE atrophy in the area of prolonged 
choroidal filling after 12 months (D and E) (Pauleikhoff et al. 1999).  
 
1.3.6.3 Optical Coherence Tomography (OCT) 
During the past two decades, optical coherence tomography (OCT) has been  
established as a non-invasive, high-resolution, cross-sectional retinal imaging 
technique (Drexler 2004). The system uses the principle of interferometry, which 
involves superimposing two light waves to create a 3-D representation of retinal 
microstructure.  Cross-sectional images of the retina (B-scans) are created by 
performing multiple axial measurements of echo time delay (A-scans). Three-
dimensional images can then be acquired by scanning the incident optical beam in a 
raster pattern, thus producing sequential cross-sectional images (Drexler and Fujimoto 
2008). OCT is now a standard clinical device in hospital ophthalmological clinics. 
However, a prospective analysis of 14 patients revealed that although OCT showed a 
good sensitivity at detecting active nAMD, specificity was only moderate. Furthermore, 
since FFA and OCT may not reflect the same structural changes caused by active 
neovascularisation, the authors concluded that OCT should be used in conjunction with 
FFA, not as a substitute technique (Henschel et al. 2009). The spectral domain OCT 
(SD-OCT), with its 40-fold increase in imaging speed and higher resolution compared 
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with time-domain scanning, is able to capture high-quality B-scans of drusen 
ultrastructure in vivo in better detail (Khanifar et al. 2008).  
 
The introduction of the SD-OCT has led to the development of algorithms that produce 
fully automated, quantitative information on the 3-dimensional geometry of the RPE. 
One particular algorithm has been shown to produce highly reproducible measurements 
of drusen volume and area (Gregori et al. 2011), which could assess disease progression 
and be used as a surrogate clinical trial end point (Yehoshua et al. 2011a). See Section 
1.6.1 for a detailed discussion of drusen volume analysis. 
1.3.6.4 Fundus Autofluorescence (FAF) 
Autofluorescent imaging of the retina relies on the stimulated emission of light from 
predominately lipofuscin molecules found in the RPE (von Rückmann et al. 1997; 
Solbach et al. 1997). Lipofuscin is a yellow-brown colour and its autofluorescent 
phosphors emit a typical yellow fluorescence when excited by blue light (Lamb and 
Simon 2004). It is produced from the oxidative decomposition of fatty acids, proteins 
and retinoids (Spaide 2003) and is thought to induce RPE apoptosis (Suter et al. 2000). 
The intensity of the FAF is correlated with the proportion of lipofuscin present in the 
retina, and hence indicates previous and possible imminent oxidative damage (Spaide 
2003). The introduction of the scanning laser ophthalmoscope allows FAF to be imaged 
over larger retinal areas and minimises autofluorescence from other retinal structures 
such as the lens (Schmitz-Valckenberg et al. 2009). Abnormalities in FAF have been 
associated with areas of drusen (von Rückmann et al. 1997; Roth et al. 2004), choroidal 
neovascularisation (von Rückmann et al. 1997; Spaide 2003), geographic atrophy (von 
Rückmann et al. 1997; Holz et al. 2001; Holz et al. 2007) and losses in macular 
sensitivity as assessed by microperimetry (Midena et al. 2007).  
1.3.6.5 Visual Acuity (VA) 
Visual acuity is the most widely used measure of visual function in both optometric and 
ophthalmological clinics. However, it is not a strong predictor of visual performance in 
everyday tasks such as mobility and face recognition (Bullimore et al. 1991; Hassan et 
al. 2002). Lesions associated with early AMD cause a reduction in VA of 
approximately two letters or fewer (Klein et al. 1995). Although statistically significant, 
this level of visual defect is clinically undetectable given that the test-retest variability 
of Log MAR charts is between one and two lines (Lovie-Kitchin and Brown 2000). 
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Furthermore, patients with AMD often show considerable between-subject variability 
in VA measurement because of the heterogeneity of their associated lesions (Sunness 
et al. 2008). Since VA is relatively unaffected until the later stages of the disease, its 
diagnostic utility is questionable (Sunness et al. 2008).  
 
1.3.6.6 Amsler Chart 
The Amsler chart, a simple square matrix, was developed in 1947 as a screening tool 
for macular disease (Marmor 2000). Despite being regularly used as a surveillance tool 
for progression to neovascular AMD, the sensitivity of the Amsler chart has been shown 
to be as poor as 56% in detecting scotomas (Schuchard 1993). Since symptoms of 
distortion may precede scotomas, the Amsler chart must be sensitive to detecting new 
distortion (Crossland and Rubin 2007). In a study of 49 patients with recent nAMD 
who were regularly observing Amsler charts, just 5 patients had reported Amsler chart 
distortion as their first visual symptom. However, when the Amsler test was performed 
on the same patients by an experienced clinician, only 5 of the 49 patients failed to 
notice any abnormality on the Amsler chart, thus highlighting the importance of 
thorough patient education (Fine et al. 1986).  
 
Some modifications have been made to the traditional Amsler chart in a bid to improve 
test sensitivity, such as threshold testing using cross-polarising filters to reduce the grid 
luminance (Wall and Sadun 1986) and presenting it as a blue grid on a yellow 
background (Mutlukan 2006). However, no peer-reviewed data on the sensitivity and 
specificity of these tests is available. The Preferential Hyperacuity Perimeter (PHP) is 
a computer-based alternative to the Amsler chart that involves a tachistoscopic 
presentation of a ‘virtual line’ of dots. However, its specificity has been found to be 
poorer than the Amsler chart (Loewenstein et al. 2003). A scanning laser device and 
virtual reality display which implements dynamic visual noise (Plummer et al. 2000), 
is reported to have a sensitivity and specificity of 82% and 100% respectively for the 
detection of AMD (Freeman et al. 2004). The ForseeHome device, which uses 
hyperacuity techniques and telemonitoring, has recently been shown in a randomised, 
controlled trial of 1997 participants to increase the likelihood of better VA after anti-
VEGF therapy, compared to standard care (AREDS2-HOME Study Research Group 
2014). However, these two devices are expensive and require additional training, 
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limiting their general applicability amongst the AMD population. Therefore, since the 
Amsler chart is still an inexpensive, simple and rudimentary screening tool, it should 
not be completely disregarded.  
 
1.3.7 Pathogenesis of AMD 
The pathogenesis of AMD is complex, multi-factorial and not fully understood at 
present. The current literature indicates that a number of processes including oxidative 
stress, choroidal vascular changes, hypoxia and local inflammation all contribute to the 
development and progression of the disease, as depicted in Figure 9. 
 
Figure 9. Proposed steps in the pathogenesis of AMD describing the possible relationship 
between oxidative, inflammatory and genetic factors (Kanda et al. 2008). 
Several literature reviews have attempted to describe the disease pathogenesis based 
upon the current evidence available (Roth et al. 2004; Tezel et al. 2004; Nowak 2006; 
Ambati and Fowler 2012; Ambati et al. 2013). 
 
1.3.7.1 Oxidative Stress 
Both experimental and clinical findings suggest that oxidative stress, i.e. cellular 
damage caused by reactive oxygen intermediates (ROIs), plays a role in the 
pathogenesis of AMD (Roth et al. 2004). These ROIs include free radicals and 
 23 
hydrogen peroxide, and are commonly the by-products of oxygen metabolism. Due to 
the high level of metabolic activity, the presence of polyunsaturated fatty acids and the 
high exposure to visible light, the retina is particularly susceptible to oxidative stress 
(Beatty et al. 2000). A number of factors such as ageing, inflammation, cigarette smoke 
and air and light pollutants encourage the formation of ROIs which, in turn, cause 
oxidative damage to cytoplasmic and nuclear components of cells and disrupt the 
extracellular matrix (Thornton et al. 2005; Zarbin 2004; Khan et al. 2006; Klein et al. 
2008b; Cong et al. 2008).  
 
The human retina is protected against the harmful effects of these ROIs by antioxidant 
enzymes such as catalase, superoxide dismutase and glutathione peroxidase, and 
carotenoids in the form of macular pigment (Beatty et al. 2000). Macular pigment not 
only acts as an antioxidant, but also absorbs short wavelength light, a potent mediator 
of photo-oxidative damage (Beatty et al. 1999). Consequently, the reduction in macular 
pigment density with ageing further promotes photo-oxidative damage. Recent 
evidence suggests that increased oxidative stress and reduced anti-oxidant defence may 
play a synergistic role in the development of AMD (Uğurlu et al. 2013). 
 
Oxidative stress not only leads to disruption of RPE cell junctions (Bailey et al. 2004) 
and RPE apoptosis (Jiang et al. 2005), but it also may contribute to an accumulation of 
lipofuscin in the RPE (Roth et al. 2004). Lipofuscin describes a group of 
autofluorescent lipid granules present in neuronal and non-neuronal tissues. With 
ageing, there is an accumulation of lipofuscin in RPE cells, which may compromise 
phagocytosis leading to cell death (Wing et al. 1978; Terman and Brunk 2006). Ma and 
colleagues have recently demonstrated that accumulation of A2E, a key component of 
ocular lipofuscin, resulted in microglia activation, reduced microglial protection of 
photoreceptors and altered complement regulation (Ma et al. 2013). However, Grey and 
colleagues observed that oxidised A2E does not, in fact, accumulate over time (Grey et 
al. 2011). Furthermore, it has recently been discovered that there is little correlation 
between the spatial distribution of A2E and lipofuscin fluorescence in the human RPE 
(Ablonczy et al. 2013), leading Smith and colleagues to conclude that A2E does not 
play a significant role in the development of AMD (Smith et al. 2013). However, it has 
been found that the oxidised A2E bisretinoids degrade into smaller, more damaging 
fragments such as methylglyoxal (Wu et al. 2010). Therefore, lower A2E levels may 
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be the result of greater lipofuscin photo-oxidation in the central RPE, and so A2E could 
still be a contributing factor in the pathogenesis of AMD (Sparrow et al. 2013). 
 
Since the RPE plays a vital role in metabolic and supportive functions for the 
photoreceptor cells, an impairment in RPE function could lead to the development of 
advanced AMD (Sparrow and Boulton 2005). There is a range of evidence consistent 
with this theory. Smoking, the chief modifiable risk factor for the development of 
AMD, is known to aggravate oxidative stress (Khan et al. 2006; Espinosa-Heidmann et 
al. 2006; Khandhadia and Lotery 2010). Furthermore, antioxidant supplementation has 
been shown to reduce the development of AMD (AREDS 2001a; Ho et al. 2011; 
AREDS2 2013). It has also been shown that patients with AMD have a higher level of 
systemic homocysteine, an amino acid that oxidises rapidly to produce ROIs 
(Rochtchina et al. 2007). RPE lipofuscin molecules, detected in vivo with fundus 
autofluorescence (FAF), have been linked topographically to regions of geographic 
atrophy (Delori et al. 1995). Several studies have suggested that increased 
autofluorescence may precede the development or progression of RPE atrophy (Holz 
et al. 2001; Schmitz-Valckenberg et al. 2006; Holz et al. 2007). However, Hwang and 
colleagues found no correlation between the area of geographic atrophy enlargement 
and the area of increased FAF (Hwang et al. 2006). Whilst the exact locations may not 
correspond, it does appear to be the case that an overall increase in the amount of FAF 
relates to the rate of geographic atrophy progression (Bearelly 2011), and may be used 
in future to predict the rate of progression of geographic atrophy. 
1.3.7.2 Inflammation and the Immune Response 
Inflammation was first implicated in the pathophysiology of AMD from the discovery 
of immune response proteins present in drusen in post-mortem eyes from people with 
AMD (Hageman 2001). These and other inflammatory cells may cause microvascular 
assault through the release of oxidants and proteolytic enzymes that damage Bruch’s 
membrane. Subsequent genetic studies discovered statistically significant correlations 
between AMD and complement pathway polymorphisms in genes such as CFH ( 
Edwards et al. 2005; Seddon et al. 2007; Despriet et al. 2009). The trigger for this 
immune response appears to be the cellular damage caused by age-related changes 
together with oxidative stress (Kanda et al. 2008). The cellular debris produced by 
compromised RPE cells is then thought to generate a pro-inflammatory signal, up-
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regulating cytokines and pro-inflammatory mediators and activating the complement 
cascade (Roth et al. 2004). Genetic susceptibility variants modulating this 
inflammatory process may consequently determine the clinical presentation of the 
disease. For example, genetic polymorphisms in the CFH gene and other complement-
related genes have been associated with the development and progression of AMD, 
altering the cellular response of the retina to insult (Bergeron-Sawitzke et al. 2009; 
Farwick et al. 2009; van de Ven et al. 2013; Yu et al. 2011).  
 
The dysregulation of retinal microglial cells and their interaction with macrophages 
derived from monocytes have been postulated to be involved in the pathogenesis of 
AMD (Ma et al. 2009; Raoul et al. 2010). These microglia are the immune cells of the 
retina, playing an important role in neuronal protection and tissue regeneration 
(Langmann 2007). The accumulation of debris in the retina can lead to continuous 
activation of the microglial cells, leading to the secretion of pro-inflammatory cytokines 
and chemokines (Langmann 2007). Recently, increased expression of the membrane 
protein CD200, a regulator of microglial activity, has been found in eyes with wet AMD 
(Singh et al. 2013). This is surprising, and led the authors to suggest that despite 
increased expression of CD200, the mechanisms controlling the retinal microglia fail 
to inhibit the inflammatory response in eyes with wet AMD. Altered regulation of the 
immune response could play an important role in AMD pathogenesis, and further 
research needs to be carried out to determine the mechanisms responsible for retinal 
microglial dysregulation. Despite the evidence showing that inflammatory cells are 
present in areas of Bruch’s membrane damage, RPE atrophy and CNV lesions in AMD, 
it is still not certain whether they play a causative or protective role (Ozaki et al. 2014). 
For comprehensive reviews of the evidence for immunological pathogenesis, the reader 
is referred to Ambati et al. (2013) and Ozaki et al. (2014). 
1.3.7.3 Hypoxia  
Normal choroidal circulation is upheld by an equilibrium between pro-angiogenic (e.g. 
VEGF) and anti-angiogenic (e.g. PEDF) growth factors. However, when the retina is 
in a hypoxic state, it triggers the upregulation of VEGF (Aiello et al. 1995; Blaauwgeers 
et al. 1999), thus stimulating choroidal angiogenesis. The evidence for this is largely 
based on signals for the overproduction of VEGF from hypoxia-inducible factors (HIF-
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1α and HIF-2α) which have been found in active CNV lesions (Inoue et al. 2007; 
Sheridan et al. 2009).  
 
It has been found that the choroidal circulation in the healthy retina is barely able to 
meet the oxygen demand in the dark adapted eye (Wangsa-Wirawan and Linsenmeier 
2003). Furthermore, the macular choroid is more sensitive to ischaemia due to the 
numerous watershed zones present there. Therefore, the alterations in choroidal blood 
flow and changes in Bruch’s membrane that occur in AMD are thought to lead to outer 
retinal hypoxia (Feigl 2009; Stefánsson et al. 2011). For more information on hypoxia 
and AMD, the reader is referred to section 1.4. 
 
1.3.8 Management 
The current management for patients with early AMD involves advising on lifestyle 
changes, for example, cessation of smoking, adopting a healthy diet and the 
consumption of nutritional supplements (see sections 1.3.5.2 and 1.3.5.5 for details). 
These changes may reduce AMD progression, but there are currently no treatments for 
early AMD. For those patients with progressive central visual loss resulting from dry, 
atrophic changes, the only management is the provision of low vision aids. Therefore, 
there is an urgent need to evaluate potential new interventions. At present, the medical 
treatments available for AMD target the neovascular form of the disease. 
1.3.8.2 Laser photocoagulation 
In thermal laser photocoagulation, a laser beam is used to occlude leaking blood vessels 
arising from choroidal neovascularisation (Chakravarthy et al. 2006). In the 1980s, the 
Macular Photocoagulation Studies (MPS) reported a favourable outcome in 20% of 
eyes with a well-defined extrafoveal CNVM (Macular Photocoagulation Study Group 
1991). However, approximately 50% of thermal laser treated eyes had persistent or 
recurrent CNV within 3 years of treatment. Furthermore, thermal laser damage to the 
overlying retinal tissue can often lead to significant vision loss (Macular 
Photocoagulation Study Group 1994).  Thus, the treatment should only be considered 
for small extrafoveal lesions away from the foveal avascular zone (Chakravarthy et al. 
2006). This is reflected in the steady decline of patients receiving this therapy for the 
treatment of CNV. Indeed, between 2006 and 2008, the proportion of newly diagnosed 
patients with nAMD on the Medicare claims database receiving laser treatment 
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decreased from 5.5% to 3.2% (Curtis et al. 2012). 
1.3.8.3 Photodynamic therapy 
Photodynamic therapy (PDT) is a two-stage procedure involving the intravenous 
administration of verteporfin, a green dye that accumulates within endothelial cells of 
blood vessels, and subsequent activation of the dye with infrared light using a non-
thermal laser (Chakravarthy et al. 2006; Lim et al. 2012). This generates free radicals 
that damage the CNV endothelium, leading to occlusion of the newly formed vessels 
(Chakravarthy et al. 2006; Cruess et al. 2009). It is deemed to be superior to laser 
photocoagulation due to the protection of the overlying retinal surface. Several 
randomised controlled clinical trials of patients with subfoveal CNV have reported PDT 
to be a ‘successful’ treatment option for classic lesions, but was less effective for occult 
CNV lesions, with success being defined as slowed loss of VA, rather than an 
improvement in VA (Schmidt-Erfurth et al. 1999; Bressler 2001; Azab et al. 2005; 
Cruess et al. 2009). The main side-effects reported with the use of PDT include back 
pain, headaches and photosensitivity (Borodoker et al. 2002). The most serious ocular 
side effect is a sudden, severe decrease in VA within 7 days of PDT due to choroidal 
infarction (Klais et al. 2005), which in some causes may be permanent (Axer-Siegel et 
al. 2004). For this reason, PDT is much less frequently used as a treatment for CNV. 
Only 5.3% of patients receiving treatment for CNV were given this route of therapy in 
2008 (Curtis et al. 2012). 
1.3.8.4 Anti-VEGF therapy 
The discovery of the key role that VEGF plays in the pathogenesis of choroidal 
neovascularisation has led to the development of drugs inhibiting its secretion.   
Intraocular injections of anti-VEGF have therefore been established as a standard of 
care for neovascular AMD since the mid-2000s (Wong et al. 2007; Rosenfeld et al. 
2006). Pegatanib sodium (Macugen, EyeTech), a selective antagonist of the 165 
isoform of VEGF-A, was the first anti-VEGF drug to be approved by the US Food and 
Drug Administration (FDA) for treatment of nAMD (Gragoudas et al. 2004). The 
second to be approved by the FDA was ranibizumab (Lucentis, Novartis), a humanised 
monoclonal antibody fragment that binds all VEGF-A isoforms (Chakravarthy et al. 
2006). Both drugs were approved for use in the treatment of nAMD in the UK by the 
NHS National Institute for Health and Clinical Excellence (NICE) in 2008. Landmark 
clinical trials using ranibizumab showed for the first time not only visual stabilisation 
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but also significant improvements in VA, as shown in Figure 10 below (Rosenfeld et 
al. 2006; Brown et al. 2006; Brown et al. 2009). The most significant improvement in 
acuity has been found to occur after the first injection, and this is maintained upon 
monthly injections of the drug. Serious adverse events, such as endophthalmitis, were 
rare.  
 
Figure 10. Mean change from baseline VA score (letters) over time, with administration of 
monthly Ranibizumab injections compared with verteporfin PDT. Vertical bars represent +/- 1 
standard error of the mean (Brown et al. 2009). 
 
Bevacizumab (Avastin, Genentech), a third anti-VEGF drug, is an off-label alternative 
treatment (Martin et al. 2011). Originally manufactured for the treatment of colourectal 
cancer, it is a full-length monoclonal antibody that also binds all VEGF-A isoforms 
(Chakravarthy et al. 2006). The recent IVAN randomised controlled trial found a 
similar efficacy between bevacizumab and ranibizumab (Chakravarthy et al. 2013). 
Despite this, the uncertainty about systemic safety means that policy makers are 
unlikely to mandate a switch to the cheaper alternative (Cheung and Wong 2013). 
Interestingly, the IVAN trial showed that a reduction in injection frequency seems to 
be associated with a reduction in treatment efficacy. The current advised treatment 
schedule comprises an initial loading phase with monthly injections for the first three 
months. This is followed by a maintenance phase, during which the patient is monitored 
on a monthly basis and given treatment as required (Mitchell et al. 2010). It remains to 
be seen whether the results from the recent IVAN trial will lead to a change in these 
guidelines.  
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The IVAN trial did, however, fail to examine the newest VEGF-binding drug, 
aflibercept. This fusion protein is given every 2 months after the initial loading phase, 
and has been approved by both the FDA and NICE after recent clinical trials showed 
that it had a comparable efficacy and safety to ranibizumab (Cheung and Wong 2013). 
1.3.8.5 Stem Cell Therapy 
Since the development of human embryonic stem cells and induced pluripotent stem 
(iPS) cells, there is been great interest in the potential of these cells to treat AMD (Li 
et al. 2012; Kokkinaki et al. 2011). Recent progress in iPS cells provides a promising 
therapy for geographic atrophy (Du et al. 2011). Indeed, it has been found that human 
RPE cells and photoreceptors can be derived from these cells by defined factors 
(Osakada et al. 2009). This will facilitate the development of transplantation therapies 
for AMD and will improve our understanding of AMD pathophysiology. Indeed, the 
first clinical trial transplanting human embryonic stem cell-derived RPE in a patient 
with dry AMD has recently been undertaken. (Schwartz et al. 2012). After 4 months, 
the transplanted RPE cells showed no signs of hyperproliferation, tumourigenicity or 
rejection, and the patient had a functional improvement in VA. Cone photoreceptor 
transplantation is a challenge yet to be addressed. Whilst cones are similar to rods in 
that must be post-mitotic in order to integrate, they do so at a much slower rate 
(Lakowski et al. 2010). However, proof-of-principle experiments have shown that cone 
transplantation is certainly feasible (Lakowski et al. 2010).    
1.4 Hypoxia and AMD 
1.4.1 Oxygen Demand of the Retina 
Even in the healthy retina, the choroidal circulation is barely adequate to supply the 120 
million rod photoreceptors which have the highest metabolic rate of any cell in the body 
(Arden 2001). Although the retinal circulation is able to sufficiently autoregulate blood 
flow, the choroid is believed to control oxygen tension poorly, and its autoregulative 
potential is equivocal (Wangsa-Wirawan and Linsenmeier 2003). Maintaining a state 
of retinal dark adaptation is a metabolically demanding activity in which photoreceptors 
are constantly depolarised, causing elevated neurotransmitter release at synapses 
(Wangsa-Wirawan and Linsenmeier 2003). This depolarisation is caused by the 
continuous flow of ions into and out of the photoreceptors, the so-called ‘dark current’, 
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which requires the activity of an ATP-driven sodium-potassium pump in the 
photoreceptor cell membrane. Intra retinal oxygen profiles obtained from animals show 
that, in the dark, the oxygen partial pressure falls to almost zero at the proximal side of 
the photoreceptor inner segments, as depicted in Figure 11A. This reflects the high rate 
of oxygen consumption required to maintain the dark current of the 120 million rod 
photoreceptors.  It is necessary for the oxygen tension to be greater in the central retina 
than peripherally due to the higher metabolic requirements of the macula (Wise et al. 
1971). For this reason, the macula is extremely vulnerable to oxygen deficiency (Feigl 
2009). Figure 11B compares the oxygen profile across the cat retina in normoxia 
compared with hyperoxia (inspiration of 100% oxygen). Breathing oxygen is seen to 
considerably increase oxygen tension, especially in the outer retina due to its higher 
oxygen demand and the limited autoregulative capacity of the choroidal circulation. 
A             B 
Figure 11. Intraretinal oxygen profiles across cat retina during light and dark adaptation. The 
retina is shown systematically at the top. The four cell types shown are (from left to right) RPE 
cells, rod photoreceptors, bipolar cells and ganglion cells (A). Intraretinal oxygen profiles in 
dark during normoxia and hyperoxia (B) (Wangsa-Wirawan and Linsenmeier 2003). 
1.4.2 Oxygen Supply to the Retina  
In a healthy eye, the oxygen demand of the retina is met by an efficient blood supply 
from both the choroidal and the retinal circulation, as previously described in section 
1.2.6. The choroid, whose vasculature arises from the short and long posterior ciliary 
arteries, supplies the outer avascular retina and the macular region. The smooth muscle 
of the choroidal vessel walls is innervated by a perivascular plexus encompassing both 
divisions of the autonomic nervous system (Lütjen-Drecoll 2006). 
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The inner retina receives its nutrients from the vascular plexi arising from the central 
retinal artery (Lange and Bainbridge 2012). Unlike the choroidal circulation, the retinal 
vasculature infiltrates the retinal tissue, reducing the diffusion distance from the 
capillaries to the retinal cells (Kong et al. 2010). The lower rate of blood flow in the 
retinal circulation is seen in the greater arteriovenous difference in oxygen saturation 
(Schweitzer et al. 1999).  The retinal circulation has been shown to have a greater 
autoregulative capacity than the choroid (Shakoor et al. 2006). Indeed, retinal blood 
flow has been shown to increase in response to a flickering light stimulus to support the 
increased oxygen requirements of the inner retina (Garhöfer et al. 2004; Riva et al. 
2005; Shakoor et al. 2006).  
 
1.4.3 Effect of Hypoxia on Visual Function 
Psychophysical tests of visual function such as colour vision (Vingrys and Garner 1987; 
Karakucuk et al. 2004; Connolly et al. 2008), dark adaptation (McFarland and Evans 
1939; Connolly and Hosking 2006)  and dynamic contrast sensitivity under mesopic 
conditions (Connolly 2011) are all adversely affected by induced mild systemic 
hypoxia in healthy humans.  
 
Mild systemic hypoxia has been shown to induce losses in colour discrimination along 
both the red-green (RG) and yellow-blue (YB) axes in mesopic luminances, with a 
greater loss occurring along the YB axis (Smith et al. 1976; Connolly 2011). The 
evidence for a loss of chromatic sensitivity caused by mild hypoxia in photopic 
conditions is equivocal: certain studies have found YB sensitivity to be marginally 
diminished (Connolly 2011), whereas others have shown a generalised loss of colour 
discrimination (Vingrys and Garner 1987). However, Connolly (2011) concluded that 
the sensitivity of the visual state to induced hypoxia depends fundamentally on light 
level.  
 
Other types of psychophysical threshold have also been shown to be elevated by mild 
systemic hypoxia in mesopic conditions. For example, low contrast acuity thresholds 
in mesopic lighting are consistently elevated by up to 25% in hypoxia compared to 
hyperoxia (100% oxygen) (Connolly and Serle 2014). When Feigl et al. (2011) 
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measured retinal luminance thresholds under mesopic conditions on a sample of 3 
healthy participants during hypoxia, their thresholds were also significantly elevated 
for all eccentricities. However, studies using static perimetry in photopic conditions 
have detected no functional deficits during mild systemic hypoxia (Fulk et al. 1991; 
Yap et al. 1995). This again indicates that the effect of hypoxia on retinal function is 
exacerbated by a reduced level of retinal illumination. 
 
Flickering stimuli, such as those used in frequency doubling perimetry, are known to 
place an increased metabolic demand on the retina. This is illustrated by the 
compensatory increase in blood flow induced in the inner retinal circulation by 
flickering lights (Kiryu et al. 1995; Polak et al. 2002; Riva et al. 2001; Riva et al. 2005; 
Shakoor et al. 2006).  Indeed, the blood flow in primate retinal arteries increases by 
30% during monochromatic light flicker (Kiryu et al. 1995). It may be expected, 
therefore, that induced hypoxia will have a greater effect on sensitivity to metabolically 
demanding flickering stimuli than to static stimuli. Connolly and Hosking (2008) 
measured visual field sensitivity over 40o of the central field using Frequency Doubling 
Technology (FDT) under photopic conditions during mild hypoxia (14% oxygen). 
Hypoxia was found to significantly reduce sensitivity from 5 to 10o eccentricity, but 
not at more peripheral locations between 10 and 20o (Connolly and Hosking 2008). 
This is in contrast with a recent study, which found no significant difference in either 
flicker or static visual field sensitivities between hypoxic and normoxic conditions 
under photopic illumination (Feigl et al. 2011). The dichotomy in results may be due to 
methodological differences; FDT uses 10o targets modulated to flicker at 25Hz, 
whereas the flicker perimeter used by Feigl et al. contained 0.43o diameter targets at 
temporal frequencies between 9 and 18Hz. The higher rate of flicker employed by 
Connolly and Hosking (2008) may have increased the effect of systemic hypoxia under 
photopic conditions. In another study, Connolly (2011) also found that hypoxia reduced 
dynamic contrast sensitivity (using FDT) by approximately 2dB in mesopic conditions 
(Connolly 2011). Flicker and chromatic thresholds are mediated by the cone pathways. 
Therefore, the evidence suggests that in mesopic conditions rod-induced hypoxia may 
compromise cone function, thus revealing ischaemic abnormalities in cone pathways 
that are undetected under photopic light levels. 
 
 33 
In addition to the elevation of steady state visual thresholds, there is also evidence to 
suggest that reduced retinal oxygenation affects the kinetics of retinal adaptation 
(McFarland and Evans 1939; Connolly and Hosking 2006). Dark adaptation, the 
recovery of visual sensitivity in darkness following a bright flash of light, is affected 
by compromised arterial circulation. Evidence supporting this is found in an elevated 
dark adapted threshold in carotid artery disease (Havelius et al. 1997a) which is 
improved after carotid endarterectomy (Havelius et al. 1997b). Furthermore, healthy 
subjects have demonstrated delayed rod cone breaks with slower rates of dark 
adaptation under conditions of mild to moderate induced hypoxia (McFarland and 
Evans 1939; Connolly and Hosking 2006), suggesting that the compromised oxygen 
supply to the outer retina impacts on the dynamic process of photopigment 
regeneration. The impairment in dark adaptation with ageing found by Jackson et al. 
(1999) was comparable to the prolongation of the dark adaptation function found by 
Connolly and Hosking (2006) in young healthy controls subjected to hypobaric 
hypoxia. This similarity may suggest that the delayed dark adaptation observed in older 
persons is attributable to a localized deficit in oxygen supply to the outer retina. 
 
As well as the substantial psychophysical evidence that visual function is affected in 
healthy individuals by induced systemic hypoxia, electrophysiological data have also 
been published (Tinjust et al. 2002; Pavlidis et al. 2005; Feigl 2007b; Feigl et al. 2008). 
Tinjust et al. (2002) found that humans experiencing mild systemic hypoxia induced by 
breathing 12% oxygen for 5 minutes had altered full-field ERG b-wave and oscillatory 
potentials with an unchanged a-wave, which led to the suggestion that the outer retina 
is more resistant to mild hypoxia than the inner retinal layers. In contrast, Shatz et al. 
found that 13 healthy volunteers breathing 13.2% oxygen for 45 minutes had 
significantly reduced a- wave amplitudes and a shallower a-wave slope of combined 
rod and cone responses (Schatz et al. 2014). This implies that when subjected to longer 
periods of hypoxia, both inner and outer retinal function are impaired. 
 
The main limitation of the full-field ERG is that it gives little information about 
localized retinal areas as it represents the summed response across the entire retina, and 
hence will mask functional alterations to discrete retinal areas. More recent studies have 
used the multifocal electroretinogram (mfERG) to identify local changes caused by 
acute hypoxia (Pavlidis et al. 2005; Feigl et al. 2008). The mfERG is especially 
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pertinent to AMD as it predominately measures bipolar cell activity often described as 
belonging to the ‘outer retina’ and because the central retinal area tested (33o diameter) 
targets the macular region affected by AMD (Hood et al. 2002). In 2008, Feigl et al. 
found, using the mfERG, that older eyes demonstrate poorer neuroretinal activity in 
systemic hypoxia (14% oxygen) than younger eyes, as shown in Figure 12, indicating 
that they may be more susceptible to hypoxia-induced neuroretinal deficits. 
 
 
Figure 12. During hypoxia, mfERG response density amplitudes for the central 5 degrees are 
significantly reduced in the young (squares) and old (circles) groups for all eccentricities, with 
a more pronounced reduction in the older group (p<0.01) (Feigl et al. 2008). 
 
Using the mfERG, ON and OFF bipolar cell function have been found to decline when 
breathing 10-14% oxygen compared with 21% in normal air at sea level, as shown in 
Figure 13 (Feigl et al. 2007b). This may be due to a lack of choroidal autoregulation 
(Shakoor et al. 2006) and a greater metabolic demand induced by the flickering stimuli 
(Kiryu et al. 1995). 
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Figure 13. 3D response density plots (above) and the waveform trace array (below) of 
neuroretinal responses in an individual before (left) and after (right) breathing 14% O2 shows 
centrally reduced responses (darker areas) for the standard mfERG (Feigl et al. 2007b).  
 
1.4.4 Hypoxia and AMD 
It is notable that the well-reported deficits in visual function seen in people with early 
AMD, including delayed dark adaptation (Owsley et al. 2001; Owsley et al. 2007; 
Dimitrov et al. 2008; Gaffney et al. 2011; Dimitrov et al. 2011), reduced flicker 
sensitivity (Dimitrov et al. 2011; Luu et al. 2013), reduced chromatic sensitivity 
(O’Neill-Biba et al. 2010) and elevated scotopic thresholds (Owsley et al. 2000), are 
similar in nature to the impairment recorded in healthy eyes under conditions of induced 
hypoxia (see section 1.4.3). This supports the hypothesis that the retinal dysfunction 
reported in early AMD may be, at least in part, attributable to retinal hypoxia. For 
example, Feigl et al. (2009) suggested that during experimental hypoxia in healthy 
adults, the metabolic demand induced by flicker could impair neuroretinal responses 
whilst, in AMD, these impaired responses may be the result of pre-existing hypoxia at 
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the retinal level. The influence of chronic systemic hypoxia on the aetiology of AMD 
is still not fully understood. There is, however, a known association between 
cardiovascular disease and AMD (Eye Disease Case-Control Study Group 1992; van 
Leeuwen et al. 2003; Chakravarthy et al. 2010), suggesting that this chronic hypoxic 
condition may have a bearing on the risk of AMD onset. This section will consider the 
evidence that hypoxia plays a role in the pathogenesis of AMD. 
There is substantial evidence demonstrating that changes to the choroidal vasculature 
play a key role in AMD development (Chen et al. 1992; Friedman et al. 1995; Ciulla et 
al. 1999; Pauleikhoff et al. 1999; Ciulla et al. 2001; Ciulla et al. 2002). Abnormalities 
in ocular blood flow have been found in both early and advanced AMD using 
qualitative and quantitative techniques such as fluorescein and indocyanine green 
(ICG) angiography (Chen et al. 1992; Pauleikhoff et al. 1999), colour Doppler imaging 
(Friedman et al. 1995; Ciulla et al. 1999) and laser Doppler flowmetry (Metelitsina et 
al. 2008; Xu et al. 2010). Indeed, the choroidal blood supply has been suggested to be 
the initial area of insult in AMD (Ciulla et al. 1999; Seddon et al. 2009). Vascular 
defects have also been demonstrated by histological evidence reporting a reduced 
lumen diameter and vessel density in AMD (Sarks 1976). Watershed zones, which 
represent the anastomoses of the choroidal vessels supplied by the different branches 
of the posterior ciliary artery, are particularly susceptible to microvascular damage. 
These regions, as well as angiographic areas of choroidal non-perfusion, are associated 
with the location of choroidal neovascular growth, suggesting the co-localisation of 
regions of choroidal ischemia and choroidal neovascularization (Goldberg et al. 1998; 
Mendrinos and Pournaras 2009). Pauleikhoff et al. also found that it was common for 
patients with AMD to exhibit prolonged choroidal filling on fluorescein angiography 
and ICG (Pauleikhoff et al. 1999). 
 
Reduced choroidal blood flow in AMD is also associated with delayed ERG implicit 
times and scotopic threshold elevation (Chen et al. 1992; Remulla et al. 1995). Chen et 
al. (1992) measured the scotopic thresholds of 8 eyes showing prolonged choroidal 
filling on fluorescein angiography and 6 eyes with a similar number of drusen but no 
perfusion defects using the Humphrey automated perimeter and fine matrix mapping.  
In 7 out of 8 eyes with delayed perfusion, scotopic thresholds were elevated by up to 
3.4 log units compared to the background sensitivity. In contrast, eyes with normal 
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choroidal filling were not found to have any discrete areas of increased scotopic 
threshold. Remulla et al. (1995) investigated the foveal cone ERG implicit time (4o 
stimulus flickering at 42 Hz) in the fellow eye of 67 patients with unilateral wet AMD. 
They found that implicit times were on average 1ms slower and were more likely to be 
delayed in eyes with abnormal choroidal perfusion than in eyes with normal filling, 
reinforcing the link between choroidal ischaemia and visual dysfunction in early AMD. 
 
In addition to the potential effects of impaired choroidal perfusion on the state of outer 
retinal oxygenation, changes to Bruch’s membrane associated with AMD are also likely 
to have an impact. The presence of drusen under the RPE and a thickening of Bruch’s 
membrane in AMD increase the distance between the choriocapillaris and the retina, 
which augments the distance over which oxygen must diffuse. According to Fick’s law 
of diffusion, this will result in a reduced oxygen supply to the retina, stimulating outer 
retinal hypoxia (Stefánsson et al. 2011). It is possible that the lipid accumulation and 
thickening of Bruch’s membrane in AMD also reduces its permeability to water-soluble 
nutrients like VEGF-A (Holz et al. 1994). In the normal eye, RPE cells primarily secrete 
VEGF-A at their basolateral side towards the choriocapillaris. This growth factor is 
required for vascular permeability, angiogenesis, lymphangiogenesis and has 
neutrotrophic functions (Witmer et al. 2003), hence, its depletion is likely to lead to 
atrophy of the choroidal circulation (Sakamoto et al. 1995; Witmer et al. 2003). 
Choroidal atrophy, in turn, will potentiate choroidal perfusion abnormalities, and 
drusen and debris accumulation at the level of Bruch’s membrane. In turn, this is likely 
to cause further outer retinal hypoxia (Zarbin 2004; Feigl 2007), leading to a cycle of 
hypoxic insult.  
 
Although the choroidal circulation is the focus of most research into vascular deficiency 
in AMD, recently, a non-invasive spectrophotometric retinal oximeter based on a 
standard fundus camera, the Oxymap Retinal Oximeter T1 (Oxymap, Reykjavik, 
Iceland), has been developed to enable the direct study of retinal oxygen metabolism 
by measuring the oxygen saturation in inner retinal arterioles and venules (Geirsdottir 
et al. 2012). The repeatability of the Oxymap T1 in retinal vasculature oxygenation 
saturation measurements is approximately 1% (Palsson et al. 2012). Using this 
instrument, the arteriovenous difference in oxygen saturation in eyes with wet AMD 
was found to be smaller than in healthy controls, suggesting that less oxygen is being 
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extracted from the retinal vessels in AMD (Geirsdóttir et al. 2014). This suggests that 
the inner retinal circulation may also be implicated in the pathogenic mechanism of 
AMD.  
 
There is also molecular evidence supporting the role of hypoxia in AMD. For example, 
autopsies have shown that VEGF is expressed in the RPE of eyes with AMD, and 
VEGF has been identified in surgically removed choroidal neovascular membranes 
(CNVMs) (Grossniklaus et al. 1992; Frank et al. 1996; Kvanta et al. 1996). Animal 
models that produce excess VEGF are also associated with the growth of CNVMs 
(Baffi et al. 2000; Schwesinger et al. 2001). Furthermore, VEGF levels are high in the 
vitreous of eyes with neovascular AMD (Wells et al. 1996; Holekamp et al. 2002). The 
upregulation of VEGF expression in response to hypoxia occurs through hypoxia-
inducible factor-1 (HIF-1), a transcription factor necessary for the regulation of oxygen 
homeostasis (Zhang et al. 2007). In normoxia, HIF-1α is rapidly degraded by the von 
Hippel-Lindau tumour suppressor protein, thus preventing it from heterodimerising 
with HIF-1β, which consequently prevents VEGF expression (Mole et al. 2001). Under 
hypoxic conditions, HIF-1α is able to dimerise with HIF-1β, leading to the upregulation 
of VEGF-A (Klettner et al. 2013). 
 
The evidence suggests that, even in the early stages of AMD, there may be retinal 
hypoxia as a result of the high metabolic demands of the photoreceptor cells (Arden et 
al. 2005). The ultimate consequence of outer retinal hypoxia may be an overexpression 
of VEGF-A in the RPE, triggering choroidal neovascularization (Spilsbury et al. 2000), 
or cell apoptosis resulting in geographic atrophy of the retina and RPE (Arden et al. 
2005). If hypoxia is responsible for the progression of AMD, it follows that most 
damage will be caused when the retina is most hypoxic, i.e. in darkness (Figure 11A). 
If the metabolic activity of the outer retina and hence oxygen demand could be reduced, 
outer retinal hypoxia would be diminished and AMD progression would be potentially 
prevented. 
 
1.5 Low-level Light Therapy for Retinal Hypoxia 
The 120 million rod photoreceptors have the highest metabolic rate of any tissue in the 
human body, which necessitates a high level of energy (provided by adenosine 
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triphosphate, ATP) and oxygen consumption (Arden 2001). Okawa et al. (2008) 
demonstrated that the ATP consumption of mammalian rod photoreceptors is >75% 
higher in the dark than the light. In the outer segment, the majority of the energy 
expenditure was required to extrude sodium ions which flow into the cell through 
cGMP gated ion channels in the dark (maintaining the rod circulating current, or ‘dark 
current’). The inner segment requires energy for the removal of sodium and calcium 
ions entering voltage-gated channels at the synaptic terminal. It can be seen from Figure 
14 that all of these processes are more active at lower light levels (fewer rhodopsin 
isomerisations per rod per second). Consequently, retinal oxygen consumption 
decreases by up to 40 to 60% in bright light, as seen in Figure 15. 
 
Figure 14. Main contributors to ATP consumption in mammalian rods over the physiological 
range of steady light intensities. (A) Outer segment. ATP required for extrusion of Na+ entering 
cGMP-gated channels (filled square), transducin GTP hydrolysis and rhodopsin 
phosphorylation (open square), cGMP synthesis (open circle), and sum of these processes (X). 
(B) Inner segment and total rod ATP consumption. ATP required for extrusion of Na+ entering 
through ih channels (open square), extrusion of Ca2+ entering voltage-gated channels at synaptic 
terminal (open circle), sum of ATP for Na+ and Ca2+ extrusion (open triangle), and sum of ATP 
turnover in whole rod (closed circle) (Okawa et al. 2008). 
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Figure 15. Intraretinal oxygen profiles across cat retina during light and dark adaptation (Arden 
2001). 
 
It follows, therefore, that if environmental light levels were increased during the hours 
of sleep, the metabolic activity of the outer retina and hence the oxygen demand would 
be reduced, thus providing a potential therapy for conditions with a hypoxic aetiology 
(Arden 2001).  
 
Diabetes is a disease that selectively damages the retinal vasculature (Wangsa-Wirawan 
and Linsenmeier 2003), causing capillary dropout, microaneurysms, cellular damage 
and neovascularisation (Kern and Engerman 1996). For a number of years, hypoxia has 
been implicated in the progression of diabetic retinopathy (Arden 2001). Because of 
the retina’s vast oxygen requirements, even minor reductions in oxygen availability due 
to basement membrane thickening (Alder et al. 1997) or increases in oxidative 
metabolism from hyperglycaemia, could lead to retinal hypoxia (Cao et al. 1998). There 
is evidence to suggest that hypoxia in diabetes occurs before any capillary dropout 
(Braun et al. 1995; Linsenmeier et al. 1998; Dean et al. 1997; Harris et al. 1996). In 
humans, oscillatory potentials are diminished during dark adaptation (Drasdo et al. 
2002) and chromatic sensitivity is reduced (Dean et al. 1997) before any vessel damage 
is observed. Hence, hypoxia may be the stimulus for VEGF upregulation and 
subsequent macular oedema and retinal neovascularisation. Since outer retinal hypoxia 
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increases during dark adaptation (Braun et al. 1995), prevention of dark adaptation 
during sleep should have therapeutic benefits on the progression of diabetic retinopathy.  
 
This hypothesis was tested recently in a phase I clinical trial of 12 diabetic patients 
(Arden et al. 2010). The light source was provided by a ‘glowpatch’, i.e. a flat oval 
sachet (75 x 55mm) containing phthalates and hydrogen peroxide that mix and emit 
light of peak output 550nm through the lids, secured in place by a light plastic 
headband. One eye was exposed to local illumination with the fellow eye acting as a 
control. The intervention was able to prevent complete dark adaptation for up to 12 
months without any adverse effects such as sleep disturbances, indicating that this form 
of treatment is acceptable to patients. Although this was a small pilot study, the results 
showed that, in the majority of treated eyes, the YB chromatic thresholds were 
significantly reduced compared to their fellows (p=0.03). Furthermore, the areas of 
microaneurysms and small dot haemorrhages decreased in the treated eyes whilst 
increasing in the fellow eyes. A limitation of the study was that the light patches did 
not give a constant output over time, leading to uncertainty as to how long light 
adaptation was maintained at night, and what light intensity was achieved. It raised the 
possibility that if higher illumination levels were used for longer periods than the 
presumed several hours provided by the glowpatch, more significant improvements in 
treated eyes could be achieved. 
 
In light of this, the same group conducted a further investigation on 34 patients with 
diabetic macular oedema (Arden et al. 2011). Sleepmasks containing light emitting 
diodes were enclosed in a cotton cover and held against the eyes by an elastic headband. 
Four 505nm light emitting diodes were used to provide a constant retinal illuminance 
in the treated eye of 2 scotopic trolands (allowing for attenuation by the eyelids), which 
was deemed sufficient to significantly reduce the rod circulating current, and hence the 
oxygen demand of the retina (Arden et al. 2011). The device was driven by a battery 
that was recharged every morning. After 6 months, Arden et al. reported a reduction in 
retinal thickness in the treated eye only, as demonstrated in Figure 16. Furthermore, 
visual acuity, achromatic sensitivity and microperimetric thresholds significantly 
improved in study eyes, and deteriorated in fellow eyes.  
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Figure 16. Cross-sectional OCT views horizontally through the macula from some 
representative patient's study eyes. In every case, the cysts have decreased over 6 months 
(Arden et al. 2011). 
 
This study provides evidence that significant structural and functional improvements 
occur in eyes with diabetic macular oedema exposed to light during the night. A 
limitation of the study is that the masks had a high rate of failure so that patients were 
not exposed to constant illumination. Furthermore, there was no eye-tracker in the 
device to ensure that the LEDs were always positioned in front of the pupil. Despite 
these limitations, trans-lid retinal illumination during the night was found to cause 
regression of diabetic macular oedema. This was attributed to a reduction in oxygen 
demand by the dark current. The same therapy could also have significant therapeutic 
benefits in other conditions of a hypoxic aetiology, such as AMD.  
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1.6 Biomarkers in AMD 
1.6.1 Drusen Volume Analysis 
Macular drusen are the hallmark lesions of early and intermediate AMD, and the 
presence of large soft drusen and retinal pigmentary abnormalities is known to indicate 
an increased risk of development of neovascular or atrophic AMD (Klaver et al. 2001; 
Klein et al. 2002; Wang et al. 2003). The natural history of drusen may comprise an 
increase in size, confluence and area followed by neovascularisation, or a regression 
leading to atrophy of the RPE and photoreceptors (Gass 1973). The recent 
Complications of Age-related Macular Degeneration Trial (CAPT), a large, population-
based study, found that 1.2% of eyes had a reduction in drusen area greater than 50% 
after 6 months (Complications of Age-Related Macular Degeneration Prevention Trial 
Research Group 2006). This proportion increased over time to 31.2% at 5 years, 
indicating that drusen are not static in nature: the reabsorption of old drusen and 
formation of new drusen can occur concurrently in the same eye.  Although the 
prognosis for drusen regression is not currently known, there is a possibility that 
treatments capable of altering drusen morphology could reduce disease progression in 
AMD (Yehoshua et al. 2011a). 
 
Traditionally, stereoscopic colour fundus photography has been the gold standard 
objective technique for the manual assessment of drusen to document drusen severity, 
drusen natural history and the likelihood of disease progression in AMD (Klein et al. 
2007). Although these photographs are beneficial in viewing the macular appearance, 
they do not provide direct information on RPE geometry. Furthermore, there is often 
considerable variation in drusen measurements between readers, especially at indistinct 
drusen margins (Jain et al. 2010). Therefore, novel algorithms have been developed for 
automated and semi-automated drusen analysis (Smith et al. 2005; Jain et al. 2010; 
Gregori et al. 2011; Yehoshua et al. 2011a; Schlanitz et al. 2011).   
 
The recent development of the SD-OCT has enabled the study of drusen morphology 
in vivo, due to its faster acquisition speeds and increased image resolution compared 
with previous time-domain OCT models (Drexler et al. 2003; Srinivasan et al. 2006).  
It is able to generate high-quality, individual B-scans that provide a cross-sectional 
view of drusen ultrastructure (Khanifar et al. 2008). Quantitative information about the 
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3-dimensional RPE deformations can be extracted from the SD-OCT datasets using 
segmentation algorithms (Yehoshua et al. 2011a). A novel, fully automated algorithm 
has been developed that is capable of acquiring drusen volume and area from these RPE 
deformations. This quantitative algorithm has been shown to produce highly repeatable 
measurements of both drusen volume and area (Gregori et al. 2011). Previously, 
Szkulmowaski et al had developed a similar algorithm, but their semi-automated 
method required much operator intervention, and its reliability was limited by the 
presence of artefacts (Szkulmowski et al. 2007). Later, Yi et al developed a similar 
strategy to that of Gregori, but it has not been validated, nor has its repeatability been 
assessed (Yi et al. 2009). Therefore, the most suitable algorithm currently available is 
that of Gregori et al. (2011). A study of the natural history of drusen morphology using 
this algorithm has shown that, over a period of 12 months, drusen exhibit a dynamic, 
undulating growth pattern that is most likely to increase over time (Yehoshua et al. 
2011a). Cube root drusen volume was shown to increase significantly (p=0.006) by 
0.0016mm (SD=0.059) over 12 months. Irrespective of initial drusen volume, 
approximately 50% of people with AMD show a significant increase in drusen volume 
over the 12 month study period i.e. beyond test-retest 95% confidence intervals. Figure 
17 shows an example of the images acquired using the SD-OCT and drusen volume 
analysis algorithm. 
 
Figure 17. Right eye of a 76-year-old woman followed up over 6 months. Drusen changed to 
geographic atrophy over 12 months. Colour fundus photograph with a line representing the 
location of OCT B-Scan (A,F), horizontal B-scan (B,G), RPE segmentation map (C,H), hybrid 
map made of OCT fundus image and drusen thickness map (D,I), and fundus autofluorescence 
(E,J). Images are shown at baseline (A-E) and 6 months (F-J). Drusen volume was 0.45mm3 at 
baseline and 0.016mm3 at 12 months (Yehoshua et al. 2011a).  
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A recent study found that measurements of drusen area from manual segmentation of 
colour fundus images were typically greater than when measured using SD-OCT 
imaging and a fully automated algorithm that detects RPE elevations (Yehoshua et al. 
2013). The difference in these measurements could be due to the fact that because the 
algorithm used by the OCT system detects drusen using a threshold to identify 
significant elevations above the virtual RPE floor and may not detect small, flat drusen 
and subretinal drusenoid deposits. However, previous studies of drusen measurements 
using semi-automated segmentation of OCT images correlate well with subjective 
human grading of fundus images (Jain et al. 2010; Iwama et al. 2012), indicating that 
it is a potentially useful alternative to drusen assessment by human graders using colour 
fundus photography. 
 
An exploratory trial using SD-OCT showed a correlation between choroidal thickness 
and drusen load (volume and area) in patients with dry AMD (Ko et al. 2013). Not 
surprisingly, patients with greater drusen load also tended to have worse visual acuity, 
independent of changes to choroidal thickness. Histological studies have also 
demonstrated that the presence of drusen is associated with underlying diffuse changes 
to Bruch’s membrane (Bressler et al. 1994). This evidence indicates that drusen load or 
volume may reflect underlying structural changes which occur in early AMD, but 
which are not visible on clinical examination. This factor, combined with the evidence 
that drusen volume tends to increase with increasing AMD disease severity, and the 
fact that the measurement of drusen volume using the SD-OCT is repeatable, objective 
and easily quantifiable, suggests that this may be a useful outcome measure for future 
clinical trials of interventions for AMD. Indeed, there is an ongoing clinical trial 
examining the effects of eculizumab on the progression of geographic atrophy and 
drusen volume in dry AMD (Yehoshua et al. 2011b). The Age-Related Eye Disease 
Study 2 is currently conducting an ancillary study to assess the ability of SD-OCT to 
predict the advancement of AMD, using change in drusen volume and area of 
geographic atrophy as primary outcome measures (Yehoshua et al. 2011b). As this 
research is yet to be published, it remains to be seen whether drusen volume will be an 
effective surrogate clinical study end point when investigating new treatments for 
AMD. 
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1.6.2 Dark Adaptation 
The human eye is able to operate over an impressive 10 log unit range of luminance 
levels through a combination of neural, mechanical and photochemical mechanisms. 
The eye is able to rapidly adapt to moderate changes in luminance. However, it takes 
approximately 40 minutes to regain maximal visual sensitivity in the dark after viewing 
a bright or prolonged flash of light, which causes a significant amount of visual pigment 
to be ‘bleached’, that is, broken down into its colourless form which is insensitive to 
light (Lamb & Pugh 2004). This recovery of sensitivity is known as dark adaptation. 
The dark adaptation curve displays the threshold intensity (logarithmically) needed to 
detect a visual stimulus against time after extinction of the adapting light. The classical 
curve, obtained after an almost total bleach, consists of two distinct phases of recovery 
(Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. A typical dark adaptation curve. The shaded area represents 80% of the group of 
subjects. Adapted with permission from Kalloniatis and Luu (2011a). 
 
The first, cone-mediated, phase of recovery shows a rapid reduction in threshold of 
approximately 2.5 log units and is complete in around 8 minutes, depending on the 
percentage of photopigment bleached. The second, rod-mediated, phase is associated 
with a reduction in threshold of over 4 log units. Rod recovery proceeds more slowly 
so that full rod adaptation can take at least 30 minutes (Hecht et al. 1937). The rod-cone 
break (RCB) is the point at which cone sensitivity plateaus and the rod system becomes 
the facilitator of threshold recovery. The recovery of visual sensitivity was previously 
thought to be a 1st order exponential process, but is now thought to follow rate-limited 
Rod-Cone Break 
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kinetics (Lamb and Pugh 2004). Indeed, there is a region of rod recovery following the 
rod-cone break over which the data exhibits linearity for every bleach level between 
0.5% and 98%. This region was termed “component S2” (where “component S1” is 
masked by cone activity) (Lamb 1981). A third and final component of recovery, S3, 
can be seen in most subjects as the threshold declines below 1.5 log units after 
photopigment bleaches greater than 20% (Lamb 1981; Lamb and Pugh 2004). 
 
The shape of the dark adaptation curve is affected by a number of factors, for example, 
the intensity and duration of the adapting light (Haig 1941; Hecht et al. 1937; Mote and 
Riopelle 1951; Wald and Clark 1937; Winsor and Clark 1936) . With increasing levels 
of initial light adaptation, achieved through increasing either the duration or the 
intensity of the adapting light, the cone branch becomes more prominent whilst the rod 
branch is delayed. It also takes longer to reach absolute threshold (Figure 19) (Hecht et 
al. 1937).  If the intensity or duration of the pre-adaptation period is low enough, a 
single rod curve may be acquired. A bi-phasic curve is only seen with a longer duration 
or more intense period of light adaptation (Wald and Clark 1937). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Dark adaptation functions for a normal observer obtained after exposure to five 
different intensities of adapting light (Hecht et al. 1937). 
 
The dark adaptation function is also affected by the location of retina stimulated by the 
test spot, due to the topographical arrangement of rods and cones in the retina.  In the 
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left panel of Figure 20, it is seen that in the central 2o test field, dark adaptation is mainly 
a cone function due to the lack of rods at the fovea. As the stimulus size increases, the 
absolute threshold decreases due to the increased rod density in the peripheral retina, 
reaching a peak at approximately 12o eccentricity (Curcio et al. 1990; Osterberg 1935). 
Figure 20. Dark adaptation thresholds measured with centrally fixated stimuli of different size 
(left panel) and with a 2o stimulus placed at different distances from fixation (right panel) 
(Hecht et al. 1937). 
 
Similarly, as the position of the stimulus moves from the central retina towards the 
periphery, the rod branch becomes more prominent (right panel, Figure 20).  Lastly, the 
wavelength of the test stimulus also influences the shape of the dark adaptation curve. 
Hecht and colleagues (1937) noted that when a long wavelength light stimulus was 
used, such as deep red, the dark adaptation curve only showed the cone branch of the 
dark adaptation function. This is because rods and cones have similar sensitivities to 
longer wavelengths. Conversely, when a short wavelength light is used, to which rods 
have maximal sensitivity, a more prominent rod branch is produced (Hecht et al. 1937). 
1.6.2.1 The Retinoid Cycle 
The molecular process underlying the recovery of visual sensitivity in dark adaptation 
involves resumption of the circulating current in the outer retina and regeneration of 
visual pigment in the photoreceptors (Neelam et al. 2009). To directly and objectively 
investigate the kinetics of visual pigment regeneration in a living human eye, fundus 
reflection densitometry was developed. Using this technique, it was found that the time 
course of threshold reduction during dark adaptation mirrors that of photopigment 
regeneration. It was originally hypothesised that the magnitude of visual threshold 
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recovery was directly proportional to the amount of unbleached photopigment available 
in the retina (Hecht et al. 1937). However, this was later refuted by the work of Granit 
and colleagues in 1938, who found that when only 20% of the pigment was bleached, 
the threshold was elevated by over 1000 fold (Granit et al. 1938). This demonstrates 
that elevated threshold during dark adaptation is not governed by the absence of 
unbleached visual pigment, but rather suggests that it is related to the presence of one 
or more photoproducts from the initial bleach, which actively reduce retinal sensitivity 
(Lamb and Pugh 2004). In order to examine how the recovery of visual sensitivity is 
related to the ‘retinoid cycle’ of photopigment regeneration, it is first necessary to 
consider the anatomy and biochemistry underlying this process. 
 
The series of biochemical reactions that results in the generation of a visual signal 
following the absorption of a photon of light is known as the phototransduction cascade 
(Figure 21). In rods, light isomerizes rhodopsin’s 11-cis retinal chromophore to the all-
trans configuration, and the retinal molecule separates from the opsin component of the 
photopigment (Wald 1968). This activates the G protein transducin, which 
consequently activates the cGMP PDE, causing a reduction in the intracellular 
concentration of cGMP, which causes the closure of cation channels in the 
photoreceptor outer segments and hyperpolarisation of the cell membrane (Burns and 
Baylor 2001). For a detailed description of the process, the reader is referred to reviews 
by Burns and Baylor 2001 and Pugh and Lamb 2000. 
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Figure 
21. The 
G-protein cascade of phototransduction (Lamb and Pugh 2006). 
 
The photopigment molecule is quickly inactivated, and can only receive another photon 
of light when the all-trans retinoid has been re-converted to 11-cis retinal, and 
recombined with opsin (Lamb and Pugh 2004). This is achieved through a sequence of 
biochemical reactions known as the “retinoid cycle” which is outlined below and 
displayed pictographically in Figure 22. For further information, the reader is directed 
to Lamb and Pugh (2004).  
 
Photoisomerization in the photoreceptor outer segment 
1.   11-cis retinal absorbs a photon of light and is isomerised to all-trans retinal, 
initiating the phototransduction cascade. 
2. The all-trans retinal and opsin molecule, now called ‘metarhodopsin’, is converted 
to metarhodopsin II and is ‘bleached’. 
 
Removal of all-trans retinoid from photoreceptor outer segment to RPE 
3.    Hydrolysis of the covalent bond between opsin and all-trans retinal occurs. Some 
of the retinoid remains non-covalently bound so that the opsin may continue to serve 
as a chaperone i.e. a binding protein that protects the retinoid, increase its solubility in 
water and carries it to another location. 
4.   The all-trans retinal that remains bound is then reduced by the enzyme all-trans 
retinol dehydrogenase (RDH) forming Ops-trans ROL. 
5.    This Ops-trans ROL releases all-trans retinol (vitamin A). 
6.   The retinoid released in step 3 moves across the membrane by ABCR and is reduced 
by RDH following hydrolysis in the cytoplasm. 
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7.   The all-trans retinol is chaperoned from the inter-photoreceptor matrix (IPM) to the 
RPE using IRBP. Within the RPE cytoplasm, cellular retinol binding protein (CRBP) 
acts as chaperone molecule. 
Reconversion of 11-cis retinal in the RPE 
8.   In the cytoplasm, the all-trans retinoid is esterified by the enzyme lecithin retinol 
acyl transferase (LRAT). This all-trans retinyl ester is chaperoned by RPE65 protein. 
9.  Isomerisation by the enzyme retinyl ester isomerohydrolase or ‘isomerase’ 
reconfigures the alcohol to 11-cis retinol. 
10.  11-cis retinol dehydrogenase (11-cis RDH) is responsible for the oxidation of 11-
cis retinol to 11-cis retinal, which is then chaperoned by cellular retinaldehyde binding 
protein (CRALBP). 
 
Transfer of 11-cis retinal to photoreceptor outer segment 
11.  The 11-cis retinal, possibly chaperoned by IRBP, travels across the IPM to the 
photoreceptor outer segment by diffusion and traverses the cytoplasmic space to enter 
the disc membrane. 
12.  It then forms a non-covalent bond with opsin at an “entry site” forming opsin-11-
cis retinal (Ops-cis RAL).  
13. A Schiff-base bond naturally occurs and the protein is transformed to produce 
rhodopsin or the cone equivalent. 
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Figure 22. The retinoid cycle of pigment regeneration. The formation and supply of 11-cis 
retinoid is marked by the solid arrows, whereas the removal, conversion and storage of all-
trans-retinoid is depicted by the dashed arrows (Lamb and Pugh 2006). 
 
It is clear from this cycle that the process of photopigment regeneration relies on healthy 
photoreceptor and RPE function, as well as the delivery of metabolites and retinal from 
the choroidal circulation via Bruch’s membrane. 
1.6.2.2 Dark Adaptation and Rhodopsin Regeneration 
It has been known for many decades that the rate of dark adaptation is somehow related 
to the regeneration of visual pigment, but the underlying cellular mechanisms have 
remained unclear. In the 1960s, it was thought that there was a linear relationship 
between the log threshold and the fraction of pigment remaining bleached, i.e. the 
unregenerated rhodopsin (Dowling 1960). This became known as the Dowling-Rushton 
relation, shown in Equation 1 below. However, later analyses found this only to be valid 
for an almost total bleach (Lamb and Pugh 2004; Lamb 1981). 
Equation 1    log (Et/Eα) = α (l - p)    
Et is the intensity of a threshold flash at any moment t in the dark after a bleach, Eα is 
the value of Et found after full dark adaptation, p is the fraction of pigment present, and 
α is a constant (Hollins and Alpern 1973).  
During dark adaptation, there is an adapting effect consisting of elevated threshold and 
improved spatial and temporal resolution which has the same effect as a steady light at 
an intensity known as the ‘equivalent background brightness’, and which gradually 
fades with time (Stiles and Crawford 1932). It has been hypothesised that the bleaching 
photoproduct responsible for the generation of this equivalent background brightness 
is free opsin (Lamb and Pugh 2004). This follows the discovery that opsin weakly 
activates phototransduction (Cornwall and Fain 1994) and when combined with 11-cis 
retinal, opsin’s activity is discontinued (Corson et al. 1990; Pepperberg et al. 1978). 
Lamb and Pugh (2004) gave evidence to support the theory that after a large bleach, 
the recovery of threshold is a rate-limited process, governed by the removal of a product 
of bleaching, which they suggest to be opsin. It is the removal of this substance that 
underlies the regeneration of rhodopsin and recovery of threshold during the second 
phase of rod adaptation. This model, although effective in linking dark adaptation, 
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pigment regeneration and retinoid processing together, needs further research to 
confirm its validity.  
1.6.2.3 Alternative Cone Pathway 
Since cones are working continuously to facilitate our daytime vision, it is necessary 
that their visual pigment is able to regenerate quickly. The retinoid cycle through the 
RPE recycles the chromophore and provides it to both rods and cones. One would 
assume that cones would be at a disadvantage in the rod-dominant human retina since 
they would have to compete with a vast number of rods for the 11-cis retinal available 
in the RPE. However, when comparable levels of rod and cone pigment are bleached, 
cones regain their sensitivity within 5 minutes whereas rods take over 30 minutes to 
reach absolute threshold (Wald and Clark 1937; Hecht et al. 1937). This implies that 
cones regenerate their visual pigment significantly faster than rods, and since the rate 
of photopigment regeneration is limited by the availability of the chromophore to the 
photoreceptors (Lamb and Pugh 2004), it implies that cones are supplied with 
chromophore faster than rods with the possible help of a second, cone-specific pathway 
(Wang and Kefalov 2009; Wang and Kefalov 2011). 
Interest in the probable existence of an alternative visual cycle was elicited by the 
discovery of retinoid derivatives in cone-dominant retinas. Das et al. (1992) found that 
the cone-dominant chicken retina could produce 11-cis retinyl ester, 11-cis retinol and 
all-trans-retinyl ester after incubation with all-trans retinol, suggesting the presence of 
at least three retinal enzymatic processes (Das et al. 1992). These processes were 
identified in chicken and ground squirrel retinas by Mata et al. (2002), thus enabling 
them to propose a model for a cone- specific visual cycle in cone-dominant retinas 
(Mata et al. 2002). The first retinal enzymatic process catalyses all-trans to 11-cis 
retinol through the activity of isomerase II. The second enzyme is retinyl ester synthase 
(RES), which converts retinol to retinyl ester. Finally, the third retinal enzyme is retinol 
dehydrogenase (RDH), which oxidizes 11-cis retinol to 11-cis retinal and would allow 
cones to regenerate pigment without involving the RPE.   
The expression by Müller cells of the protein CRALBP, which specifically binds 11-
cis retinol, implies that these cells may be involved in the chromophore visual cycle 
(Bunt-Milam and Saari 1983; Saari and Bredberg 1987). Indeed, Das et al. (1992) found 
that Müller cells in cone-dominated chicken retina are able to synthesize 11-cis retinol 
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from all-trans retinol. This suggests that Müller cells may be involved in regenerating 
cone visual pigment. Mata et al. (2002) proposed that the chromophore is recycled in 
the Müller cells and released into the cytoplasm to be taken up by the cones for the final 
enzymatic conversion to 11-cis retinal. They concluded that this separate pathway could 
regenerate opsin at a rate 20 times faster than the RPE pathway, which would account 
for the sustained photosensitivity of vertebrate retinas in daylight. 
However, to be of any clinical relevance, this cone-specific pathway must be proven to 
be functional in human retinas. This was examined by taking ERG recordings from the 
fovea of freshly removed human retinas whose photoreceptors were initially bleached 
and then incubated in darkness for 3 hours following enucleation (Wang and Kefalov 
2009). It was indeed found that, after dark adaptation, cones recovered their sensitivity 
whereas rods did not. Furthermore, when Müller cell function was inhibited with 
gliotoxin, recovery of cone threshold was prevented. These results demonstrate that the 
neural retinal visual cycle is indeed present in humans and is essential for maintaining 
cone-mediated daytime vision. 
1.6.2.4 The Effect of Age & Pathology on Dark Adaptation 
A common visual problem reported among older adults is difficulty seeing under low 
light levels, even in the absence ocular pathology (McGregor and Chaparro 2005). It 
has been shown that there is an increase in the scotopic absolute threshold of 
approximately 0.5 log units with age (Jackson et al. 1998). This is partly attributable to 
the increased crystalline lens density and senile miosis in the ageing eye (Sturr et al. 
1997), but also correlates with histopathological studies reporting a 30% reduction in 
the density of rod photoreceptors from age 34 to 90 years (Curcio et al. 1993). However, 
since scotopic sensitivity loss among older adults is seen in peripheral retinal locations 
where there is minimal rod loss and is not worsened in areas of greater rod loss (Jackson 
et al. 1998), it follows that  rod loss alone cannot account for this age-related decline in 
scotopic sensitivity. Furthermore, although rod density decreases with age, the 
remaining rod outer segments are seen to expand to fill any gaps and to maintain the 
rhodopsin coverage (Curcio et al. 1993). Since the concentration of rhodopsin remains 
constant throughout life, it cannot be a contributing factor in the reduced retinal 
sensitivity (Plantner et al. 1988). 
Another possible explanation for symptoms of poor night vision in older adults is that 
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the retinoid cycle responsible for regenerating visual pigment slows with age, resulting 
in a reduced rate of dark adaptation, since a delay in the visual cycle would be 
associated with a delay in threshold recovery during dark adaptation. In 1992, the rate 
of foveal cone dark adaptation was found to decline with age (Coile and Baker 1992). 
This was confirmed by Gaffney, Binns, & Margrain (2012) who found that the time 
constant of cone recovery increased by 16.4s/decade of life (Gaffney et al. 2012). In 
1999, Jackson and colleagues also found significant delays in rod-mediated dark 
adaptation with increasing age, particularly in the second and third components of 
recovery. Indeed, it took 10 minutes longer for 70-year-olds to regain their visual 
sensitivity than for those in their 20s, as seen in Figure 23 below (Jackson et al. 1999). 
These findings are consistent with the delay in rhodopsin regeneration with age found 
using retinal densitometry (Liem et al. 1991). 
 
Figure 23. Dark adaptation as a function of decade. Arrows indicate the portion of the function 
representing the rod-cone break and the second and third components of rod-mediated dark 
adaptation. Note that with increasing decade, the curve shifts to the right, indicating a slowing 
of the rate of dark adaptation with increasing age (Jackson et al. 1999). 
A likely reason for this slowing of visual pigment regeneration is that, with age, a 
progressive accumulation of lipids causes a thickening of Bruch’s membrane 
(Newsome et al. 1987; Pauleikhoff et al. 1990; Bird 1992). This could reduce metabolic 
exchange of vitamin A by creating a diffusion barrier between the photoreceptors and 
the choroid, thus creating an effective retinol deficiency at the outer retina, and hence 
delaying rhodopsin regeneration (Bird 1992). Consistent with this hypothesis, 
psychophysical data show that rod-mediated dark adaptation was faster when older 
adults with normal retinal health received a high-dose (50,000IU) course of oral retinol 
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(preformed vitamin A) for 30 days (Owsley et al. 2006). 
Since vitamin A is necessary for the retinoid cycle to work efficiently, it is not 
surprising that systemic deficiency of vitamin A leads to slowed pigment regeneration 
and dark adaptation (Kemp et al. 1988; Cideciyan et al. 1997). Similar complications 
are found in other diseases that affect the structures involved in the retinoid cycle, for 
example, Sorsby fundus dystrophy (Cideciyan et al. 1997; Jacobson et al. 1995), 
congenital stationary night blindness (Carr 1974), diabetic retinopathy (Greenstein et 
al. 1993; Henson and North 1979) and age-related macular degeneration (Brown and 
Kitchin 1983; Owsley et al. 2000; Owsley et al. 2001; Owsley et al. 2007; Dimitrov et 
al. 2008; Dimitrov et al. 2011; Gaffney et al. 2011). 
1.6.2.5 Dark Adaptation and Age-Related Macular Degeneration  
There is strong agreement in the literature that rod-mediated dark adaptation delays are 
a hallmark of early age-related macular degeneration (AMD) (Brown and Kitchin 1983; 
Owsley et al. 2000; Owsley et al. 2001; Owsley et al. 2007; Dimitrov et al. 2008; 
Dimitrov et al. 2011; Gaffney et al. 2011). The effect of early AMD on cone adaptation 
is a matter of debate, with some studies finding little evidence of delayed recovery after 
a bleach (Owsley et al. 2007) whilst others report a significant delay in cone adaptation 
(Phipps et al. 2003; Dimitrov et al. 2008; Gaffney et al. 2011; Dimitrov et al. 2011; 
Dimitrov et al. 2012; Gaffney et al. 2013). 
Table 2 (Appendix 1) summarises twenty three studies investigating the effect of early 
AMD on dark adaptation. The earlier investigations were mainly concerned with the 
steady-state dark adaptation function, i.e. scotopic (rod-mediated) and photopic (cone-
mediated) sensitivity. Scotopic sensitivity refers to the measurement of retinal 
sensitivity following a period of 30-45 minutes in the dark using a short-wavelength 
stimulus target (approx. 450-555nm). Conversely, photopic sensitivity measures 
sensitivity after a pre-adaptation period of 5-10 minutes to light using a long 
wavelength target (approx. 600-650nm). The kinetic aspect of dark adaptation 
predominates in latter studies, that is, the recovery of retinal sensitivity to its baseline 
level following a bright light that bleaches a significant amount of visual pigment, 
measuring both rod and cone function (Neelam et al. 2009). 
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Of the ten studies that investigated scotopic retinal sensitivity, the vast majority found 
a reduction in sensitivity with early AMD (Brown and Kitchin 1983; Brown et al. 
1986a; Sunness et al. 1988; Steinmetz et al. 1993; Owsley et al. 2001; Owsley et al. 
2000; Haimovici et al. 2002; Scholl et al. 2004), which is consistent with the 
histopathologic observations of rod vulnerability in this condition (Curcio et al. 1996; 
Medeiros and Curcio 2001). Scholl et al. (2004) reported a reduction in scotopic 
sensitivity even in eyes with drusen only. Sunness et al. (1988), found no difference in 
the scotopic sensitivity of areas overlying drusen compared with non-drusen areas, 
regardless of the size of drusen, which ranged from 120 to 340μm. This suggests that 
the sensitivity loss in early AMD is not co-localised to the position of the drusen, 
perhaps suggesting that it is not the presence of drusen per se which causes the elevation 
of threshold, but rather that the drusen are markers of underlying diffuse changes 
affecting sensitivity, which are not visible ophthalmoscopically. Sunness et al did, 
however, find marked sensitivity loss in areas of advanced AMD such as RPE atrophy. 
Haimovici et al. (2002) found that scotopic sensitivities in their cohort of 31 participants 
with early AMD were generally good, which in this case may have been because the 
patients were not selected on the basis of being symptomatic of night vision problems, 
unlike previous studies. They did, however, find the kinetics of dark adaptation to be 
dysfunctional in patients from all categories of early AMD. The fact that scotopic 
sensitivity and dark adaptation are not correlated with each other here suggests that the 
mechanisms underlying these functions are different. It is, therefore, possible that a 
person with normal scotopic sensitivity may have abnormal dark adaptation kinetics. 
Similarly, Owsley et al. (2001) found that out of their 20 early AMD patients, 85% had 
abnormal rod-mediated dark adaptation, whereas only 25% had reduced scotopic 
sensitivity. This implies that dark adaptation is better at detecting early functional 
deficits in AMD. 
 
Indeed, fifteen studies investigating the kinetics of dark adaptation have found 
significant abnormalities in early AMD.  A limitation of the earlier studies is that they 
did not classify early AMD using a standardised fundus grading system, therefore the 
subtype or severity or AMD investigated is unknown (Brown et al. 1986b). 
Furthermore, they tend to have smaller sample sizes, which weaken their diagnostic 
power (Brown et al. 1986a; Steinmetz et al. 1993). Despite these and other 
methodological differences in the literature, the general trend shows dark adaptation to 
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be consistently delayed in AMD. Owsley et al. (2001) measured rod dark adaptation in 
20 participants with early AMD. After determining pre-bleach sensitivity following 30 
minutes in the dark, subjects were exposed to a 0.25ms adapting light that bleached 
98% of photopigment. Recovery was then examined using a 500nm target at 12o 
inferior eccentricity. Figure 24 displays the dark adaptation plots for three people with 
AMD plotted alongside an age-matched control. 
 
  
 
 
 
 
 
Figure 24. The dark adaptation functions measured in three people with AMD and one older 
healthy adult. All participants had at least 6/7.5 visual acuity (Owsley et al. 2001). 
 
The rod-cone break was significantly delayed by approximately 10 minutes in AMD, a 
finding which has been substantiated by further studies (Owsley et al. 2007; Dimitrov 
et al. 2008; Jackson and Edwards 2008). The AMD group also had a slower recovery 
during the second component of dark adaptation than the control group. This 
prolongation of the time constant of rod-mediated dark adaptation demonstrates that 
AMD impairs the recovery of sensitivity in the visual cycle. In contrast to this, Jackson 
et al. (2006) did not find abnormalities in dark adaptation in 19 people with early AMD 
compared with elderly controls using the Scotopic Sensitivity Tester-1 (SST-1, LKC 
Technologies, Gaithersburg, MD, USA). The same group later designed a novel 
instrument to measure dark adaptation using a 4o foveal stimulus (AdaptDx, Apeliotus 
Technologies, Atlanta, GA). The “rod intercept”, i.e. the time taken for sensitivity to 
recover to a stimulus with a 4 log unit intensity, was measured since it reflected rod 
function only and took just 20 minutes to attain. Using this device, dark adaptation was 
substantially slower in early AMD compared with old and young controls, and the delay 
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increased with disease severity, which shows its potential to be used as a clinical 
outcome measure (Jackson and Edwards 2008). More recently, Jackson et al. found that 
a reduced testing time of up to 6.5 minutes using the AdaptDx had a diagnostic 
sensitivity of 90.6% (P<0.001) and a specificity of 90.5% (P<0.027) in a cohort of 127 
AMD patients and 21 normal adults (Jackson et al. 2014). The clear discrepancy in 
findings between AdaptDx and SST-1 is likely to be due to the fact that the latter uses 
a full-field test stimulus, which elicits a response from the entire retina. In people with 
AMD, the sensitivity of the healthy peripheral retina would be likely to mask any small 
functional deficits at the macula, and thus a full-field stimulus is unlikely to be sensitive 
to early disease.  
There is also evidence that delayed dark adaptation may predict the development of 
advanced AMD. In a small, 45-month prospective study of 18 patients by Sunness et 
al. (1989), foveal dark-adapted sensitivity predicted the development of advanced 
AMD in eyes with drusen with 100% sensitivity and 92% specificity. Haimovici et al. 
(2002) postulated that the fellow eye of patients with a RPE detachment would have 
significantly slower dark adaptation than the fellow eye of patients with CNV or drusen 
only. This hypothesis was based on the pathogenesis of retinal pigment epithelial 
detachment, and the increased risk of RPE detachment in the second eye of individuals 
with a unilateral detachment. The deposition of lipids in Bruch’s membrane causes it 
to become hydrophobic. This reduces its hydraulic conductivity, causing retinal fluid 
to accumulate in the sub-RPE space, causing RPE detachment, and increasing the time 
taken for the photopigment to regenerate (Bird 1992). Hydraulic conductivity is thought 
to be more reduced in eyes at risk of RPE detachment than CNV (Bird 1992; 
Pauleikhoff et al. 1999). Haimovici et al. did find evidence that dark adaptation was 
more delayed in the fellow eyes of eyes with RPE detachments, although the differences 
between the groups did not reach statistical significance due to the limited sample size. 
Until recently, histopathologic studies on human donor retinas with early AMD have 
only found rod photoreceptors to be affected in early stages of the disease (Curcio et al. 
1996). Consistent with this evidence, Owsley et al. (2007) found disturbances in rod- 
but not cone- mediated dark adaptation in the parafovea (12o eccentricity). They 
suggested that cones were unaffected due to the alternative source of retinol from the 
Müller cells, which allows cone photopigment to regenerate more rapidly than rods (see 
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section 1.6.2.3). However, in contrast to this, Dimitrov et al. (2008) found abnormal 
cone recovery dynamics in early AMD, using a 4 degree diameter foveally presented 
spot stimulus. Furthermore, Gaffney et al. (2011) found the time constant of cone 
recovery to be significantly impaired in early AMD compared with control subjects, 
when assessed using an annular target with a radius of 12o. A possible reason for this 
conflicting evidence is the bleaching method used in the different studies, i.e. the latter 
study used a steady-state bleach lasting 2 minutes whereas Owsley et al. used an 11-
millisecond photoflash. Steady-state bleaches involve prolonged metabolic activity, 
which could interfere with the Müller cell pathway causing cones to be more dependent 
on the 11-cis-retinal derived from the RPE, the structure that is damaged in early AMD 
(Gaffney et al. 2011). Therefore, a steady-state bleach could reveal impairments in 
cone-mediated dark adaptation that would be otherwise masked. It is also possible that 
the different stimulus sizes used to monitor threshold recovery could contribute to the 
discrepancy in results. The smaller the stimulus, the greater the variability in the data, 
since it will be more affected by focal retinal abnormalities (Gaffney et al. 2011).  
Indeed, Owsley et al. (2007), who used a small spot stimulus, found large standard 
deviations in their intermediate AMD cohort whereas Dimitrov et al. (2008), who used 
a larger spot stimulus, reported little variability in their data. Further studies by 
Dimitrov and colleagues (Dimitrov et al. 2011; Dimitrov et al. 2012) have confirmed 
that cone adaptation is just as diagnostic in early AMD as rod-mediated dark adaptation. 
This may be explained by the fact that rod and cone dark adaptation are both, ultimately, 
reliant upon the supply of retinal and metabolites from the choroidal circulation via 
Bruch’s membrane and the RPE. Therefore, rod and cone adaptational defects may both 
reflect the same pathological changes to underlying structures. 
In conclusion, patients with early AMD exhibit significant abnormalities in both 
scotopic sensitivity and the kinetic aspects of dark adaptation. However, the latter 
appears to be more sensitive in detecting functional impairments in early AMD and 
since it takes less time to perform, it is more clinically applicable. Both rod- and cone- 
mediated dark adaptation have been found to be diagnostic of early AMD. For this 
reason, dark adaptation has the potential to provide a functional measure of disease 
progression for monitoring the efficacy of potential new therapies in clinical trials. 
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1.6.3 Photostress Recovery Test (PSRT) 
The photostress recovery test (PSRT), also known as glare or macular recovery, is a 
simple technique that assesses the dynamic response of the retina after exposure to an 
intense light, and measures the time taken for visual acuity or contrast sensitivity to 
recover to a pre-determined level (Margrain and Thomson 2002). It can be used to 
distinguish between macular disease and optic neuropathy when the retinal appearance 
is equivocal (Glaser et al. 1977). The reduction in sensitivity after intense illumination 
is primarily attributed to photopigment depletion and the rate of recovery is dependent 
upon the rate of photopigment regeneration (Margrain and Thomson 2002). Severin et 
al. (1963) postulated that a higher degree of macular function is required for the 
recovery of visual acuity than for contrast discrimination, since some patients with 
macular disease demonstrated prolonged visual acuity with normal contrast sensitivity 
(Severin et al. 1963).  
 
The PST is an objective technique that takes very little time to perform and can be 
easily implemented in optometric practice. Why, then, is it seldom used? It must be due 
to the lack of standardised methodology and the wide variability in the observed 
recovery time (Neelam et al. 2009). Several studies have investigated the effect of age 
on PSRT on normal patients; however, the results are equivocal. Sandberg et al. (1995) 
found that recovery time increased by 0.19 log seconds per decade, whereas other 
investigators failed to find any effect of ageing on PSRT (Wu et al. 1990; Glaser et al. 
1977). This inconsistency is mostly attributed to the lack of standardisation in test 
protocol. Wood et al (2011) showed that the reliability and repeatability of the ERG 
PST was improved by using an equilibrium bleach compared to a photoflash. Using 
this bleaching method, the time constant of recovery increased with age at a rate of 27 
seconds per decade (Wood et al. 2011). 
 
The Eger Macular Stressometer (EMS; Gulden Ophthalmics, USA) was developed in 
attempt to resolve these problems, and three published studies have examined its 
clinical validity in the assessment of macular disease (see Table 3 in Appendix I for a 
summary of studies investigating the PSRT in AMD). A pilot study using this device 
found no difference in EMS recovery time between patients with AMD (n=30) and 
those with cataract (n=30), diabetic retinopathy (n=16) or glaucoma (n=16) (Schmitt et 
al. 2003). However, Bartlett and colleagues found that patients with both early (n=17) 
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and advanced (n=12) AMD had significantly longer photostress recovery times with 
the EMS compared with age-matched controls. EMS sensitivity was moderate at 29% 
for early and 50% for advanced AMD, and readings were repeatable to within 7 seconds 
(Bartlett et al. 2004). Wolffsohn and colleagues found a much larger coefficient of 
repeatability (10.2 seconds) in their prospective study of 156 AMD patients (Wolffsohn 
et al. 2006). Furthermore, it was not predictive of those patients whose vision decreased 
over the following year. They concluded that the EMS with its short photoflash did not 
sufficiently bleach photopigment and hence was unable to identify people with AMD 
or to indicate risk of disease progression. Indeed, flash devices require accurate patient 
fixation and lack of blinking. Exposing the eye to light from a direct ophthalmoscope 
for 30 seconds has been suggested to be more reliable, since more visual pigment is 
bleached and pupil size effects are minimized (Margrain and Thomson 2002). 
Furthermore, a prolonged exposure to a high intensity light will result in an equilibrium 
being obtained between photopigment bleached and photopigment recovery, such that 
small losses in fixation or blinks are unlikely to have a substantial impact on the final 
level of pigment bleach obtained (Hollins and Alpern 1973). 
 
The Macular Automated Photostress (MAP) test uses the Humphrey Field Analyser to 
evaluate foveal sensitivity before and after a photostress stimulus lasting 5 seconds 
(Dhalla and Fantin 2005). In a pilot study, foveal sensitivity after the macular 
photostress and recovery time to baseline sensitivity were significantly delayed in 15 
people with AMD compared with 55 controls of varying age. Furthermore, recovery 
rate was delayed with increasing disease severity (Dhalla et al. 2007). Given that there 
is currently no published data on the repeatability of this device, its clinical applicability 
in detecting and monitoring AMD remains to be seen. 
 
Despite the variability in methodology, the majority of studies investigating PSRT in 
patients with AMD have found a delayed recovery time compared with controls 
(Chilaris 1962; Severin et al. 1963; Forsius et al. 1964; Glaser et al. 1977; Smiddy and 
Fine 1984; Wu et al. 1990; Collins and Brown 1989; Cheng and Vingrys 1993; Remulla 
et al. 1995; Sandberg et al. 1998; Midena et al. 1997; Bartlett et al. 2004; Binns and 
Margrain 2007; Dhalla et al. 2007; Sandberg and Gaudio 1995). Indeed, Collins and 
Brown (1989) found significant delays in recovery time in people with early AMD and 
good visual acuity. The only two studies that failed to detect a significant difference 
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were likely due to the limitations of the EMS apparatus, as described above (Schmitt et 
al. 2003; Wolffsohn et al. 2006). There is, however, conflicting evidence regarding the 
correlation between PSRT and disease severity. Midena and colleagues (1997) found 
macular recovery function to be the most sensitive test in documenting the progression 
of AMD, due to the significant increase in PSRT with increasing drusen confluence, 
focal hyperpigmentation and geographic atrophy. Cheng and Vingrys (1993) also found 
a correlation between PSRT and pigmentary changes but, contrary to the previous 
study, they failed to detect any association between drusen confluence and PSRT. 
Smiddy and Fine (1984), in a prospective study (4.3 years) of 71 patients with bilateral 
drusen, found no relationship between PSRT and disease severity. 
 
Sandberg et al. (1998) also conducted a prospective study evaluating the predictive 
value of PSRT in AMD. One hundred and twenty-seven patients with unilateral nAMD 
were observed for up to 4.5 years. PSRT was measured by recovery of VA in the fellow 
eye with early AMD (VA 20/20 to 20/60) following a 10 second exposure to a bleaching 
light. The risk of CNV development was found to increase by a factor of 30% for each 
additional minute of recovery time. Figure 25 demonstrates how the PSRT may be used 
to predict neovascularisation in the fellow eyes of patients with unilateral AMD.  
 
 
 
 
 
 
 
 
 
 
Figure 25. Cumulative proportion of at-risk patients who developed nAMD in their study eye 
statified by baseline PSRT. The number of patients at baseline were 88 in the group with a 
PSRT 200 seconds or less and 39 in the group with PSRT more than 200 seconds (Sandberg et 
al. 1998). 
In conclusion, patients with early AMD clearly demonstrate a delay in PSRT compared 
with healthy controls. Whilst PSRT effectively reflects the kinetics of photopigment 
regeneration, as does the assessment of cone dark adaptation, the advantage of the 
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former is that it may be assessed rapidly in the clinic using basic equipment such as an 
ophthalmoscope and visual acuity chart. In addition, the recovery time may have the 
potential to predict those eyes at high risk of developing nAMD. However, a repeatable, 
standardised technique still needs to be developed in order for photostress recovery to 
be implemented in a clinical setting. 
 
1.6.4 Colour Vision 
Colour vision is another aspect of visual function that can be altered in AMD. The term 
colour vision describes the ability to distinguish objects on the basis of the wavelengths 
of light they emit. An individual will perceive a colour as a result of the photoreceptor 
reactions to the wavelength distribution and spatial variables (Neelam et al. 2009). 
There are three classes of cone photopigment: long-wavelength sensitive (L-cones), 
middle-wavelength sensitive (M-cones) and short-wavelength sensitive (S- cones). 
Figure 26 shows how these three have different spectral sensitivities; yet they overlap 
in some parts of the spectrum. L&M cones predominate in the fovea, whereas S cones, 
which make up 8-10% of total cone density, are relatively sparse at the fovea, peaking 
in concentration at the foveal slope (Williams et al. 1981; Neelam et al. 2009) 
 
 
 
 
 
 
 
 
 
Figure 26. The absorption 
spectra of S-, M- and L-cones (Kalloniatis and Luu, 2011b). 
 
A colour vision defect may be either congenital or acquired. The latter can be caused 
by a defect in any part of the chromatic pathway from the photoreceptors to the visual 
cortex. Changes to the optical media are also known to impair colour vision. One of the 
earliest changes to the visual system in degenerative retinal conditions, such as AMD, 
is a disruption of normal colour vision (Pokorny and Birch 1979). Certainly, a person 
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with macular disease can present with chromatic defects even when their visual acuity 
is normal (Bowman 1980; Applegate et al. 1987; Collins 1986). Table 4 (Appendix 1) 
summarises the main studies investigating colour vision defects in AMD. In 1912, 
Köllner postulated that blue-yellow defects are most prevalent in macular disease. This 
rule has since been corroborated by numerous studies (Collins 1986; Applegate et al. 
1987; Cheng and Vingrys 1993; Holz et al. 1995; Arden and Wolf 2004). Red-green 
discrimination is thought to be more affected in the later stages of the disease (O’Neill-
Biba et al. 2010).  A number of techniques have been developed to assess these 
impairments in chromatic sensitivity, for example, surface colour methods (colour 
arrangement tests), colour matching and colour contrast sensitivity.  
 
1.6.4.1 Colour Arrangement Tests 
Surface colour tests have been the most commonly used techniques in both research 
and clinical environments to assess acquired chromatic loss. The Farnsworth-Munsell 
(FM) 100 hue test is often preferred for research purposes as it provides quantitative 
information regarding colour discrimination. However, in clinical practice, the Panel 
D-15 test is more often used because it takes less time and is simpler to perform. Note 
that it is necessary for these tests to be carried out under standard illumination levels 
(Commission Internationale de l’Eclairage, Standard Illuminant C) to provide accurate 
results (Neelam et al. 2009). 
 
The FM-100 hue test was used in early studies to determine the relationship between 
colour vision and AMD. These studies showed an increase in tritan-like thresholds in 
the early stages of the disease (Bowman 1980; Applegate et al. 1987). Furthermore, 
colour vision was found to deteriorate with decreasing luminance to a greater extent in 
patients with AMD than in elderly controls (Bowman 1978; Bowman 1980). Applegate 
et al. (1987) tested the colour vision of 3 people with early AMD every 3-4 months for 
2 years using the FM-100 hue and D-15 tests. Despite the modest sample size, it was 
found that tritan-like defects increased over time, particularly in one patient who 
developed a small, exudative PED. An increase in red-green sensitivity loss was also 
found in this patient at this stage. In contrast to the previous reports, Midena et al. 
(1997) failed to detect impairments in the chromatic sensitivity of 47 patients with early 
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AMD using the FM-100 hue test. They postulated that this was because the colour 
vision impairments in early AMD are too subtle to be detected by commercially 
available tests, such as the FM-100 hue. Atchison and Lovie-Kitchin (1990) also failed 
to observe a difference in chromatic discrimination between 15 early AMD subjects 
and 15 age-matched controls using the desaturated D-15. However, this was probably 
due to the fact that the early AMD cohort only had hard drusen and early pigmentary 
changes, which is a description of normal ageing changes rather than AMD.  
 
Using the desaturated D-15 test, Collins (1986) found significant blue-yellow 
sensitivity losses in patients with normal visual acuity (6/6 or better) and pigmentary 
disturbances at the macula, compared with 11 age-matched controls. This implies that 
the desaturated D-15 test is more sensitive in detecting early functional defects than 
visual acuity. Unfortunately it is limited by a low specificity and has proved difficult 
for elderly patients to perform, hence producing many false positives (Cheng and 
Vingrys 1993). Additionally, a prospective 1-year study of 13 patients with early AMD 
found no significant change in the desaturated D-15 score over time (Feigl et al. 2004). 
This suggests that either chromatic sensitivity did not significantly deteriorate during 
this period, or that the test was simply unable to detect the deterioration. However, the 
study was limited by its small sample size, thus may not have been powered to detect 
significant changes in one year.   Further longitudinal analysis using different tests is 
needed to determine the validity of using colour vision surface tests as a predictive 
biomarker for AMD.  
1.6.4.2 Colour Matching 
The trichromacy of normal human colour vision enables all colours to be matched by a 
mixture of three colours. This is the principle behind the anomaloscope, the gold 
standard method of distinguishing protan from deutan deficiencies. The observer is 
required to colour-match one half of a circular field illuminated with yellow with a 
mixture of red and green in the other half. Eisner and colleagues examined the 
predictive value of this technique and the D-15 test in their prospective study of 47 
participants with unilateral nAMD who were followed for at least 18 months (Eisner et 
al. 1992). The D-15 test at baseline was moderately sensitive at predicting those 
subjects who would progress to nAMD, with 8 out of 11 failing the D-15 at baseline. 
However, as described above, it was neither specific nor independent of age. The 
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colour-match area, i.e. the difference in the amount of red and green required to match 
a smaller and larger subfield and thought to be an indicator of the quantum catching 
ability of foveal cones (Smith et al. 1988), was in the best predictor of disease 
progression when combined with dark adaptation time constant. The effectiveness of 
this combination was equal to the most effective funduscopic risk indicators. This may 
be due to the reduced quantal absorption capacity in some eyes with a neovascular 
outcome, resulting in a spuriously normal DA result, but an abnormal colour-match 
area. 
1.6.4.3 Colour Contrast Sensitivity 
The chromatic sensitivity of a normal trichromat can be displayed using a sequence of 
ellipses on the 1931 CIE chromaticity diagram. Isochromatic zones represent the 
corresponding results for dichromats (Birch et al. 1992). Provided that no luminance 
difference can be detected, colours within ellipses or isochromatic zones appear the 
same. It is essential for colour matching tests to achieve isoluminance by removing 
luminance contrast. Colour contrast sensitivity (CS) tests employ isoluminant stimuli 
which allow separation of a chromatic defect along the colour confusion lines (protan, 
deutan and tritan) from luminance contrast differences (Holz et al. 1995).  
 
Holz et al. (1995) used a computer graphics technique developed by Arden et al. (1988) 
to evaluate colour contrast sensitivity in 84 patients with early AMD compared with 
age-matched controls over a 2 year follow-up period. At baseline, the mean foveal tritan 
threshold was elevated to 26% whereas the parafoveal tritan threshold was within 
normal limits. However, the parafoveal tritan threshold did not change significantly 
over time, whereas the foveal tritan threshold did. The colour contrast sensitivity for 
green and red did not show any significant change at either location. This implies that 
YB colour contrast sensitivity may serve as a measure of assessing progression of AMD 
over time, prior to visual acuity loss. In addition, the eight patients who developed 
nAMD or GA during the study had significantly higher tritan thresholds at baseline 
than those who did not progress to advanced AMD, which suggests that an increased 
tritan threshold may allow the identification of patients at higher risk of progression. 
This theory was substantiated by Frennesson et al. (1995) in their study of 27 patients 
with soft drusen, in which a correlation was found between tritan threshold and 
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fluorescein angiography. In 2004, Arden and Wolf measured colour contrast thresholds 
along tritan and protan confusion axes for two sizes of optotypes (6.5o and 1.5o). Every 
one of the 24 patients with AMD had tritan test results for the 1.5o optotype greater than 
2 standard deviations above the normal mean, and tritan abnormalities were even 
identified in the unaffected eyes of people with unilateral AMD (Arden and Wolf 2004).  
 
A new computer-based technology has recently been developed for the assessment of 
colour vision by the Civil Aviation Authority.  The Colour Assessment and Diagnosis 
(CAD) test employs the statistical limits of colour discrimination in normal trichromats 
and is thought to be able to detect, classify and monitor both small and large colour 
deficiencies (Barbur and Rodriguez-Carmona 2006). The CAD test is able to isolate 
red-green (RG) and yellow-blue (YB) thresholds by using dynamic luminance contrast 
noise to mask any luminance contrast cues that may be present in the test stimulus 
(Birch et al. 1992). A four-alternative, forced-choice technique is used to measure the 
patient’s chromatic thresholds along 16 different directions in colour space, ensuring 
that the patient is relying entirely on the use of colour signals to discriminate the 
direction of motion of the colour-defined stimulus (Barbur et al. 2009a). The thresholds 
of 238 normal trichromats and 250 colour deficient observers have been measured to 
provide the statistical limits for the standard normal (SN) observer on the CAD test 
(Barbur and Rodriguez-Carmona 2006). Figure 27 shows the CAD test template for the 
SN observer. 
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Figure 27. Data showing the 97.5 and 2.5% statistical limits that define the “standard” normal 
CAD test observer (in grey). The dotted, black ellipse is based on the median RG and YB 
thresholds measured in 250 observers. The deuteranopic, protanopic and tritanopic confusion 
bands are displayed in gree, red and blue, respectively. The background chromaticity (x,y) is 
indicated by the black cross (0.305, 0.323). The coloured symbols show data measured for a 
typical normal trichromat. (Barbur and Rodriguez-Carmona 2006). 
 
In 2010, O’Neill-Biba et al. examined the loss of chromatic sensitivity in both eyes of 
18 patients with varying severity of AMD severity using the CAD test (O’Neill-Biba et 
al. 2010). All subjects with AMD displayed abnormal YB and RG thresholds. The 
greatest loss was recorded in YB thresholds, and was seen to increase linearly with 
disease severity. This once again suggests that YB loss is a good indicator of disease 
progression. Interestingly, the fellow normal eye of one patient with unilateral nAMD 
showed the greatest YB loss in the clinically normal eye. It would therefore be of value 
to see if this finding extends to other patients with unilateral nAMD, and to determine 
whether YB CAD thresholds can be used to determine the eyes at risk of progression. 
The authors postulated that the greater YB than RG loss found may be due to the 
relative fragility and scarcity of S-cones, which would therefore have a larger effect on 
YB sensitivity (Nork 2000). The loss may also be due to receptoral or post-receptoral 
damage (O’Neill-Biba et al. 2010), or a selective susceptibility of the S-cone pathway 
to hypoxic damage (Hood et al. 1984). Evidently, the structural cause behind this 
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functional abnormality remains to be seen. However, it is clear that the YB chromatic 
deficiencies found in early AMD have the potential to be used as biomarkers for disease 
progression, and further longitudinal studies are necessary to substantiate this 
possibility.  
1.6.5 Temporal Sensitivity 
Temporal sensitivity describes the ability of the eye to respond to a flickering light. It 
has been suggested that temporally modulated stimuli may be used to detect functional 
deficiencies of the retina earlier than static stimuli due to the increased metabolic 
demand elicited by the task (Phipps et al. 2004; Kiryu et al. 1995). The human eye is 
able to resolve flickering stimuli up to 60-80 Hertz (Hz) (Brown and Kitchin 1987b). 
However, above 10-20 Hz, visual sensitivity is reduced due to the numerous neural 
filtering stages, distributed across retinal and cortical loci, that are involved in the 
processing of high temporal frequencies (Shady et al. 2004). The magnocellular and 
parvocellular visual pathways are thought to be sensitive to higher and lower temporal 
frequencies, respectively (Seiple et al. 2001). 
 
The two types of stimuli used in assessment of temporal sensitivity are mean-modulated 
flicker (Figure 28, top panel) and luminance-pedestal flicker (Figure 28, bottom panel). 
The former modulates luminance about a mean background level and so does not alter 
the time-averaged luminance (Mayer et al. 1992b). The latter modulates a luminance 
increment, which results in a flickering component and increases the time-averaged 
luminance above the background level (Phipps et al. 2004). Flicker can also be 
modulated according to different temporal luminance profiles, for example, square-
wave, sinusoidal and saw tooth. The opponent (chromatic) and non-opponent 
(luminance) systems mediate flicker detection for low and high alteration rates, 
respectively (Mayer et al. 1994). 
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Figure 28.  Diagram illustrating the 
differences between mean-modulated 
flicker and luminance-pedestal flicker. L: luminance; B: background luminance (Anderson and 
Vingrys 2000). 
 
A number of studies (Table 5, Appendix I) have established a loss of temporal 
sensitivity in patients with AMD (Mayer et al. 1992a; Mayer et al. 1992b; Mayer et al. 
1994; Phipps et al. 2004; Dimitrov et al. 2011; Luu et al. 2013), which is greater than 
the generalised loss of flicker sensitivity that occurs in normal ageing (Kim and Mayer 
1994).  
1.6.5.1 Critical Flicker Frequency 
The critical flicker frequency (CFF) is the highest rate of flicker that can be detected at 
a given modulation depth, and is the temporal analogue of spatial visual acuity 
resolution. Since it only measures one part of the temporal contrast sensitivity function, 
it provides less information regarding the eye’s temporal sensitivity (Alexander and 
Fishman 1984). Brown and Lovie-Kitchin demonstrated a significant reduction in CFF 
in patients with early AMD compared with age-matched controls (Brown and Lovie-
Kitchin 1987b). Furthermore, unlike in healthy contral eyes, they found no variation in 
CFF with increasing retinal eccentricity in patients with AMD, indicating that temporal 
function does not vary across the retina. These authors later found that temporal 
summation was unaffected in AMD, and concluded that the mechanisms that mediate 
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temporal summation are more resistant than temporal discrimination to the structural 
damage which occurs in AMD (Brown and Lovie-Kitchin 1989). 
1.6.5.2 Temporal Contrast Sensitivity 
The temporal contrast sensitivity (TCS) function, as depicted in Figure 29, is a measure 
of how temporal contrast sensitivity varies with the temporal frequency of a sinusoidal 
flickering stimulus (Neelam et al. 2009). The eye is most sensitive to flicker of 15 to 
20Hz at high luminances, i.e. photopic vision. Temporal sensitivity decreases 
gradually, and peak sensitivity and the high frequency cut-off shift towards lower 
temporal frequencies, as luminance is reduced.  
Brown and Lovie-Kitchin investigated TCS in people with early AMD compared with 
age-matched controls across a wide range of temporal frequencies, and found that AMD 
causes the greatest reduction in sensitivity at low and medium temporal frequencies 
(Brown and Lovie-Kitchin 1987b). It is debatable as to whether temporal sensitivity 
loss in AMD is caused by photoreceptoral or post-receptoral damage (Hogg and 
Chakravarthy 2006). An investigation of two-colour increment thresholds and flicker 
contrast thresholds in patients with AMD and healthy controls revealed that the ability 
to detect 25Hz flicker was significantly reduced in AMD, despite having normal L-
cone increment thresholds (Haegerstrom-Portnoy and Brown 1989). This was 
substantiated by Applegate et al, who detected a 0.5 log unit reduction in flicker 
sensitivity in patients with early AMD with normal L-M cone sensitivities (Applegate 
et al. 1987). If temporal sensitivity loss occurred at the level of the photoreceptors, there 
would have been a greater L-M cone deficiency. This led both groups to propose that a 
post-receptoral channel involved in flicker detection may be affected in AMD. 
 
Visual stimulation by a flickering stimulus increases the metabolic demand of the inner 
retina (Falsini et al. 2002), leading to increased optic nerve blood flow (Garhöfer et al. 
2004) and chorioretinal vascular oxygen tension (Shakoor et al. 2006) in addition to a 
compensatory retinal vasodilation (Formaz et al. 1997). In patients with AMD, these 
structural mechanisms may be impeded so that further compensation cannot occur, 
allowing clinical detection of the resulting functional impairments (Feigl et al. 2007a).  
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Figure 29. Temporal Contrast Sensitivity Function for spatial frequencies of 0 (a) and 3 (b) 
cycles/deg, and different adaptation levels of 1.67 (squares), 16.7 (diamonds), 167 (triangles) 
and 1670 td (circles)  (Kelly 1972). 
 
Mayer and colleagues investigated temporal contrast sensitivity in the fellow eyes of 
patients with unilateral nAMD. They, too, found the greatest reduction in foveal flicker 
sensitivity at mid-temporal frequencies in patients with AMD (Mayer et al. 1992b). 
Using step-wise discriminant analysis, they also found that healthy eyes could be 
distinguished from those at risk of developing nAMD with a 78% accuracy using 10 or 
14Hz flickering stimuli (Mayer et al. 1992a). In a longitudinal follow-up study, they 
found that flicker modulation sensitivity (5 and 10Hz) at baseline was able to 
discriminate a pre-exudative eye from a healthy eye with 100% accuracy (Mayer et al. 
1994). However, since this was a post-hoc analysis, it should be interpreted with 
caution. 
 
Similarly, Dimitrov et al. (2011) found that 4 and 14Hz flicker thresholds had a 
moderate ability to detect abnormal cases of AMD, and were able to diagnose AMD 
with a ROC analysis AUC of 0.82 (±0.023) and 0.84 (±0.021) respectively. Flicker is 
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an ideal test to monitor functional changes in early AMD, as it is fast, reproducible, 
user-friendly and highly diagnostic. For this reason, Dimitrov and colleagues rated 14 
Hz flicker highest amongst a battery of other functional tests as the most potentially 
useful clinical tool in the diagnosis and monitoring of AMD (Dimitrov et al. 2011). In 
a further study of 357 participants (64 controls and 293 AMD patients classified into 
12 subgroups according to disease severity), the same group found that 14Hz flicker 
declined gradually along the entire hierarchy of retinal changes (Dimitrov et al. 2012). 
This supports the claim that flicker may be an effective tool for following AMD 
progression and assessing the efficacy of therapeutic interventions. However, more 
prospective studies need to be carried out in order to substantiate these findings. 
1.6.6 Spatial Contrast Sensitivity 
Spatial contrast threshold describes the smallest detectable difference in luminance 
between two components of a scene, as a proportion of the mean or background light 
level. The clinically measured contrast sensitivity (CS) is the reciprocal of this 
threshold. Figure 30 depicts the contrast sensitivity function (CSF) for different age 
groups, which is determined by measuring the spatial contrast threshold for the 
detection of sinusoidal gratings over a range of spatial frequencies. The curve follows 
a band-pass function, peaking at mid-spatial frequencies (2-6 cycles/degree) with a 
gradual roll-off at lower and a steeper cut-off at higher spatial frequencies (Campbell 
and Green 1965). Visual acuity represents the maximum spatial frequency that can be 
detected at 100% contrast. The main factors limiting the CSF include optical changes 
such as diffraction and aberrations, and neural changes such as spatial summation 
(Owsley et al. 1983; Owsley 2003).  
 
Since CS is mediated by lateral inhibitory mechanisms from retinal horizontal and 
amacrine cells, it may be more sensitive to local retinal pathology than other functional 
techniques (Hogg and Chakravarthy 2006). Furthermore, the assessment of contrast 
sensitivity may be a better indicator of an individual’s visual abilities in daily life 
compared with the traditional high-contrast visual acuity measurement. Indeed, a two-
fold decline in CS is associated with a three- to fivefold increased chance of reporting 
difficulty with daily tasks (Rubin et al. 2001). 
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Figure 30. 
Photopic contrast sensitivity function for different age groups (Owsley et al. 1983). 
 
The most common method used to measure CS in clinical research is to use sinusoidal 
gratings of varying contrast, presented on a computer monitor. However, despite their 
ability to measure CS over a wide range of spatial frequencies, the task is time-
consuming and therefore unsuitable for use in clinical practice. A viable alternative is 
to use letter-optotype charts, for example, the Pelli-Robson chart. The advantages of 
this chart are that patients are more familiar with the task, it is inexpensive, abnormal 
results can be compared with normative data (Elliott et al. 1990) and it is a reliable 
indicator of reading performance (Whittaker and Lovie-Kitchin 1993).  However, 
threshold is assessed for one letter size only, so limited spatial frequency data are 
obtained.  
 
It is well known that most older adults exhibit a reduction in photopic spatial contrast 
sensitivity in the absence of ocular or neurological disease, as seen in Figure 30 
(Owsley et al. 1983; Burton et al. 1993; Elliott et al. 1990). However, sensitivity to 
lower spatial frequencies is relatively spared in photopic conditions (Owsley 2011). 
Using the Pelli-Robson chart, Elliott and colleagues found that the average CS among 
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older adults was 1.65 log units, compared with 1.80 log units in the younger population. 
Furthermore, older adults in their 70s require three times more contrast to detect a 
stimulus than adults in their 20s. The reduction in CS with increasing age should 
therefore be taken into consideration when examining visual function in AMD.  
1.6.6.1 Contrast Sensitivity and AMD 
The earliest study examining the effect of AMD on contrast sensitivity was conducted 
by Sjostrand and Frisen in 1977. In their cohort of 3 subjects with AMD and 10 healthy 
controls, it was found that patients with relatively good visual acuity showed a marked 
deficit in contrast sensitivity for medium and high spatial frequencies. In more 
advanced AMD, the impairment also extended to lower spatial frequencies (Sjostrand 
and Frisén 1977). A later study postulated that this might be because advanced AMD 
affects a wider retinal area (Sjostrand 1979). However, since the control subjects were 
not age-matched, this finding could simply be due to normal ageing changes. A larger 
study involving 100 patients with AMD found a reduction in peak contrast sensitivity 
in 80% of the AMD cohort compared with elderly controls (Alexander et al. 1988). 
Peak contrast sensitivity and visual acuity had a correlation coefficient of 0.62 in this 
study; however, Hyvarinen et al. showed that AMD can cause a considerable 
dissociation between these two functional tests. They proposed the concept of “hidden 
vision” in which advanced AMD patients may have greatly reduced visual acuity with 
nearly normal CS at medium and low spatial frequencies, or vice versa (Hyvärinen et 
al. 1983).  
 
People with AMD often have difficulties in adapting to changes in luminance level. 
These symptoms led Brown and colleagues to examine the effect of luminance on the 
CSF of 6 people with AMD and 5 age-matched controls (Brown and Kitchin 1983). 
The contrast sensitivity of the individuals with AMD was depressed at photopic and 
mesopic luminances and relatively spared at scotopic luminances, with the peak of their 
CSF shifting to low SFs at all luminance levels. These findings suggest that the 
adaptation mechanisms responsible for achieving optimal contrast sensitivity in 
medium and high light levels are disrupted in AMD. 
 
Several cross-sectional studies have been conducted to determine whether there is any 
correlation between CS and disease progression. Midena et al. (1997) examined the 
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contrast sensitivity of 47 subjects with early AMD, using sinusoidal gratings of five 
different SFs. Although contrast sensitivity was significantly impaired in the 
participants with early AMD compared with age-matched controls, there was no 
significant difference between subjects with bilateral early AMD and unilateral 
neovascular AMD. This substantiates the previous findings of Stangos and colleagues, 
who concluded that contrast sensitivity was not a good predictor of conversion to 
neovascular AMD (Stangos et al. 1995). However, in the same study Midena did find 
a progressive impairment of contrast sensitivity at higher spatial frequencies, which 
was associated with the severity of fundus appearance in terms of drusen confluence, 
presence of geographic atrophy and focal RPE hyperpigmentation (Midena et al. 1997). 
Similarly, Kleiner et al. found a reduction in peak CS with increasing drusen severity 
(Kleiner et al. 1988). This suggests that CS loss may reflect disease progression in terms 
of retinal appearance, and may be due to a selective impairment of different retinal cells 
and neural channels in AMD.  
 
One of the main limitations of CS is that it is not selectively affected in AMD. Despite 
this, it is still a useful functional test. Indeed, various clinical trials of therapeutic 
interventions for AMD have used contrast sensitivity as an outcome measure (Bellmann 
et al. 2003; Bressler 2001). Bellmann et al. (2003) looked at VA and CS changes over 
2 years and found that, although VA and CS only show a moderate correlation, they 
both provide important information regarding functional ability. There is a strong 
association between CS loss and difficulty in daily living tasks such as facial 
recognition, seeing kerbs and other low-contrast structures (Marron and Bailey 1982). 
For this reason, contrast sensitivity is able to examine the functional effect of potential 
new therapies on a patient’s visual disability and hence, their quality of life. 
 
1.6.7 Discussion 
Studies investigating colour-matching ranges (Smith et al. 1988; Eisner et al. 1992), 
cone-adaptational kinetics (Phipps et al. 2003; Dimitrov et al. 2008; Gaffney et al. 2011; 
Dimitrov et al. 2011; Dimitrov et al. 2012), colour contrast sensitivity (Holz et al. 1995; 
Arden and Wolf 2004; O’Neill-Biba et al. 2010), temporal vision (Brown and Kitchin 
1987b; Mayer et al. 1992b; Mayer et al. 1994; Phipps et al. 2004; Dimitrov et al. 2011; 
Dimitrov et al. 2012; Luu et al. 2013), and contrast sensitivity (Sjostrand and Frisén 
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1977; Sjostrand 1979; Brown and Garner 1983; Brown and Kitchin 1987a; Kleiner et 
al. 1988; Midena et al. 1997)  all report that there is a high degree of cone dysfunction 
in early AMD. Abnormal rod function is evidenced by the elevation of scotopic 
thresholds  (Brown and Kitchin 1983; Steinmetz et al. 1993; Owsley et al. 2000; Owsley 
et al. 2001) and delayed rates of rod adaptation  (Owsley et al. 2001; Haimovici et al. 
2002; Owsley et al. 2007; Jackson and Edwards 2008; Dimitrov et al. 2008; Dimitrov 
et al. 2011; Dimitrov et al. 2012; Jackson et al. 2014). 
Histopathological studies on donor retinas show that there is a preferential loss of  rods 
over cones in early AMD with maximum loss occuring in the parafovea i.e. 3.5-10 
degrees from fixation. Furthermore, the vast majority of photoreceptors remaining in 
eyes with late AMD are cones (Curcio et al. 1996; Medeiros and Curcio 2001). Whilst 
this may support the evidence of rod dysfunction in AMD, it does not explain the 
mounting psychophysical evidence that shows cone dysfunction to be a reliable 
predictor of early AMD. This discrepancy led Shelley and colleagues to study the 
morphological differences between the macular photoreceptors in eyes with AMD 
compared with normals (Shelley et al. 2009). They found that although rod death did 
indeed precede cone death, numerous cone nuclei were displaced or prolapased, which 
would cause them to lose their synaptic contact and thus affect their functionality 
(Gartner and Henkind 1981). Furthermore, they found an abnormal distribution of opsin 
and distal cone axon anomalies in the normal aged macula which may suggest a 
predilection to AMD. Sullivan, Woldemussie and Pow (2007) reported similar findings 
of aberrant cone axon projections into the OPL in AMD . This new evidence provides 
a possible explanation as to why cone function has been repeatedly found to be affected 
in psychophysical  AMD studies.  
As outlined in Section 1.3.7, a complex interaction of oxidative stress, genetics,  
inflammation and environmental influences have been linked to the pathogenesis of 
AMD (Lange and Bainbridge 2012). It has also been suggested that outer retinal 
ischaemia and hypoxia are involved in AMD progression (Feigl 2009; Stefánsson et al. 
2011). It is still not  certain whether the functional deficits found in early AMD, such 
as abnormal dark adaptation kinetics, are originally caused by photoreceptoral or post-
receptoral abnormalities (Feigl et al. 2007a), or by morphological changes to structures 
such as the RPE/Bruch’s membrane complex (Guymer et al. 1999; Pauleikhoff et al. 
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1990) and the choroid (Chen et al. 1992; Ciulla et al. 2002; Metelitsina et al. 2008). If 
the primary location of damage is known, it will improve the efficiency of future 
therapies in early AMD.  
1.7 Overview and Aims  
Age-related macular degeneration is the leading cause of visual impairment in the 
developed world. Despite recent developments in treatment options for wet AMD with 
the introduction of anti-VEGF therapies such as Ranibizumab, there remains as yet no 
treatment for dry AMD. With the predicted ageing of the population in future years, the 
prevalence of this blinding eye condition will continue to escalate, causing not only 
personal suffering for those affected but also significant financial burdens on national 
healthcare institutions.  For this reason, there is a pressing need to evaluate new 
treatments for early AMD to prevent the progression of the disease. Furthermore, with 
the development of these novel therapies, there is also a need for functional biomarkers 
with a high sensitivity and specificity in order to identify patients at risk of the 
development and progression of AMD and to evaluate the efficacy of new treatment 
options.  
 
There is a body of evidence to suggest that outer retinal hypoxia may play a role in the 
pathogenesis of AMD. The oxygen demand of the retina is at its greatest in the dark, 
when the metabolic activity of the photoreceptors is upregulated to support the dark 
current. It has been hypothesized that, by illuminating the retina with a low level of 
light through the night, the progression of diseases with a hypoxic mechanism may be 
slowed. In order to conduct a clinical trial of such an intervention, it is first necessary 
to use the current evidence base to optimize the study design. 
 
Therefore, the aims of this study were to: 
 
1) Develop functional biomarkers for early AMD, and to determine their 
repeatability so that they may be implemented in future clinical trials exploring 
novel interventions for age-related macular degeneration. 
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2) Investigate the topography of dark adaptation deficits in AMD in order to 
determine the most appropriate stimulus for assessing dark adaptation in future 
clinical trials of treatments for AMD.  
 
3) Develop a protocol for a clinical trial investigating the effect of low-level night-
time light therapy in age-related macular degeneration. 
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Chapter 2. The Topography, Repeatability and Diagnostic 
Validity of Dark Adaptation  
2.1 Introduction 
Dark adaptation kinetics have been examined since 1935 in order to evaluate outer 
retinal function (Hecht et al. 1935; Hecht et al. 1937; Haig 1941; Henson and North 
1979; Lamb and Pugh 2004; Jackson and Edwards 2008) and have played a significant 
role in the diagnosis of conditions such as retinitis pigmentosa (Sandberg et al. 1999), 
vitamin A deficiency (Kemp et al. 1988; Cideciyan et al. 1997) Oguchi disease (Lamb 
and Pugh 2004), fundus albipunctatus (Cideciyan et al. 2000), diabetic retinopathy 
(Phipps et al. 2006) and AMD (Owsley et al. 2001; Phipps et al. 2003; Binns and 
Margrain 2007; Owsley et al. 2007; Dimitrov et al. 2008; Dimitrov et al. 2011; Gaffney 
et al. 2011). 
 
Only a small number of studies have examined the effect of retinal location on the 
dynamics of dark adaptation (Hecht et al. 1935; Dimitrov et al. 2008; Gaffney et al. 
2011). These are in agreement that with increasing retinal eccentricity, the RCB takes 
place sooner, the rod branch of the curve is more prominent and a lower final threshold 
is obtained. A possible reason for this variability in dark adaptation with different 
retinal locations is the relative photoreceptor density and receptive field size. The 
maximum density of cone photoreceptors is found at the fovea (200,000cells/mm2), 
decreasing rapidly with increasing eccentricity. This is reflected in the shape of the dark 
adaptation curve using a foveal stimulus, in which a prominent cone branch is 
produced. Ganglion cell density peaks 1.5-7o from the fovea and declines with 
increasing eccentricity so that the dendritic and thus receptive field size has to increase 
accordingly (Dacey and Petersen 1992). Rod photoreceptors first appear in the 
parafovea, increasing with eccentricity to a maximum density at approximately 12-18o 
from the fovea (150,000cells/mm2) (Curcio et al. 1990). Consequently, the rod branch 
of the dark adaptation curve becomes increasingly more prominent and the absolute 
threshold decreases. 
 
There is a growing amount of evidence to suggest that dark adaptation is a sensitive 
biomarker in AMD (Brown and Kitchin 1983; Eisner et al. 1991; Owsley et al. 2001; 
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Phipps et al. 2003; Binns and Margrain 2007; Owsley et al. 2007; Dimitrov et al. 2008; 
Dimitrov et al. 2011; Gaffney et al. 2011; Dimitrov et al. 2012). Indeed, abnormalities 
in dark adaptation appear to be the most sensitive indicators of the condition when 
compared with other aspects of visual function (Eisner et al. 1991; Owsley et al. 2001; 
Phipps et al. 2003; Dimitrov et al. 2011). For example, Dimitrov et al. found the rate of 
rod recovery in dark adaptation to have the best diagnostic capacity compared with 
flicker sensitivity, photostress recovery and colour vision (Dimitrov et al. 2011). 
However, the lengthy recording period and test difficulty led the researchers to 
conclude that it had limited clinical applicability. For this reason, the measurement of 
cone dark adaptation has been of interest due to its ability to detect people with AMD 
with a shorter test duration (Phipps et al. 2003; Dimitrov et al. 2008; Gaffney et al. 
2011) 
 
Gaffney et al. (2011) investigated the diagnostic ability of cone dark adaptation using 
a foveal spot of 0.5o radius and achromatic annuli of 2o, 7o and 12o radii. They found 
that the time constant of cone recovery had the greatest diagnostic potential when 
measured using a 12o annular stimulus, providing an area under the ROC curve of 0.99 
± 0.02. Given that this parameter may be quantified in as little as 10 minutes, this has 
great clinical potential. However, due to the relatively small sample size (n=10), the 
results of the study may have been influenced by outliers. In addition, since the stimuli 
investigated were not area-matched, there remains some uncertainty as to whether the 
12o stimulus truly has a greater diagnostic potential than the 0.5 o, 2o or 7o stimuli, or 
whether it just had less variability due to the larger area of retina stimulated. 
Furthermore, for dark adaptation to be implemented as a functional biomarker in a 
clinical trial, it is necessary to determine its inter-session repeatability. 
2.2 Aims 
Given the heterogeneity of the retinal mosaic, one would assume that dark adaptation 
would vary with retinal location. The first aim of this study was to re-assess the 
dynamics of dark adaptation as a function of retinal eccentricity in a group of healthy 
participants using area-matched stimuli. Since the ultimate goal is to implement the 
dark adaptation procedure in a clinical environment, the second aim was to assess the 
inter-session repeatability of dark adaptation at each retinal location. The final aim was 
to assess the diagnostic ability of dark adaptation in the assessment of AMD, to 
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determine which retinal location provided the best discrimination between people with 
early AMD and healthy controls. 
2.3 Methods 
Participants 
The first part of this study addressing aims 1 and 2 involved the recruitment of 10 
healthy older adults and 11 healthy young adults. To address aim 3, an additional 11 
participants with AMD were recruited. All participants had a corrected visual acuity of 
6/7.5 or better in the test eye, clear ocular media, Van Herick anterior chamber angle 
grade 2 or higher, normal retinal appearance and no history of ocular or systemic 
pathology or medication known to alter retinal function. Written informed consent was 
received from all participants prior to commencing the study, and all procedures were 
carried out in accordance with the tenets of the Declaration of Helsinki. 
 
Apparatus 
All stimuli were displayed on a calibrated, high-resolution CRT monitor (Iiyama LS 
902UT) driven by an 8-bit graphics board (nVIDIA Geforce 9) under software control 
(MATLAB, R2009a, The MathWorks Inc). The luminance output of the monitor was 
γ-corrected (Metha et al. 1993) and its background luminance (-0.85 log cd/m2) was 
attenuated throughout all recordings by a 1.2 neutral density (ND) filter.  As the subject 
approached the lower end of the luminance range, additional filters were mounted on 
the screen to determine the full extent of retinal threshold recovery. The three stimuli 
generated were a spot of 2 o radius, 2o width (area 12.56) and annuli of 7o radius, 0.3o 
width (area 12.91) and 12o radius 0.2o width (area 14.95), as depicted in Figure 31. 
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Figure 31. Diagrammatic representation of the three stimuli (2o radius spot, 7o radius annulus 
and 12o radius annulus) centred on the fovea of a healthy participant.  
 
Dark adaptation was monitored using a computerized 3-down 1-up modified staircase 
psychophysical procedure (Jackson et al. 1999). The protocol was similar to previous 
work carried out and published in our laboratory (Gaffney et al 2011). Each stimulus 
was presented for 200ms followed by a 600ms response window with a random 
interstimulus delay of 0.9 to 2.4 seconds. If the subject failed to respond to the stimulus 
in 600ms, the intensity of the stimulus was increased by 0.1 log units. If, however, the 
participant responded correctly to the stimulus within 600ms, the luminance of the 
stimulus was reduced by 0.3 log units on the following presentation. Dark adaptation 
recovery was sampled for 25 minutes in all participants. The code for this MATLAB 
programme can be found in Appendix II (‘The topography of dark adaptation’). 
 
Experimental procedure  
At the participant’s first visit, baseline examinations of patient history, logMAR visual 
acuity (ETDRS), fundus photography (Canon CR-DGi Camera) and media opacity 
grading (Chylack et al. 1993) were conducted. Participants were then dilated with one 
drop of 1.0% tropicamide in the test eye before dark adaptation was carried out. The 
eye with better visual acuity was chosen as the test eye. If acuities were equal, the right 
eye was tested. Refractive correction was worn as necessary and the fellow eye was 
occluded with an eye patch.  All participants were given instruction on how to perform 
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the dark adaptation test, after which they undertook a 5-minute practice session. This 
was repeated until the participant’s performance was deemed to be proficient by the 
investigator. 
 
A Maxwellian view optical system (Figure 32) incorporating an amber filter (LEE 
filters HT 015 ‘deep straw’) was used to bleach 84% of cone photopigment and 74% 
of rod photopigment (5.20 log phot Td.s-1) (Hollins and Alpern 1973) in the central 
43.6o of the test eye for 120 seconds. After the bleach, all lights were extinguished and 
participants were instructed to place their chin on the rest facing the computer screen 
and the dark adaptation programme simultaneously commenced. Participants focused 
their test eye on the fixation cross in the centre of the screen (or the gap in the middle 
of the cross for the 2o spot stimulus) and indicated when they perceived the flashing 
stimulus using the computer keyboard. Threshold recovery was continuously 
monitored for 25 minutes for each stimulus. 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. The Maxwellian view optical system. The participant positioned their chin on the 
rest at the front of the device and fixated the central cross for 120 seconds. 
Three different dark adaptation functions were recorded in a randomised order, using 
the 2o, 7o and 12o radius stimuli, centred on the fovea. A one-hour washout period 
separated successive bleaches. In the healthy control participants, the entire procedure 
was repeated on a separate day within a one-month period so that each participant 
completed a total of six dark adaptation functions. Some participants with AMD 
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required a second visit if fatigue prevented the collection of all data on a single 
occasion. 
Statistical analysis 
All threshold recovery data were fitted using an exponential-linear model of dark 
adaptation (McGwin et al. 1999) on a least squares basis using the solver function in 
Microsoft Excel (2003) (Equation 2). Cone threshold recovery was modelled by the 
exponential component of the curve, and rod recovery by the linear components. The 
two parameters of interest were the time constant of cone recovery (cone τ) and time to 
rod-cone-break (RCB). The recording protocol was not long enough to reliably obtain 
the rod recovery parameters from all participants, but the inclusion of the linear portion 
of the model facilitated the localisation of the RCB. 
Equation 2. T(t) = [a + (b.exp(-t/τ))] + [c.(max(t – rcb,0))] 
where T is the threshold (log cd/m2) at time t after termination of the bleach, a is the 
final cone threshold, b is the change in cone threshold from t = 0, τ is the time constant 
of cone recovery, c is the slope of the second component of rod recovery, max is a logic 
statement and rcb describes the time to the RCB from cessation of the bleach (McGwin 
et al. 1999). 
The repeatability of cone τ and time to RCB were assessed using established statistical 
techniques such as the coefficient of repeatability (CoR) (Bland and Altman 1986). The 
CoR was calculated by multiplying the standard deviation of the differences between 
the two visits by 1.96. Confidence intervals for the CoR were calculated by determining 
the appropriate point of the t-distribution with n-1 degrees of freedom. The confidence 
intervals were from the observed value minus t standard errors to the observed value 
plus t standard errors (Bland and Altman 1986). Repeatability was graphically analysed 
using the method advocated by Bland and Altman (1986) whereby the differences 
between visits for each individual are plotted against the mean value. Paired t-tests were 
carried out to determine any significant differences in parameters between visit one and 
visit two, which may be suggestive of a learning effect. Receiver operating 
characteristic (ROC) curves were constructed using statistical software (SPSS, Version 
20.0) to assess the diagnostic potential of dark adaptation parameters that showed a 
statistically significant difference between the AMD and control groups. 
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2.4 Results 
Dark adaptation data were obtained from 28 healthy control participants, 2 of whom 
withdrew from the study after their first visit and 4 were excluded either due to an 
inability to understand the test or to follow the instructions given. One additional person 
was excluded due to an uncertain AMD status. Therefore, dark adaptation curves for 
each of the 3 stimuli on 2 occasions were analysed from 11 healthy younger participants 
(mean age 23.3 ± 4.7 years) and 10 healthy older participants (mean age 72.7 ± 6.0 
years). Typical recovery data for the three retinal locations at both visits from one older 
and one younger participant are displayed in Figure 33 and Figure 34 respectively. In 
all observers, as the retinal eccentricity of the stimulus increased, the time constant of 
cone recovery was shorter, the RCB took place earlier and the rod branch of the dark 
adaptation function became more prominent with a lower final threshold. Tables 6 and 
7 display the cone tau and RCB data from all participants at all 3 locations. 
Figure 33. Dark adaptation curves recorded for a typical older participant (CR, 62 years) in 
response to all three stimulus sizes: 2 degree (blue), 7 degree (red) and 12 degree (green) on 
visit 1 (left panel) and visit 2 (right panel). The 12 degree curve is correctly placed with respect 
to the vertical axis. The other two curves have been displaced upwards by an additional 0.5 log 
units to aid visualisation. The cone phase and rod-cone break (RCB) are indicated on the curves. 
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Figure 34. Dark adaptation curves recorded for a typical younger participant (CM, 23 years) 
in response to all three stimulus sizes: 2 degree (blue), 7 degree (red) and 12 degree (green) on 
visit 1 (left panel) and visit 2 (right panel). The 12 degree curve is correctly placed with respect 
to the vertical axis. The other two curves have been displaced upwards by an additional 0.5 log 
units to aid visualisation. The cone phase and rod-cone break (RCB) are indicated on the curves. 
 
Participant 2 o Cone τ (mins) 7 o Cone τ (mins) 12 o Cone τ (mins) 
Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2 
AB 2.57 2.73 1.29 1.29 1.52 1.29 
CM 1.59 1.44 1.10 1.34 1.41 1.07 
AA 1.70 1.75 1.38 1.35 1.16 1.23 
JB 1.63 1.96 1.29 1.31 1.31 1.39 
NM 2.15 1.95 1.39 1.66 1.43 1.48 
RN 1.78 0.90 1.25 1.24 1.34 1.57 
NS 1.94 1.52 * 1.09 * * 
SP 1.80 2.08 1.48 1.37 1.11 1.59 
AA 1.48 1.59 0.39 1.05 0.62 0.85 
JB 1.30 1.29 0.85 0.54 0.60 0.82 
RB 1.78 1.72 0.90 1.37 0.90 1.08 
CR 2.40 2.28 1.90 1.53 0.99 1.42 
AB 2.76 2.66 1.06 1.15 1.24 1.00 
MH 2.56 2.42 1.79 1.23 1.31 0.97 
CS 2.20 2.50 1.44 1.58 0.73 1.35 
DT 2.93 3.74 2.21 2.18 1.24 1.39 
DG 3.33 3.35 2.91 2.27 1.82 1.01 
EBM 2.91 3.52 2.89 2.68 2.05 1.61 
PF 3.61 4.25 3.67 2.55 2.62 2.59 
RG 2.89 2.25 1.43 1.11 1.40 1.31 
RE 1.38 1.95 1.39 1.40 0.74 1.13 
MEAN 2.22 2.28 1.64 1.49 1.28 1.31 
SD 0.67 0.86 0.77 0.52 0.49 0.39 
Table 6. Cone τ for all participants using 2 o, 7 o and 12o stimuli. * Indicates results that were 
excluded from analysis due to variability of results as caused by fatigue. 
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Participant 2 o RCB (mins) 7o RCB (mins) 12 o RCB (mins) 
Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2 
AB 7.87 8.75 7.97 7.97 8.05 7.97 
CM 10.84 11.52 9.62 9.48 6.69 8.17 
AA 10.22 10.81 10.33 9.77 6.73 8.70 
JB 9.79 8.69 10.38 6.61 8.47 9.15 
NM 11.76 11.86 9.06 10.34 7.28 7.01 
RN 12.36 11.65 9.04 10.05 9.86 6.71 
NS 8.51 8.76 * 9.34 * * 
SP 10.81 11.19 7.89 9.47 7.87 8.51 
AA 11.20 7.91 3.66 9.89 5.44 5.46 
JB 12.17 10.93 7.34 4.36 7.15 5.86 
RB 12.00 10.15 8.88 8.79 5.54 6.56 
CR 15.55 13.43 11.30 13.13 7.09 10.43 
AB 5.74 14.25 6.34 10.80 9.73 7.56 
MH 11.80 13.21 8.12 7.80 8.92 5.73 
CS 14.40 14.35 11.25 10.84 6.63 8.28 
DT 19.23 11.85 11.88 11.45 8.12 12.07 
DG 22.75 17.69 11.50 8.28 9.47 10.42 
EBM 25 25 10.28 10.53 7.16 7.87 
PF 25 25 16.69 18.75 11.90 10.22 
RG 15.47 15.32 12.25 10.64 9.19 9.89 
RE 12.82 12.92 10.35 9.63 7.48 7.47 
MEAN 13.59 13.11 9.70 9.90 7.94 8.20 
SD 5.31 4.62 2.65 2.72 1.58 1.77 
Table 7. Time to rod-cone-break (RCB) for all participants using 2 o, 7 o and 12o stimuli. * 
Indicates results that were excluded from analysis due to variability of results as caused by 
fatigue. 
 
Bland-Altman plots of the difference in cone τ and time to RCB recorded at the first 
and second visit against the mean cone τ and time to RCB for each stimulus size are 
displayed in Figure 35 and Figure 36. Figure 35 shows that all 3 stimuli had an equally 
small range between the limits of agreement for the cone τ. Figure 36 shows that with 
the time to RCB, there is a progressively smaller range between the two limits of 
agreement with increasing stimulus eccentricity. The Bland Altman plots all showed a 
mean difference between visits that was around zero, indicating a lack of bias in the 
data, i.e. there was no significant learning effect between visits.   
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a. 
 
b. 
 
c. 
 
Figure 35.  Bland-Altman plots for 2o (a), 7o (b) and 12o (c) radius stimuli cone τ. The difference 
between the value recorded at visit 1 and visit 2 is plotted as a function of the mean value for 
all participants with the bias (solid pink line) and 95% limits of agreement (dashed blue lines). 
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Figure 36. Bland-Altman plot for 2o (a), 7o (b) and 12o (c) radius stimuli time to RCB. The 
difference between the value recorded at visit 1 and visit 2 is plotted as a function of the mean 
value for all participants with the bias (solid pink line) and 95% limits of agreement (dashed 
blue lines). 
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The COR for each parameter was determined, as shown in Table 8. The COR was also 
expressed as a percentage of the group mean for each parameter to facilitate 
comparison. The percentage COR ranged from 36.4% to 53.3%. The lowest percentage 
COR was obtained using the 2o radius stimulus. Figure 37 displays this graphically, 
with the associated 95% confidence intervals. For both parameters, it is seen that the 
confidence intervals are overlapping for the different stimuli, suggesting that there is 
no significant difference in repeatability between the retinal locations.    
Psychophysical Method Coefficient of 
Repeatability (mins) 
Coefficient of 
Repeatability (%) 
2o τ 0.82 36.4 
7o τ 0.74 47.1 
12 o τ 0.69 53.3 
2 o RCB 5.77 43.2 
7 o RCB 4.67 47.5 
12o RCB 3.69 45.9 
Table 8. Coefficient of Repeatability for the 6 psychophysical parameters investigated, also 
expressed as a percentage of the group mean value.  
 
  
Figure 37. Coefficient of Repeatability for each psychophysical parameter (i.e. cone tau and 
time to RCB for stimuli of radius 2o, 7o, 12o with 95% confidence limits. 
 
The means (± standard deviation) of cone τ and time to RCB for visits one and two for 
all 21 participants are shown in Table 9. There was no statistically significant difference 
in any of these parameters between the two visits (paired two-tailed t-test, p > 0.05), 
which signifies that there was no significant bias, for example, no learning effect upon 
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the second visit. 
 Mean (± standard deviation) p-value  
(paired t-test) 
Visit 1 Visit 2 
2o Cone τ (mins) 2.22 (± 0.67) 2.28 (± 0.86) 0.556 
7o Cone τ (mins) 1.64 (± 0.77) 1.49 (± 0.52) 0.149 
12o Cone τ (mins) 1.28 (± 0.49) 1.31 (± 0.39) 0.716 
2o RCB (mins) 13.59 (± 5.31) 13.11 (± 4.62) 0.464 
7o RCB (mins) 9.70 (± 2.65) 9.90 (± 2.72) 0.675 
12o RCB (mins) 7.94 (± 1.58) 8.20 (± 1.77) 0.537 
Table 9. Mean (± standard deviation) of dark adaptation parameters assessed at visits one and 
two. P-values relate to a paired t-test comparing data from visits one and two.  
The clinical characteristics of the AMD cohort are shown in Table 10. One participant 
with AMD was unable to perform the test due to physical restrictions, and so was 
excluded from the study. In total, the dark adaptation data from 10 participants with 
AMD were analysed. There was no significant difference in mean age between the 
AMD (mean age 72.9 ± 7.23 years) and control (mean age 72.7 ± 6.0 years) groups 
(independent samples two-tailed t-test, p=0.95).  
 Test Eye 
Fellow Eye 
Participant Age Gender Eye VA  AMD status VA  AMD status 
RS 78 M R 0.04 Early 0.24 Intermediate 
RJ 68 M L 0.0 Early 1.2 Advanced 
AP 82 F R 0.0 Early 0.0 Early 
WG 76 M R -0.1 Normal -0.1 Early 
UH 77 F R -0.06 Early 0.02 Advanced 
DP 62 M R -0.08 Early 0.0 Early 
DN 83 M R 0.06 Early 0.24 Early 
AD 70 M L -0.08 Early -0.04 Advanced 
LG 67 F R -0.1 Early -0.1 Early 
ED 66 F R -0.06 Early 0.32 Early 
Table 10. Clinical characteristics of the AMD cohort. AMD status was determined according 
to the Age-Related Eye Disease Study severity scale (Davis et al. 2005) in which step 1 
represents normal retinal ageing changes, steps 2-6 indicate early AMD, steps 7-9 denote 
intermediate AMD and steps 10-11 represent advanced AMD. VA was measured in logMAR. 
 
Table 11 shows the cone τ and time to RCB at three retinal eccentricities for each older 
control and for each participant with AMD determined by the best fitting exponential-
linear model. An example of typical dark adaptation curves for a participant with AMD 
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is shown in Figure 38, which can be compared with the typical dark adaptation data of 
an older control as shown previously in Figure 33. 
  
Participant 2 o stimulus 7o stimulus 12 o stimulus 
Cone τ 
(mins) 
RCB 
(mins) 
Cone τ 
(mins) 
RCB 
(mins) 
Cone τ 
(mins) 
RCB 
(mins) 
Controls  
CR  2.40 15.55 1.90 11.30 0.99 7.09 
AB 2.76 5.74 1.06 6.34 1.24 9.73 
MH 2.56 11.80 1.79 8.12 1.31 8.92 
CS 2.20 14.40 1.44 11.25 0.73 6.63 
DT 2.93 19.23 2.21 11.88 1.24 8.12 
DG 3.33 22.75 2.91 11.50 1.82 9.47 
EBM 2.91 25 2.89 10.28 2.05 7.16 
PF 3.61 25 3.67 16.69 2.62 11.90 
RG 2.89 15.47 1.43 12.25 1.40 9.19 
RE 1.38 12.82 1.39 10.35 0.74 7.48 
AMD  
RS 4.03 25 3.31 17.62 2.45 16.48 
RJ 5.61 25 3.69 25 2.38 16.20 
AP 10.09 25 5.47 25 3.06 18.46 
WG 4.78 25 2.58 12.79 1.70 10.63 
UH 9.41 25 4.77 25 3.30 25 
DP 1.80 13.36 1.47 11.38 1.31 6.83 
DN 7.34 25 3.77 25 4.73 25 
AD 3.65 25 2.22 15.69 1.46 10.25 
LG 3.98 25 2.75 18.58 2.50 14.14 
ED 6.15 25 3.17 25 2.10 10.94 
Table 11. Cone τ and time to RCB, determined by the best fitting exponential-linear model 
for all older controls and participants with AMD at each retinal location. Where there was no 
RCB within the trial period, it was assigned a value of 25 minutes. 
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Figure 38. Dark adaptation curves 
recorded for a typical participant with AMD (RS) in response to all three stimuli: 2o (blue), 7o 
(red) and 12o (green). The 12o curve is correctly placed with respect to the vertical axis. The 
other two curves have been displaced upwards by an additional 0.5 log units to aid visualisation. 
 
The mean dark adaptation parameters for the two groups are given in Table 12. In cases 
where the RCB did not occur within the recording period, it was assigned a value of 25 
minutes. Therefore, the full extent of the delay in rod dark adaptation with AMD is not 
demonstrated in the figures below. The mean times to RCB and cone τ at all 3 retinal 
locations for control and AMD groups are also displayed graphically in Figure 39, with 
95% confidence intervals.  
 Stimulus 
radius 
Control AMD Univariate 
comparison 
Cone τ (mins) 2o 2.70 (0.62) 5.84 (2.89) p= 0.009 
 7o 2.07 (0.84) 3.41 (1.32) p= 0.040 
 12o 1.41 (0.60) 2.69 (1.30) p= 0.017 
Time to RCB (mins) 2o 16.78 (6.22) 23.84 (4.11) p= 0.024 
 7o 11.0 (2.71) 19.68 (5.97) p= 0.004 
   12o 8.57 (1.60) 16.10 (6.70) p= 0.012 
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Table 12. Mean (± standard deviation) dark adaptation parameters in older control and 
AMD groups. P-values relate to independent samples t-tests comparing parameters 
between groups 
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Figure 39. Summary of mean time to RCB (left panel) and cone τ (right panel) at each retinal 
eccentricity, shown with 95% confidence intervals. 
 
Significant differences between groups were evident for all stimuli for both parameters 
(two-tailed t-test, p <0.05). The greatest absolute difference in cone recovery time 
between participants with AMD compared with controls was found using the 2o radius 
stimulus and this difference was highly significant (p=0.009). However, with respect to 
time to RCB, the difference between groups was most significant for the 7o radius 
stimulus (P=0.004), possibly due to the high level of variability in the control data for 
time to RCB of the 2o radius stimulus.  
 
Receiver operating characteristic (ROC) curves for all parameters are shown in Figure 
40. The area under the curve (AUC) provides a global assessment of the diagnostic 
performance of each parameter. This area indicates the probability that a test has a 
higher diagnostic value than random chance. For example, an AUC of 1 indicates 100% 
sensitivity and specificity, whilst an AUC of 0.5 indicates that the test is no better than 
chance alone at distinguishing between groups (Altman and Bland 1994).  Both the 
time to RCB and cone τ were highly diagnostic for AMD, with AUCs ranging from 
0.83 to 0.94. If a cone tau greater than 3.63 minutes is considered to be abnormal, the 
test is able to distinguish between controls and people with AMD with a sensitivity of 
90% and a specificity of 100%. There were no statistically significant differences in the 
AUC obtained for the 3 stimuli for either parameter (z  <  1.96)  (Hanley and McNeil 
1982).  
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Figure 40. ROC curves (plots of sensitivity against 1-specificity) for all parameters for 10 older 
controls and 10 participants with AMD, and areas under the ROC curves.  
2.5 Discussion 
These data demonstrate that cone adaptation, measured at different macular locations 
is highly diagnostic for AMD. This study has also shown that this technique has good 
inter-session repeatability in normal subjects. In agreement with previous studies 
(Hecht et al. 1935; Dimitrov et al. 2008), the results showed that as the eccentricity of 
the stimulus increased, dark adaptation recovery (cone τ and time to RCB) was faster, 
revealing a more prominent rod curve and a lower final threshold.  
Consistent with Dimitrov et al. (2008), cone dark adaptation took longer at the fovea, 
the location of peak cone photoreceptor density (Curcio et al. 1990). The increased 
photoreceptor density increases competition for the limited supply of 11-cis retinal 
available, which may account for the slower cone recovery at the fovea. The time to 
RCB, a measure of rod function, was faster with increasing retinal eccentricity. This is 
possibly due to the increased rod photoreceptor density, receptive field size and spatial 
summation that occurs as retinal eccentricity increases from a foveal to a more 
peripheral location (Dacey and Petersen 1992).  
When assessing a technique’s clinical applicability, it is necessary to calculate the 
coefficient of repeatability (CoR), a measure of the inherent variability in a test, which 
Test Parameter AUC 
2o cone τ  (blue 
line) 
.910 
7o cone τ 
(green line) 
.830 
12o cone τ 
(brown line) 
.850 
2o RCB 
(purple line) 
.840 
7o RCB 
(yellow line) 
.940 
12o RCB    (red 
line) 
.880 
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can determine the smallest change over time that can be deemed to be clinically 
significant (Bland and Altman 1986). This is particularly important if a technique is to 
be used in a longitudinal study, such as a clinical trial. A clinically significant change 
in dark adaptation recovery between visits must be greater than or equal to the CoR 
value. Therefore, the lower the CoR, the greater the test’s potential to pick up small 
functional losses associated with disease progression. The CoR obtained for cone τ and 
time to RCB using the 3 different stimuli ranged from 36.4% to 53.3% of the group 
mean value for these parameters. There were no significant differences in the 
repeatability of cone τ and time to RCB parameters between the 3 retinal locations. 
Therefore, any of these stimuli may be used in the longitudinal assessment of dark 
adaptation. If the 2o cone tau, which produced the lowest CoR, was chosen as a 
parameter in a longitudinal study of dark adaptation, any difference between two 
measurements greater than 0.82 minutes may be considered to be clinically significant. 
The mean difference in 2o cone tau between healthy controls and participants with 
AMD was 3.14 minutes, which is considerably greater than the repeatability limit of 
0.82 minutes, therefore has sufficient repeatability to detect disease effects.  
The investigation of dark adaptation parameters in participants with AMD and older 
controls revealed that cone τ and time to RCB are both highly diagnostic for all stimuli, 
with areas under ROC curves between 0.83 and 0.94. For example, if a cone τ greater 
than 3.63 minutes is considered to be abnormal, the 2o stimulus is able to distinguish 
those subjects with AMD from healthy older controls with 90% sensitivity and 100% 
specificity. There was no significant difference in the AUC for cone τ or time to RCB 
for any stimulus. Consequently, both parameters, regardless of stimulus size, can be 
used to identify patients with AMD with similar sensitivity and specificity. The greatest 
difference in mean cone τ between groups was at the fovea, which is consistent with 
previous studies (Dimitrov et al. 2008; Gaffney et al. 2011). Since cone density is 
maximal at the fovea (200,000 cells/mm2) (Curcio et al. 1990), there will be more 
competition for 11-cis-retinal, which may explain the greater functional deficit seen at 
this location. Contrary to the findings of Gaffney et al. (2011), the foveal stimulus did 
not show elevated variability compared to other locations and thus the separation 
between groups at this location was good, as depicted in Figure 39. Gaffney, however, 
used a smaller stimulus than that used in this study (1o vs. 4o diameter). Due to the 
heterogenous nature of AMD lesions, the results obtained with smaller stimuli will be 
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more influenced by the chance of the stimulus targeting a healthy or unhealthy part of 
the retina. Using a larger spot size will ensure that the thresholds obtained will be 
determined by the part of the retina that is most healthy, thus providing less variable 
results, as found in this study. 
A limitation of the 2o stimulus is that it produced the least separation between groups 
in the time to RCB. This is because the vast majority of participants with AMD did not 
reach their RCB within the 25-minute trial period, and so the time to RCB was assigned 
a nominal value of 25 minutes, which would underestimate their actual measurement. 
Also, this stimulus gave the most variable results for the control group with respect to 
time to RCB. Therefore, if a measure of rod function is required as a diagnostic tool, 
the 7o annular stimulus would be more suitable. However, given that the 2o cone τ 
produced the greatest separation between subjects with AMD and healthy controls and 
can be measured within a few minutes (Gaffney et al 2011), it would be an appropriate 
parameter to use as a functional biomarker in AMD.  
The results from this study confirm the previous findings of delayed cone dark 
adaptation in the peripheral macular region (Gaffney et al 2011), which was 
contradictory to the work of Owsley et al. (2007) who failed to find a significant effect 
of AMD on cone dark adaptation at 12o retinal eccentricity. A possible explanation for 
these discrepancies lies in the different techniques used to bleach the photopigment. 
Owsley and colleagues used a photo-flash method, in which small errors in exposure 
time will have a relatively large effect on the amount of photopigment bleached 
(Margrain and Thomson 2002). Following the longer duration bleach used in this study, 
that produces an equilibrium bleach, the time constant of cone recovery is not 
dependent on the percentage of photopigment bleached, and the effects of blinking and 
eye movements during flash delivery are minimised (Hollins and Alpern 1973). 
Furthermore, recovery is faster following a photoflash even if the same percentage of 
pigment is bleached, therefore less time would be available to collect recovery data. 
There is a further, physiological explanation for the greater deficit in cone adaptation 
recorded following an equilibrium bleach. The regeneration of visual pigment 
following a bleach is dependent upon the local availability of 11-cis-retinal (Lamb and 
Pugh 2004). Cones have an additional Müller cell pathway that allows them to 
regenerate visual pigment more rapidly than rods, which are solely dependent on the 
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RPE. It is possible that the prolonged metabolic activity that occurs during a longer 
duration bleach could be detrimental to the Müller cell retinoid pathway, causing cone 
photoreceptors to be more dependent on the RPE-derived 11-cis-retinal. Since the RPE 
is one of the primary sites of damage in AMD, any impairment to cone-mediated dark 
adaptation would be more apparent under these conditions than with a photo-flash 
bleaching technique (Gaffney et al. 2011). 
A limitation of the time to RCB as a measure of rod function is that it also depends on 
cone final threshold. However, Gaffney et al. (2011) found no difference between cone 
final threshold in subjects with early AMD compared with healthy controls. Hence, any 
delay in the time to RCB may be assumed to be due to an abnormality in the individual’s 
rod adaptation. Although this study had a modest sample size, our intention was to 
determine whether dark adaptation was both reproducible and able to distinguish 
persons with early AMD from age-matched controls and to determine the retinal 
location that provided the best repeatability and diagnostic capacity. Despite the small 
sample, there was a statistically significant difference between the two groups in both 
cone recovery and time to RCB.  
In conclusion, this study has demonstrated that the inter-session repeatability of dark 
adaptation was not significantly different between the three retinal locations 
investigated. Nevertheless, the repeatability values reported in the results of this study 
may be used in future clinical trials to determine the smallest change that can be 
considered to be clinically significant. Furthermore, it was found that all three retinal 
locations were able to discriminate between people with early AMD and healthy 
controls. Although the 2o radius stimulus produced the greatest separation between 
these two groups with respect to cone tau, and the 7o radius stimulus was most 
diagnostic in terms of time to RCB, these differences between stimuli were not 
statistically significant. However, since the 2o stimulus may be used to measure the 
time constant of cone recovery in as little as 10 minutes, it would be a suitable parameter 
to use in future clinical trials using dark adaptation as a functional biomarker. 
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Chapter 3. The Repeatability of Functional Biomarkers for 
AMD 
3.1 Introduction 
With the imminent development of new therapies for AMD, a potential obstruction to 
their clinical evaluation is the lack of an outcome measure that can evaluate a reduction 
in disease progression over a relatively short timeframe. Early AMD develops very 
slowly over time (Davis et al. 2005) and, therefore, it is not practicable to use end stage 
disease as an outcome measure in early stage trials. For this reason, there is a pressing 
need to develop biomarkers that are able to reliably and repeatably detect small changes 
in visual function, acting as surrogate markers of disease progression.  
 
Given that AMD is a disease primarily affecting the outer retina, tests that specifically 
target the photoreceptors, RPE and Bruch’s membrane should be most sensitive to 
disease progression. However, the standard method of assessing retinal function, visual 
acuity (VA), involves a considerable amount of higher order cortical processing 
(Thibos and Bradley 1993). Furthermore, the inherent between session variability of 
this test (8 letters, logMAR 0.15) (Siderov and Tiu 1999) will often mask the small 
changes in VA that occur in early AMD (2 letter loss, logMAR 0.04) (Klein et al. 1995). 
Alternative functional tests examining the outer retina more directly would, therefore, 
be likely to be better able to monitor disease progression.  
 
Although histopathological studies have reported that cones are relatively spared in 
early AMD (Curcio et al. 1996), this does mean that they are not affected by the disease. 
Shelley and colleagues found that numerous cone nuclei were displaced and prolapsed 
in AMD, which would cause them to lose their synaptic contact and thus affect their 
functionality (Shelley et al. 2009). Furthermore, there is mounting psychophysical 
evidence to show cone function to be a reliable indicator of AMD. Indeed, (Eisner et 
al. 1992) found that the colour-match area, in combination with dark adaptation, was 
the best predictor of disease progression in AMD.  Tritan colour contrast thresholds are 
abnormal in patients with AMD and minimal lens opacities (Arden and Wolf 2004), 
and they also change significantly more over time in patients with early AMD 
compared with age-matched controls (Holz et al. 1995). However, for chromatic 
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sensitivity to be employed as a functional biomarker of AMD, a means of accurately 
quantifying chromatic thresholds is required, which falls beyond the remit of standard 
clinical colour vision tests. A computer-based technology has recently been developed 
for the assessment of colour contrast sensitivity by the Civil Aviation Authority (CAA), 
which is now being used as their gold standard colour vision test. The Colour 
Assessment and Diagnosis (CAD) test is postulated to be able to detect, classify and 
monitor both large and small colour vision deficiencies. The statistical limits for the 
standard normal (SN) observer were established using the thresholds of 238 normal 
trichromats and 250 patients with colour deficiencies (Barbur and Rodriguez-Carmona 
2006). By implementing dynamic luminance contrast noise, it is able to isolate red-
green (RG) and yellow-blue (YB) thresholds (Birch et al. 1992). This allows a rapid 
quantification of thresholds along 16 different directions in the x,y co-ordinates of CIE 
colour space (Barbur et al 2009b). Using the CAD test, YB thresholds in patients with 
AMD have been shown to increase linearly with disease severity, which again indicates 
that YB loss is a good indicator of disease progression (O’Neill-Biba et al. 2010). 
O’Neill-Biba et al. (2010) reported evidence of an elevation in threshold, even when 
the retina appeared normal, in individuals whose fellow eye demonstrated signs of 
advanced AMD, indicating that impaired colour vision may be an early functional 
indicator of retinal dysfunction in AMD. Barbur and Konstantakopoulou (2012) 
evaluated an approach to maximizing the diagnostic sensitivity of the test through the 
calculation of an index representing chromatic threshold as a function of light level in 
the low photopic, high mesopic range (Barbur and Konstantakopoulou 2012). This 
resulted in a reduction in the substantial between subject variability in chromatic 
thresholds conferred by individual differences in factors such as media opacity, pupil 
diameter and macular pigment optical density, and removed the effect of age on colour 
vision in healthy individuals. However, to date, the only data that have been published 
regarding the between session variability of the CAD test is on a computer-based web 
version under different experimental conditions (Seshadri et al. 2005). 
 
Numerous studies have found that temporal sensitivity is also adversely affected in 
patients with AMD (Mayer et al 1992b; Mayer et al. 1994; Phipps et al. 2003; Phipps 
et al. 2004; Dimitrov et al. 2011; Dimitrov et al. 2012; Luu et al. 2013), to a greater 
extent than the generalised loss which occurs due to normal ageing (Kim and Mayer 
1994). This is thought to be due to the compromised outer retinal oxygen supply in 
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AMD being unable to meet the increased metabolic demand elicited by flickering 
stimuli (Kiryu et al. 1995; Riva et al. 2001).  Flicker frequencies of above 10Hz have 
been shown to increase the difference in oxygen tension between retinal arterial and 
venous blood substantially more than lower frequencies (Shakoor et al. 2006). This 
indicates that the metabolic activity of the retinal tissue is upregulated in response to 
this high temporal frequency stimulation. Given the recent evidence to suggest that 
early functional changes in AMD are initiated by chronic retinal ischemia (Feigl et al. 
2007a), a functional test which causes a greater demand on the retinal oxygen 
metabolism is more likely to detect the ischemic deficits in early AMD. 
 
Flicker detection is a desirable test to use when monitoring functional changes in AMD 
as it can be performed quickly, is reproducible and diagnostically sensitive (Phipps et 
al. 2004; Dimitrov et al. 2011). For this reason, Dimitrov et al. rated 14 Hz flicker 
threshold measurement as having the highest potential clinical value out of a battery of 
functional tests in the diagnosis and monitoring of AMD (Dimitrov et al. 2011). 
Furthermore, flicker threshold has also been shown to increase gradually with disease 
progression (Dimitrov et al. 2012), thus supporting the claim that temporal sensitivity 
may also be an effective tool for monitoring AMD progression and assessing the 
efficacy of therapeutic interventions. The flickering stimulus can be generated by either 
modulating luminance about a mean background level (mean-modulated flicker) 
(Mayer et al 1992b) or by modulating a luminance increment (luminance-pedestal 
flicker) (Anderson and Vingrys 2000). The latter is thought to be superior in detecting 
early AMD, due to its invocation of local adaptation effects (Anderson and Vingrys 
2000) and rod-cone interactions from neighbouring areas (Coletta and Adams 1984).  
 
Clinical tests must fulfill two key requirements to be useful as biomarkers for use as 
outcome measures in clinical trials: they must be sensitive to disease progression, and 
they must show a good level of between session repeatability. It is clear that both the 
14-Hz flicker threshold and CAD chromatic sensitivity tests may be useful functional 
biomarkers, fulfilling the first requirement of showing a sensitivity to increased severity 
of funduscopic changes associated with AMD (O’Neill-Biba et al. 2010; Dimitrov et 
al. 2011; Dimitrov et al. 2012). Repeatability data have recently been published for the 
assessment of cone dark adaptation (Gaffney et al. 2014), another potentially important 
biomarker for early AMD (Brown and Kitchin 1983; Eisner et al. 1991; Owsley et al. 
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2001; Owsley et al. 2007; Binns and Margrain 2007; Gaffney et al. 2011; Dimitrov et 
al. 2011; Dimitrov et al. 2012). However, there is currently little published data 
regarding the inter-session repeatability of the flicker and chromatic threshold 
assessment techniques. This is crucial in determining the minimum change in each 
parameter which may be considered to be clinically significant – an important issue 
when powering trials and interpreting outcomes, as well as in the clinical management 
of patients with early AMD.  The data presented in this section has been accepted for 
publication in a peer-reviewed journal (see Appendix IV). 
3.2 Aims 
The aim of this study was to assess the inter-session repeatability of the colour 
assessment and diagnosis (CAD) test and the 14-Hz flicker test in a population of 
healthy participants. 
3.3 Methods 
Participants 
Thirty healthy adults with limited experience in psychophysical experiments were 
recruited to the study from the staff and students at the School of Optometry and Vision 
Sciences, Cardiff University. This study was powered to detect within subject standard 
deviation to within 25% of the true population value (Bland 2010). All participants had 
corrected visual acuity of 6/6 or better (logMAR 0.0) in their test eye, age-normal lens 
clarity, a normal retinal appearance with no history of any ocular or systemic disease 
known to affect visual function. As a random sample of the population was desired, 
subjects were not excluded on the basis of having a colour vision defect. The School’s 
Research Ethics Committee approved the study and all procedures were carried out in 
accordance with the tenets of the Declaration of Helsinki. All participants provided 
written consent to taking part in the study, having received an information sheet prior 
to their appointment and having had the opportunity to ask any questions. 
 
Experimental procedure 
All participants attended the laboratory on two separate days within a period of two 
weeks. Baseline data were obtained at the beginning of the first session. This included 
patient history, logMAR visual acuity (ETDRS) OCT and fundus photography (Topcon 
3D OCT 1000). Lens clarity was assessed using a slit lamp biomicroscope, and graded 
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according to the LOCS III system for nuclear opalescence (NO), nuclear colour (NC), 
cortical opacity (C) and posterior subcapsular opacity (P) (Chylack et al. 1993).  
 
Stimuli for both psychophysical tests were presented on a calibrated, high-resolution 
24” widescreen LCD monitor (NEC MultiSync PA241W) with a frame rate of 60Hz, 
as depicted in Figure 41. The luminance of the monitor was ϒ-corrected (Appendix III) 
(Metha et al. 1993). In a dimly illuminated room, participants were positioned 1.4m 
away from the monitor, and any required refractive correction, appropriate for the 
viewing distance, was provided. The test eye was the eye with better visual acuity or, 
in the case of equal acuity, the right eye was selected. The fellow eye was occluded. 
The test order was randomised between subjects, but kept the same on both visits for 
each subject. 
 
Figure 41. Images showing the appearance of the moving coloured stimulus (Barbur et al. 
2006) (left panel) and flickering stimulus (right panel) used during the test. 
 
14-Hz Flicker Sensitivity 
Flicker thresholds were determined using the well-established Bayesian adaptive 
psychometric method known as QUEST (Watson and Pelli 1983; King-Smith et al. 
1994). In this method, the strength of each successive stimulus presentation is set to 
match the current most probable estimate of threshold. In practice, QUEST was 
implemented in Matlab (The Math Works Inc.) using routines available within 
Psychophysics Toolbox to drive a go / no-go adaptive staircase (Brainard 1997). The 
results from a practice run that included 10 trials were used as the starting point for a 
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final threshold estimate that converged after 40 trials. False positive responses were 
deemed to be responses that occurred more than 1s after stimulus offset. 
 
Subjects were asked to fixate the centre of the screen where the test stimulus, a 4o 
diameter foveated Gaussian blob at a temporal frequency of 14Hz, was presented for a 
duration of 2 seconds. The flickering stimulus was generated by modulating a 
luminance increment following a sinusoidal temporal profile. The mean luminance of 
the monitor was 51 cd/m2 and the x,y chromaticity co-ordinates of CIE colour space 
were 0.305, 0.323. To ensure that participants could not anticipate the next presentation, 
the inter stimulus interval was varied randomly between 4 and 10 seconds. The 
participants received verbal instructions on how to perform the test before undertaking 
the familiarisation trial. Their task was to press a button on a keypad as soon as they 
perceived a flickering stimulus in the centre of the monitor. If more than one false 
positive response was made, the practice trial was repeated until they were able to 
complete the familiarisation trial with a maximum of 1 false positive response. 
 
Colour Contrast Sensitivity 
Colour contrast sensitivity was assessed using the CAD test (v2.2.4, City Occupational 
Ltd). RG and YB colour detection thresholds were measured by employing coloured 
stimuli moving against an achromatic background. The background (CIE x,y 
chromaticity co-ordinates 0.305, 0.323; mean luminance 26 cd/m2) comprised a 
checkerboard of 15x15 squares (total 3.3 degrees diameter), which fluctuated randomly 
in luminance above and below the average background level in order to generate 
dynamic luminance contrast noise. The check luminance was distributed with equal 
probability within +/- 55% of background luminance. This noise masked the detection 
of residual luminance contrast cues in the isoluminant coloured stimulus. The colour-
defined stimulus comprised a checkerboard of 5 × 5 squares (total 1.1° diameter) 
moving diagonally across the checkerboard, in one of four directions. The stimulus 
duration was 600ms. A four-alternative forced choice procedure was used. 
Displacement thresholds were measured in 16 directions in colour space (6 red, 6 green, 
2 blue, 2 yellow), with colour directions selected to correspond to the red / green colour 
confusion lines (140 to 175 degrees) and the S-cone isolating axes (58 to 68 degrees). 
Threshold was determined using a two-down, one-up staircase in which colour intensity 
was reduced by an initial step size of 0.006 CAD units until the coloured stimulus could 
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not be distinguished from the background by the observer. This staircase procedure was 
repeated for nine reversals, at each of which the step size was reduced by 0.001 CAD 
units until a final step size of 0.002 CAD units was attained. Thresholds were obtained 
by averaging the chromatic distance in the CIE colour space during the last four 
staircase reversals.  
 
The participant’s task was to press one of four buttons on a keypad to indicate the 
observed direction of motion of the coloured stimulus. Each stimulus presentation was 
followed by an audible ‘bleep’ to indicate when to respond. A response was required, 
even if the participant was uncertain of the direction of movement. Any trial could be 
presented for a second time at the participant’s request. A suprathreshold familiarisation 
trial lasting 1 minute was performed prior to the main trial. A 100% correct response 
rate was required to ensure that the subject understood the requirements of the test. The 
‘definitive’ CAD program was then implemented and RG and YB thresholds were 
measured over 12 to 15 minute period.  
 
Figure 42 below shows the CAD test template for the standard normal (SN) observer, 
in which the shaded area represents the normal colour vision spectrum. The two ellipses 
denote the 2.5% and 97.5% confidence limits for a normal population and the black 
dotted line represents the median value for the standard normal CAD observer, i.e. 1 
standard normal unit (SNU) (Barbur and Rodriguez-Carmona 2006). The CAD test 
background had a luminance of 26 cd/m2. 
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Figure 42. The dotted, 
black ellipse is based on the 
median RG and YB thresholds from 250 observers, with the grey shaded area representing the 
95% limits of variability of these observers. The deuteranopic, protanopic and tritanopic 
confusion bands are displayed in green, red and blue, respectively. The background 
chromaticity (x,y) is indicated by the black cross (0.305, 0.323). The coloured symbols show 
data measured for a typical normal trichromat (Barbur and Rodriguez-Carmona 2006). 
 
Statistical Analysis 
Flicker thresholds were transformed into Weber contrast values by dividing pedestal 
luminance (I - Ib) by the average luminance (Ib).  The repeatability of the colour and 
flicker thresholds was assessed using established statistical techniques (Bland and 
Altman 1986). The coefficient of repeatability (CoR) was calculated by multiplying the 
standard deviation of the differences between the two visits by 1.96. Confidence 
intervals for the CoR were calculated according to the method described by Bland and 
Altman (Bland and Altman 1986).  
3.4 Results 
The thirty participants (13 female) were aged between 22-72 years (mean 36.3 ± 14.1 
years). All participants had a LOCS score of 0 for all parameters, apart from RE, who 
had NO2 and NC2 (LOCS III) (Chylack et al. 1993). One participant TM had a 
previously diagnosed protanopic colour vision defect.  
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Chromatic sensitivity and flicker thresholds were successfully obtained from all 30 
participants on two separate days. Data from the 2 visits were generally collected on 
successive days but always within two weeks. None of the participants required 
additional practice sessions for either test, which minimized potential inter-individual 
differences in any learning effect. An example of the flicker data obtained on both visits 
from a typical participant (AB) is shown in Figure 43. In each plot, the solid horizontal 
line represents the final threshold and the dashed horizontal lines denote the 95% 
confidence intervals. Sample CAD results from the same observer are shown in Figure 
44. 
 
 
Figure 43. 14Hz Flicker data for participant AB at visit 1 (a) and visit 2 (b), shown with the 
threshold in decibels. The dashed lines represent the 95% confidence intervals, with the solid 
line depicting the final threshold. 
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Figure 44. CAD data for participant AB at visit 1 (left panel) and visit 2 (right panel). The 
dotted black ellipse is based on the median RG and YB thresholds, with the grey shaded area 
representing the 95% limits of variability. The green, red and blue bands display the 
deuteranopic, protanopic and tritanopic confusion lines, respectively. The coloured symbols 
show the data measured for participant AB. 
 
Table 13 shows the CAD and flicker thresholds obtained for all 30 participants. Only 1 
subject (TM) with a congenital protanopic deficiency had a RG CAD threshold outside 
of the statistically determined normal limits (Barbur and Rodriguez-Carmona 2006). 
Similarly, only 1 subject (RE) had YB thresholds outside of the normal range. The lens 
opacities of this 72-year old participant had been graded as NO2 and NC2 (LOCS III) 
(Chylack et al. 1993), so this abnormal YB defect is most likely due to the early stages 
of nuclear cataract. Both of these participants, whilst falling outside of the published 
limits of normality (Barbur and Rodriguez-Carmona 2006), showed repeatable results. 
 
The difference in RG thresholds recorded at the first and second visit is plotted as a 
function of the mean RG threshold for all 30 participants in the Bland and Altman plots 
shown in Figure 45a, whereas Figure 45b shows the Bland Altman plot for RG 
thresholds with the protanopic individual’s data point removed to aid visualisation of 
the spread of the other data.  Similar plots for all 30 individuals are shown for YB and 
14Hz flicker thresholds in Figure 45c and d.  
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Table 13. RG, YB and 14Hz flicker thresholds for all 30 participants. 
 
 
 
Participant RG Threshold 
(CAD units) 
YB Threshold 
(CAD units) 
14Hz Flicker Threshold 
(Decibels) 
 Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2 
RH 1.26 1.08 1.06 1.05 0.025 0.034 
CM 1.31 1.32 0.87 1.07 0.021 0.018 
RN 1.47 1.26 1.91 2.05 0.027 0.024 
JS 1.53 1.66 1.33 1.5 0.025 0.025 
FVN 1.55 1.48 1.27 1.17 0.045 0.038 
BF 1.33 1.5 1.14 1.12 0.039 0.030 
EM 1.55 1.39 1.93 1.84 0.032 0.033 
CJ 1.26 1.12 1.2 1.31 0.014 0.008 
SH 1.94 1.78 1.84 1.39 0.020 0.013 
GM 1.54 1.37 1.18 1.21 0.044 0.033 
AW 1.48 1.37 1.46 1.19 0.032 0.024 
MD 1.49 2.01 1.16 1.11 0.039 0.019 
AB 1.1 1.12 1.08 0.75 0.016 0.016 
RW 1.32 1.3 1.28 0.82 0.032 0.031 
PB 1.19 1.09 0.82 0.94 0.039 0.032 
JT 1.12 1.01 0.99 0.76 0.039 0.018 
LT 2.08 2.03 1.71 1.7 0.027 0.027 
JC 1.84 1.4 1.14 1.5 0.051 0.036 
TH 1.49 1.25 1.06 0.75 0.030 0.024 
TR 0.91 0.99 0.88 0.67 0.024 0.018 
RD 1.61 1.39 2.35 2.04 0.037 0.031 
AN 1.35 1.02 1.66 1.65 0.025 0.023 
NW 2.21 2.31 1.73 1.96 0.033 0.029 
TK 1.41 1.03 1.06 1.03 0.022 0.024 
JF 1.24 0.98 1.14 0.76 0.016 0.017 
EM 1.47 1.19 1.32 1.26 0.022 0.016 
KA 1.27 1.26 1.59 1.19 0.031 0.047 
JA 1.24 1.2 1.34 1.36 0.019 0.018 
TM 26.48 26.39 1.42 1.17 0.015 0.015 
RE 2.77 2.32 3.69 3.43 0.059 0.046 
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Figure 45. Bland Altman plots for RG chromatic thresholds (a), RG chromatic thresholds 
excluding participant TM (b), YB chromatic thresholds (c) and 14Hz flicker thresholds (d). The 
difference between the measurements from visits 1 and 2 is plotted as a function of the mean 
of visits 1 and 2 for all 30 participants, and is shown with the bias (solid line) and 95% limits 
of agreement (dashed lines). 
 
In each graph in Figure 45, the solid horizontal line depicts the bias, i.e. the mean 
difference between the two visits, and the dashed horizontal lines represent the 95% 
limits of agreement, i.e. the mean difference ± the coefficient of repeatability (CoR). 
These plots describe the between session repeatability for all 3 measures. There was no 
evidence of a systematic change in repeatability with increasing thresholds (i.e. no 
heteroscadicity). The bias line crosses the y-axis slightly above 0 in all cases. Relative 
to visit 1, thresholds improved by 4.72%, 6.33% and 13.3% for RG, YB and 14-Hz 
flicker respectively, indicating the presence of a possible small learning effect.  
 
The mean RG, YB chromatic thresholds and 14-Hz flicker thresholds for visits one and 
two are shown in Table 14, along with the CoR for each test. The expression of the CoR 
as a percentage of the group averaged test result (at visits 1 and 2) allows a direct 
comparison of the repeatability of parameters with different units. Although the RG 
thresholds were more repeatable than the YB thresholds, the difference in the CoR was 
not significant (95% confidence intervals did not overlap). There was also no 
significant difference in repeatability between the YB CAD thresholds and 14-Hz 
flicker. However, the CoR for the RG CAD thresholds was significantly better than that 
of the 14-Hz flicker (see Table 14). Scatter plots showing the effect of age on the 
between visit variability are shown in Figure 46. There was no evidence of any 
systematic effect of age on variability for any parameter.  
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 Mean (± standard deviation) CoR (95% 
CI) 
CoR as % of 
mean 
threshold 
(95% CI) Visit 1 Visit 2 
RG Threshold 2.33 (± 4.58) 2.22 (± 4.58) 0.39 (± 0.13) 17.1 (± 5.6%) 
YB Threshold 1.42 (± 0.56) 1.33 (± 0.56) 0.43 (± 0.14) 31.1            
(± 10.2%) 
14-Hz Flicker 
Threshold 
0.030 (± 0.01) 0.026 (± 
0.009) 
0.015 (± 
0.005) 
53.4             
(± 17.6%) 
Table 14. Mean (± standard deviation) of all three parameters assessed at visit one and visit 
two. Coefficient of repeatability is given for each parameter, and as a percentage of the mean 
value.  
 
Figure 46. Scatter plots demonstrating the relationship between age and between visit threshold 
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variation for RG chromatic thresholds (A), YB chromatic thresholds (B) and 14-Hz flicker 
thresholds (C). Note the lack of a systematic relationship with age for any parameter. 
 
3.5 Discussion 
In order to monitor the progression of AMD and determine the efficacy of novel 
therapies, functional tests must be used that are reliable, repeatable and clinically 
applicable. This will allow candidate treatments to be assessed with maximum 
efficiency by minimising the sample size and follow-up duration required to achieve a 
useful end point. The development of functional tests sensitive to subtle changes in 
AMD status is also important in the clinical diagnosis and management of the condition 
in clinical settings. Visual acuity, despite the common acknowledgement that it is a 
poor assay of early AMD, is still the standard functional vision test amongst both 
clinicians and researchers. It is therefore necessary that new visual function tests are 
introduced that are as quick to perform and have the same ease of use as VA, but with 
improved sensitivity to disease progression and better inter-session repeatability. Two 
such tests that have shown to sensitive to disease severity in AMD are the 14Hz flicker 
and CAD chromatic sensitivity test (O’Neill-Biba et al. 2010; Dimitrov et al. 2011; 
Dimitrov et al. 2012). The flicker test employs a stimulus which is bigger (4 degrees 
diameter) than the stimulus presented in the CAD test (1.1 degree diameter). However, 
the CAD stimulus moves out from a central fixation position to a location extending to 
2.3 degrees into the parafovea. Hence both stimuli are assessing a region of the macula 
extending to around 2 degrees from fixation. This targets the parafoveal region in which 
functional deficits have been identified early in the AMD disease process (Owsley et 
al. 2001).  
 
The coefficient of repeatability (CoR) is an important statistical technique due to its 
potential to describe the smallest change that can be deemed clinically significant 
(Bland and Altman 1986). This is helpful in identifying those individuals who have 
shown a “clinically significant decline” in performance, and can therefore be used to 
determine the optimal sample size for a trial, i.e. it can be powered to detect a certain 
percentage of participants who show this level of functional decline. The most 
repeatable test was found to be the RG CAD threshold test. This performed significantly 
better than the 14-Hz flicker test which produced the least repeatable results. 
 116 
 
The Bland Altman plots all showed a mean difference between visits that was slightly 
above zero, suggesting a small learning effect for both the 14-Hz flicker test and the 
CAD parameters. This was confirmed by a post hoc paired samples t-test (p < 0.05) for 
all tests. This learning effect may have been minimised by the familiarisation trials 
which were carried out for the two techniques before both visits. If more than 1 false 
positive occurred on the 14-Hz flicker practice trial lasting 1 minute or if the subject 
did not score 100% in the CAD practice trial which also took 1 minute to complete, 
they were made to repeat it until they achieved the required standard and were deemed 
competent in task performance. However, the familiarisation trials were clearly not 
sufficient to saturate learning. 
 
A limitation of the study is that different repeatability values will need to be established 
if the tests are applied under different experimental conditions. A change in stimulus 
size, eccentricity, temporal frequency, retinal illuminance, or a change in the 
psychophysical procedure used, are all likely to affect the measured variability of the 
techniques. The repeatability index may also be different if the patient has disease or 
colour vision loss. For example, in their recent evaluation of the effect of retinal 
illuminance on chromatic thresholds, Barbur et al. hypothesized that the assessment of 
colour vision at mesopic levels may increase the diagnostic sensitivity of the test, 
through the exacerbation of the effect of disease-related hypoxia (Barbur and 
Konstantakopoulou 2012). Their ‘healthy retina index’ (HRindex) is a measure of the 
effect of retinal illuminance on chromatic thresholds. Additional repeatability data will 
be required to evaluate the clinical interpretation of mesopic chromatic thresholds and 
the HRindex. Inter-session repeatability is also likely to be influenced by the 
characteristics of the patient population. Hence, a further potential limitation of the 
repeatability data reported in this study is that the participant cohort was recruited from 
a University environment, and may not be generalizable to the population of patients 
with age-related macular degeneration. However, the age-range of participants 
extended to 72 years, and only 3 of the participants had previously taken part in 
psychophysical experiments hence, the group may be considered to be broadly 
representative of naïve participants in a clinical environment. Furthermore, we found 
no evidence of an effect of age on the between session variability, suggesting that the 
findings of this study will be broadly applicable across age groups. 
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One limitation of the go / no-go adaptive staircase procedure used in the flicker 
sensitivity test is that results are dependent on stimulus strength and an individual’s 
response criterion i.e. their willingness to guess. Response criterion can vary between 
and within individuals. We attempted to minimize within subject changes in response 
criteria by providing identical instructions at each visit. However, we cannot rule out 
the possibility that the systematic difference between visits (i.e. the bias) was due to a 
change in response criterion. Many things, including instructions, can induce the 
observer to raise or lower his or her criterion, causing threshold to shift up or down. 
This unknown internal criterion of the observer typically differs among observers and 
may vary across populations and over time. The four alternative forced choice paradigm 
employed by the CAD test negates the effect of inter-individual differences in the 
response criterion. 
 
The published limits of normality for the CAD test are based on data collected from 
250 colour normal participants (Barbur and Rodriguez-Carmona 2006). The majority 
of participants in this study produced thresholds which fell within these limits, apart 
from one protanope (TM), and one older participant with significant nuclear lens 
opacities (RE). Excluding these 2 participants, the mean (SD) RG thresholds for visit 1 
were 1.45 (0.29) and for YB 1.34 (0.37). The RG threshold is very similar to that 
reported by O’Neill-Biba et al. (2010) but the YB value is somewhat lower than that 
reported previously 1.6 (0.15). Control participants in the O’Neill-Biba study were on 
average 20 years older than those studied here and increasing lens opacification may 
therefore, explain the difference. Barbur et al reported that chromatic thresholds, 
uncorrected for differences in media absorption and pupil diameter, increase 
significantly with increasing age in the healthy population (Barbur and 
Konstantakopoulou 2012). 
 
In summary, this study has described the inter session repeatability of two tests that 
may be used in the diagnosis and monitoring of AMD. Both colour vision and flicker 
sensitivity tests have been shown to have excellent diagnostic capacity (Bowman 1978; 
Collins 1986; Brown and Kitchin 1987b; Applegate et al. 1987; Eisner et al. 1991; Holz 
et al. 1995; Frennesson et al. 1995; Phipps et al. 2003; Phipps et al. 2004; Arden and 
Wolf 2004; O’Neill-Biba et al. 2010; Dimitrov et al. 2011; Dimitrov et al. 2012; Luu 
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et al. 2013). The results of this study will help clinicians to determine if changes 
observed over time are due to measurement imprecision or disease progression, 
provided that the experimental conditions and psychophysical procedures are kept 
constant. The observation that a small but significant learning effect exists highlights 
the need for control groups in clinical trials of new AMD therapies. These and other 
candidate biomarkers must now be validated in longitudinal studies to confirm their 
prognostic and predictive capabilities. 
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Chapter 4. Clinical Trial Development 
As discussed in section 1.4, there is an growing amount of evidence implicating 
hypoxia as a major factor in the pathogenesis of AMD (Feigl 2007; Feigl 2009; 
Stefánsson et al. 2011). The maintenance of the dark current requires a vast oxygen 
supply. When this oxygen supply is further depleted in AMD, the resultant hypoxia 
may initiate increased VEGF production and apoptosis (Witmer et al. 2003). The 
metabolic demands of the outer retina could be significantly reduced by increasing 
environmental light levels during the night, thus reducing the oxygen demand and 
delaying hypoxia-induced disease progression (Arden 2001). Recent clinical trials in 
diabetes showed low-level night-time light therapy to be safe, well tolerated by patients 
and caused a reduction in diabetic macular oedema (Arden et al. 2010; Arden et al. 
2011). The same therapy could have substantial therapeutic benefits for people with 
AMD.  
 
This chapter will discuss the design of a pilot randomised controlled trial to investigate 
the effectiveness of low-level night-time light therapy for the treatment of AMD. The 
study design considerations include determining the optimal retinal illuminance for the 
therapy and the optimal mode of light presentation, as well as the specification of 
outcome measures, eligibility criteria, and sample size. The manuscript of this clinical 
trial protocol has been accepted for publication in a peer-reviewed journal (see 
Appendix IV). 
 
4.1 Calculating Retinal Illuminance 
Scotopic trolands are a measure of the retinal illuminance. If we designate corneal 
luminance as C (cd/m2), pupil area as P (πr2) then the resulting retinal illuminance, I, 
in trolands (Td) is described by Equation 3 (Thomas and Lamb 1999). 
Equation 3.    I = CP 
For a flash stimulus of duration t (s), the integrated retinal illuminance (L) is defined 
by Equation 4 (Thomas and Lamb 1999). 
Equation 4.    L = I t 
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Scotopic trolands may then be converted to the number of photoisomerisations per rod, 
Φ, using a conversion factor K, described in Equation 5 (Thomas and Lamb 1999). 
Equation 5.    Φ = LK 
Where K = 8.6 photoisomerisations s-1 per rod per scotopic troland. Note that this only 
applies if the bleach is not overly bright and the retina has recovered from any prior 
bleach (Thomas and Lamb 1999). 
 
As seen above, the measurement of scotopic trolands relies upon knowledge of the pupil 
diameter. Winn et al. (1994) measured the pupil diameters of 91 subjects (aged 17 to 
83 years) using an objective infrared-based continuous recording technique (Winn et 
al. 1994), at a luminance level of 9cdm-2. Figure 47 shows that the average pupil 
diameter in low-level lighting is between 4-6mm for people in the age range affected 
by AMD i.e. over 55 years of age. 
 
 
 
 
 
 
 
 
Figure 47. Pupil diameter as a function of age for a luminance of 9cdm-2. Data are fitted by 
linear regression with the 95% confidence limits indicated by the dotted line (Winn et al. 1994). 
4.2 Determining the optimal retinal illuminance for low level night-
time light therapy 
The light level employed must be sufficient to adequately suppress the rod circulating 
current, and at the same time be dim enough so as to not disrupt melatonin secretion 
and, consequently, circadian rhythms. The exact amount by which the rod circulating 
current needs to be reduced to produce a disease modifying effect on the level of retinal 
hypoxia is not known at present. Arden et al. used a retinal illuminance of 2 scotopic 
trolands in their recent clinical trial, citing Hamer et al. (2005) as the scientific 
justification for this value (Arden et al. 2011). 
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Hamer et al. aimed to produce a unified model of vertebrate rod phototransduction 
(Hamer et al. 2005). Part of their work involved an investigation into the effects of light 
adaptation on circulating current in toads and salamander rods (using previous data 
from Koutalos et al. (1995)). Increasing the intensity of the background adapting light 
was found to cause the circulating current to progressively decrease until, at the highest 
intensity background, circulating current was completely eradicated (Figure 48). 
 
 
 
 
 
 
 
 
 
Figure 48. The unified model is a reproduction of Koutalos et al.’s steady-state measurements 
of circulating current as a function of background light adaptation in salamander rods (Koutalos 
et al. 1995). J/Jdark is the ratio of circulating current to dark adapted circulated current. R*s-1 is 
the number of isomerized rhodopsin molecules per second. Data points: Koutalos et al.’s 
measures of rod steady-state current in Ringers (black triangles) or under a calcium clamp (blue 
circles). Dashed curves: Koutalos et al.’s model with a dark calcium value of 500nM. Data and 
model were shifted along the horizontal axis to compensate for differences in sensitivity 
between the salamander rods and Hamer et al.’s toad model. Solid curves: Corresponding 
predictions from Hamer et al.’s unified model. (Hamer et al. 2005). 
 
Arden et al. (2011) determined that the 505nm light used in their trial increased rod 
threshold by approximately 3 log units, which equated to a retinal illuminance of 2 
scotopic trolands (Td). It was stated that this would considerably reduce rod dark 
current and hence diminish oxygen demand, citing the work of Hamer et al. (2005) to 
substantiate this claim. However, this conflicts with previous reports from Thomas and 
Lamb (1999), who examined steady state light adaptation in eight human adults. The 
maximum size of the a-wave of the electroretinogram, amax, which provides a measure 
of the total rod photoreceptor circulating current (Hood et al. 1993), was recorded 
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during light and dark adaptation. This was determined by analysing the rising phase of 
the rod-isolated flash responses over a wide range of light intensities. Prior to the start 
of any recordings, the participant was dark adapted for 15 minutes. Bleaching was 
accomplished by presenting at least 1 ‘white’ flash for a duration of 1 millisecond in a 
Ganzfeld bowl. The larger bleaches were achieved by presenting multiple flashes at 5 
second intervals. 
 
 
 
 
 
 
 
 
 
 
 
Figure 49. Dependence of maximal response amax on background intensity collected from eight 
human subjects. The blue arrow indicates that a background intensity of 70 scotopic Td is 
needed to achieve a 50% reduction in amax. The red arrow indicates that 2 scotopic Td does not 
significantly reduce amax (Thomas and Lamb 1999).  
 
As shown in Figure 49, Thomas and Lamb found that the rod’s circulating current 
declined to half at a steady-state background intensity of 70 scotopic Td, which 
corresponds to approximately 600 photoisomerisations s-1 per rod. This suggests that 
the light intensity used by Arden et al. did not significantly reduce the circulating 
current (see red arrow in Figure 49). The data from Thomas and Lamb (1999) is 
substantiated by Nikonov et al. (2000), who found that about 400 photoisomerisations 
s-1 reduced the circulating current by 50% in salamander rods (see Figure 50). It is also 
comparable to the value of 100 Td that can be extracted for one human subject from 
97B of Pepperberg et al. (1997) and is close to the 58 scotopic Td (500 
photoisomerisations sec-1) required to reduce circulating current by 50% in a human 
subject from Kraft et al. (1993), shown in Figure 51 below. It also compares with 
findings from further animal studies, such as the 250 photoisomerisations s-1 per rod 
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required to diminish the rod circulating current by 50% in a mouse, shown in Figure 52 
(Lyubarsky et al. 1999). 
 
 
 
 
 
 
 
 
 
Figure 50. Dependence of steady circulating current of salamander rods on background 
intensity. Filled symbols indicated results from Nikonov et al.’s investigation, symbols from 
three previous studies are: ○, Hodgkin and Nunn, 1988; □, Matthews et al. 1988, average of 
seven cells; ⋄, Koutalos et al. 1995b, average of six cells (Nikonov et al. 2000). 
 
 
 
 
 
 
 
 
 
 
Figure 51. Responses to steps of light from rod photoreceptors. Filled circles plot steady-state 
response amplitude averaged over t = 4-6s as a function of light intensity. Open circles plot the 
amplitudes at 200ms. The curves plot the expected response amplitudes based on the 
instantaneous saturation function measured with brief flashes (Kraft et al. 1993) 
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Figure 52. Inferred steady “photocurrent” response amplitudes of rods to the background light 
steps, derived from a separate a-wave ERG (circles) and from data of two other mice (triangles) 
(Lyubarsky et al. 1999). 
 
Given this substantial evidence, including human data, it seems that 2 scotopic trolands 
is not a sufficient retinal illuminance to be confident of adequately reducing the rod 
circulating current. Whilst it is not known how much of a reduction would be ‘adequate’ 
to slow disease progression, a reduction of 50% will certainly reduce the oxygen 
demand in the outer retina in the dark. Using the data from Thomas and Lamb (1999), 
which is corroborated by Nikonov et al. (2000), Pepperberg et al. (1997) and Kraft et 
al. (1993), this suggests that 70 scotopic trolands may be a desirable light intensity for 
low-level light therapy. 
4.3 Potential problems associated with melatonin disruption 
4.3.1 Disruption of Circadian Rhythms 
A concern regarding the use of low-level light at night is the potential disruption of 
circadian rhythms due to a reduction in melatonin secretion (Brainard et al. 2001a). It 
is important in designing a night time light therapy to consider the light intensity at 
which melatonin secretion is likely to be affected.  
 
Circadian rhythms describe biological processes with an endogenously generated, 24-
hour cycle. They are generated by the central circadian pacemaker located in the 
suprachiasmatic nucleus (SCN) of the hypothalamus and are primarily entrained to the 
24-hour day by the light-dark cycle (Skene and Arendt 2006). Examples of human 
circadian rhythms include core body temperature and secretion of hormones such as 
cortisol and melatonin. As seen in Figure 53, these rhythms have a phase relationship 
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i.e. a set time interval between the different rhythms, however the timing of these 
rhythms is also entrained by the cycle of exogenous lightness and darkness. Indeed, 
because blind individuals lack a light-dark cycle, their circadian rhythms can become 
desynchronised from the 24-hour day (Lockley et al. 1997).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 53. Diagrammatic representation of the 
circadian rhythms of plasma melatonin, core body temperature, subjective alertness and task 
performance. The peak in the melatonin rhythm is indicated by the dotted line (Skene and 
Arendt 2006). 
 
Both animal (Lyubarsky et al. 1999; Lucas et al. 1999) and human (Brainard et al. 
2001a; Thapan et al. 2001) studies have discovered a novel photoreceptor system which 
is responsible for mediating non-image forming functions such as synchronisation of 
the circadian clock, inhibition of pineal melatonin, core body temperature elevation, 
alertness and performance. The discovery of the photopigment melanopsin (Provencio 
et al. 1998) and a network of melanopsin-containing intrinsically photosensitive retinal 
ganglion cells (ipRGCs) (Berson et al. 2002) provides a framework for understanding 
how light signals are transmitted to the SCN and consequently to the pineal gland. In 
primates, ipRGCs are larger, but display similar morphologies to mice (Dacey et al. 
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2005). These ipRGCs are now known to be critical in modulating numerous behaviors 
including circadian photoentrainment, the pupillary light reflex and sleep/arousal 
(Berson et al. 2002; Göz et al. 2008; Güler et al. 2008; Altimus et al. 2010; Ecker et al. 
2010).  
 
The pineal hormone melatonin is a primary circadian pacemaker, synchronising the 
endogenous hormonal environment to the exogenous light-dark cycle. Plasma 
melatonin is a most reliable indicator for the timing of the circadian rhythm and it is 
thought to be a valid biomarker of circadian disruption in humans (Kerenyi et al. 1990; 
Klerman et al. 2002; Mirick and Davis 2008). Melatonin in saliva, plasma or urine is 
preferable to other biomarkers such as core body temperature due to its comparative 
robustness in the presence of external influences such as stress and physical activity 
(Stevens and Davis 1996; Pandi-Perumal et al. 2007). During clinical investigations of 
circadian dysfunction, the melatonin “onset” i.e. the beginning of the evening rise in 
melatonin levels has been often used as a phase marker of the body clock, since it is 
simple and fast to measure. The disadvantage to this is that nothing is known of the 
duration, total production or peak level of melatonin secretion (Arendt 2005). 
The synthesis and secretion of melatonin from the pineal gland is most active during 
the night. Indeed, exposure to light can greatly suppress melatonin secretion (Lewy et 
al. 1980; Boyce and Kennaway 1987). The level of suppression is determined not only 
by the intensity of light, but also by its wavelength. Brainard and colleagues (2001) 
showed that in healthy humans, monochromatic light at 505 nm is circa four times 
stronger than 555 nm in suppressing melatonin (Brainard et al. 2001b). Lewy and 
colleagues (1980) were the first to discover that light intensity had an effect on the 
plasma melatonin levels in humans, shown in Figure 54 below. They found that 2500 
lux was able to suppress melatonin to daytime levels in 6 normal humans; 1500 lux 
produced an intermediate amount of inhibition and 500 lux was insufficient to cause 
suppression. 
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Figure 54. The mean + SEM % control-adjusted melatonin change values (N=8) at 505nm 
monochromatic light exposure. Note that progressively higher light irradiance exposure 
produces increasing melatonin suppression (Lewy et al. 1980). 
 
Boyce and Kennaway (1987) found rather different results to those of Lewy et al. in 
that 2500 lux in their study did not suppress melatonin to daytime levels, as depicted in 
Figure 55. They postulated that the reason for this discrepancy was that their study was 
conducted at midnight, whereas Lewy’s study was carried out between 2 and 4am. If 
such a circadian variation exists, it suggests that more light is required to suppress 
melatonin in the middle of the dark phase than early morning. 
 
 
 
 
 
 
 
 
 
 
 
Figure 55. Serum melatonin with 4 different light intensities (Boyce and Kennaway 1987) 
 
In 1989, McIntyre et al. examined the effect of five intensities of light on melatonin 
concentrations following one hour of light at midnight (McIntyre et al. 1989). 
Maximum suppression of melatonin was 71%, 67%, 44%, 38%, and 16% with 
intensities of 3,000, 1,000, 500, 350, and 200 lux, respectively. Unlike Boyce and 
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Kennaway, they found that 1000lux was sufficient to suppress melatonin to near 
daytime levels.  
 
Brainard and colleagues (1988) exposed 6 healthy adult males to 0.01, 0.3, 1.6,5, or 13 
μW/cm2 of 509 nm monochromatic light for 1 h during the night on separate occasions 
(Brainard et al. 1988). Light irradiance was found to reduce melatonin in a dose-
response pattern, the results of which are shown in Table 15. This shows that 
approximately 5 μW/cm2 (86 Scotopic lux) is sufficient to suppress the melatonin 
secretion by 50%. Arden et al. (2011) stated that the retinal illumination (480 nm) 
required to reduce melatonin secretion by 50% is 25 μW/cm2 (Arden et al. 2011), using 
data from the rod and cone outer segments of rhesus monkeys (Young 1971) and 
Sprague-Dawley rats (Schremser and Williams 1995) to justify this. Given the 
substantial published data regarding the effect of light on melatonin suppression in 
humans, it seems more appropriate to use this evidence as the basis for determining the 
threshold light level that reduces melatonin secretion by 50%, i.e. the more conservative 
estimate of 5 μW/cm2. Therefore, the irradiance employed by the sleep mask must be 
less than 5 μW/cm2 so as to not significantly disrupt the circadian cycle. 
Table 15. The effect of 509nm irradiances on suppression of plasma melatonin (Brainard et al. 
1988). 
 
4.3.2 Increased cancer risk 
One of the main concerns regarding exposure to artificial light at night is the hypothesis 
that the decreased melatonin production increases the risk of developing cancer 
(Kerenyi et al. 1990). Indeed, Stevens and Davis (1996) postulated that the light-
induced reduction in melatonin secretion led to an increased risk of breast cancer due 
to the increase in reproductive hormones such as oestrogens, which induced hormone-
sensitive tumours in breast tissue. Experimental studies support this hypothesis, 
showing that physiological and pharmacological doses of melatonin reduce the growth 
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of malignant cells in the breast (Hill and Blask 1988; Cos et al. 1996) and other tumour 
locations (Petranka et al. 1999). Furthermore, clinical trials have demonstrated the 
therapeutic potential of melatonin in the treatment of cancer (Lissoni et al. 1995). 
 
Numerous studies have been carried out to assess the risk of shift work on the 
development of breast cancer. In hospitals and office environments, where the majority 
of these studies have been conducted, the photopic illuminance is approximately 
between 100 and 300 photopic lux compared with 0.1 and 5 lux when asleep during the 
night and day, and 10,000 lux outdoors during daylight (Figueiro et al. 2006). A 
suggested threshold level for melatonin suppression is 30 lux of white light (Figueiro 
et al. 2006). On this basis, it is a reasonable assumption that night-shift women 
experience light levels that are bright enough and long enough to suppress nocturnal 
melatonin. A meta-analysis of 13 observational studies in 2005 suggested that shift 
work increased the risk of breast cancer by 48% (Megdal et al. 2005). However, there 
was evidence suggestive of confounding due to incomplete adjustment for risk factors 
such as reproductive history. Swerdlow (2003) mirrored this statement in his critical 
review of the epidemiological evidence. He concluded that although there is notable 
evidence for an association between shift work and breast cancer, it remains unclear 
whether this is simply as a consequence of confounding factors (Swerdlow 2003). A 
further systematic review also examined the role of nightshift work in other tumour 
locations, such as prostate and colon cancer. Three of the eight studies on breast cancer 
in women showed that long-term shift work (greater than 20-30 years) significantly 
increased the risk of breast cancer. However, since risk estimates were only moderately 
raised, there were few studies conducted and the studies all involved the same 
occupational group (nurses on nightshift), the results may be subject to bias, chance 
and confounding. The author found insufficient evidence of a causal association for any 
other cancers investigated (Kolstad 2008).  
O’Leary et al. (2006) found that women who frequently turned lights on at home during 
the night (≥ twice/week and ≥ twice/night) had increased risks of developing breast 
cancer. However, this may simply reflect response biases, especially since the overnight 
shift workers interviewed yielded reduced risk estimates. Similarly, Davis et al. (2001) 
asked 813 breast cancer patients and 793 control subjects about their bedroom ambient 
light levels, by selecting one of three categories (see hand in front of face; see the end 
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of the bed; read comfortably). The brightest bedrooms had an increased risk of breast 
cancer among subjects, however the result was not statistically significant (Odds ratio 
(OR) = 1.4, Confidence interval (CI)= 0.8 to 2.6).  
The limitation of these two studies is that they both relied upon self-report outcome 
measures. Hence, information bias may have played a significant role in these findings. 
At present, it is uncertain as to whether low-level lighting would have a significant 
effect on nocturnal melatonin production. Therefore, it is necessary for further 
experimental studies on the effect of chronic low-level light on melatonin expression 
to be conducted. 
4.4 Light Attenuation by the Human Eyelid 
In order to determine the retinal illuminance provided during sleep by an external light 
source, it is necessary to know how much light is transmitted through the eyelid. This 
has been investigated by several different researchers, the findings of which are 
summarised below. 
Moseley et al. (1988) transilluminated closed eyelids of 3 subjects (1 Asian, 1 
Caucasian, 1 Oriental) with an embedded optic fibre in an opaque contact lens. Light 
transmission at 500nm was found to be approximately 1%, with no significant 
difference between races. Later, Robinson et al. (1991) measured light transmission in 
vivo in 5 adults and 9 neonatals using a monochromatic grating presented though a 
fibre-optic mounted onto a contact lens underneath the lid and the signal was detected 
using a photodiode on the skin. At 505nm, about 2% light was transmitted through the 
eyelid, as depicted in Figure 56. 
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Figure 56. 
Transmission of light through the adult and neonatal human eyelid. Each point represents the 
mean of the data obtained from 5 adult subjects or 9 neonatals. The bars indicated the SEM 
(Robinson et al. 1991). 
 
More recently, Ando and Kripke (1996) used an optical diffuser, illuminated by a LED 
and placed 2cm from the eye, to measure light transmission. 11 subjects (6 men, 5 
women, 8 Caucasian, 3 Asian) were examined, and visual thresholds were determined 
for large fields and short exposure. Estimated light transmission for blue light was 0.3% 
(±0.2), with no significant different difference in the age or race of subjects. Females 
were found to transmit a slightly higher percentage of light.  
 
The difference in values for transmission found by the 3 studies is likely to be mainly 
due to the differences in measurement techniques. Moseley et al. (1988) required 
precise alignment of the source and detector to obtain maximum signal strength, 
whereas Robinson et al. had 200x larger sample and reference signals, enabling a better 
signal-noise ratio. Both of these studies used a contact lens, which caused measurement 
of scattered light to be variable. Ando and Kripke used a method that examined light 
from a wide visual field. In conclusion, the light transmission through the human eyelid 
at 505nm is approximately 1%. 
4.5 Delivery of Light  
As discussed in Section 4.2, it would be desirable to reduce rod dark current and thus 
oxygen consumption of rods by approximately 50%. The illumination required to 
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preferentially stimulate rod photoreceptors would have a peak output of approximately 
500nm, with less output at longer and shorter wavelengths. The latter is particularly 
important to avoid the ‘blue light hazard’ that occurs below 480nm (Taylor et al. 1992; 
Bradnam et al. 1995), in which the short-wavelength photons can cause damage at 
lower fluxes. Furthermore, the 500nm wavelength is close to the peak rod sensitivity, 
and so will be efficient at suppressing the rod dark current.  
 
One simple, cost-effective means of delivering light to patients during sleep is the use 
of a simple bedside lamp. The advantage of this is that it could be easily implemented 
in homes without creating substantial financial burdens on either the individual or the 
NHS. In order to ensure that both eyes were receiving the same level of illumination 
using an angle poise lamp, the sleep position of the participant would need to be supine. 
However, adults are much more likely to adopt a lateral sleeping position (De Koninck 
et al. 1983). Therefore, it would be impossible to ensure that all participants were 
receiving a standardised amount of light during the night. Although this would be 
acceptable for a pragmatic phase III clinical trial, it would not be appropriate for an 
exploratory phase I/II trial with a small number of subjects.  
 
An alternative method of light delivery is for participants to wear an eye mask that 
emits a small amount of illumination during the night. In the pilot study of the effect of 
light therapy on diabetic retinopathy, Arden et al. (2010) made a mask that involved 
chemical luminescent ‘glow patches’ designed by Omniglow Corporation. These were 
safety certified, soft capsules with the appearance of a standard eye patch. When 
compressed, the two chemicals inside the capsules mixed together producing light with 
a dominant wavelength through the lids of 550nm. Headbands were needed to keep the 
glow patch in place, which were made of a light plastic that was inert and medically 
approved for comfort and safety.  The 12 patients in the study who wore the glow patch 
over one eye for periods of up to 1 year had no ocular or systemic adverse effects, and 
did not suffer from any sleep disruption whilst wearing the glow patches. Since there 
were no dropouts during the study, it suggests that the non-invasive sleep mask was 
acceptable to the participants. However, the illumination of these disposable devices 
was not consistent and reduced significantly with time. For this reason, in their second 
trial, light emitting diodes (LEDs) were preferred as the new light source (Arden et al. 
2011). The replacement frequency was modified from daily replacement to a 2-yearly 
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disposable eye mask, which permitted a more reliable and efficient light source. The 
four LEDs, each drawing 200uA current producing a peak wavelength of 505nm, were 
contained in a transparent silicone rubber shell and the printed circuit board was 
enclosed in a thick cotton cover, held against the eyes by an elastic headband. The 
device was driven by a battery that was recharged every morning. After 6 months, none 
of the participants reported any difficulty in wearing the masks, or any sleeping 
problems or mood alterations during the trial period. A limitation of the masks is that 
they had no means of assessing whether the LEDs were always positioned in front of 
the pupil during the night. This risk could be reduced by ensuring that the masks are 
properly fitted on the patient, with the headbands securely fastened.  
 
A 12-weekly disposable light mask (Polyphotonix Medical, UK) has been developed 
recently, which is able to deliver precise illumination levels. The replacement 
frequency is higher than that of the previous light mask used by Arden et al. (2011), 
which ensures that the illumination remains constant over time. It presents organic LED 
illumination with a peak output of 502nm and a luminance of 75 photopic cd/m2. This 
equates to 186 scotopic cd/m2 when adjusted for the spectral sensitivity of rod 
photoreceptors (Wyszechki and Stiles 1982). Under this illumination, pupil diameter 
for people aged 60-85 years is approximately 4mm (Winn et al. 1994). This will 
produce a retinal illuminance of 23 scotopic trolands, assuming an eyelid transmission 
of 1%. This will reduce the rod circulating current by approximately 25%, according to 
the human data presented in Figure 49. 
 
In order to standardise the period of mask usage by all individuals, the masks can be 
pre-programmed to function during a specific time period e.g. 8pm to 8am. If worn 
outside of these hours, the masks will not function. The mask illuminates when a sensor 
on the device is lightly pressed for 3 seconds. The mask will deactivate if not worn 
continuously for the first 15 minutes, after which it will remain on for 8 hours. The 
mask also contains a chip with a sensor that records when the mask is in contact with 
the face, providing precise information regarding the number of hours the mask is worn 
each night. This enables study investigators to objectively evaluate treatment fidelity. 
Each mask is also encrypted with a unique patient identification code, so that 
compliance data will be non-identifiable except via a password-protected database. In 
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order to assess treatment acceptability, a monthly interview would be recommended 
with each participant, during which a diary of mask usage should be discussed. 
4.6 Summary of Study Design   
A prospective Phase I/IIa proof of concept randomised controlled trial (RCT), 
consisting of two parallel groups with a 12-month follow-up period is proposed. Trial 
recruitment and data collection will take place in a medical retina clinic at a local eye 
hospital. Ophthalmologists will identify potential trial participants who are attending 
for their first appointment at the wet AMD clinic. Eligible participants will have 
neovascular AMD in one eye, and early AMD only in the fellow eye. The early AMD 
eye will be the study eye. Sixty participants will be recruited to the trial. In addition, 40 
control participants and participants with grade 1 AMD (AREDS simplified scale) for 
a baseline cross-sectional analysis will be recruited by local optometrists in Bristol and 
Cardiff, from a database of elderly volunteers, from the Bristol Eye Hospital, from the 
list of research volunteers at the Cardiff University Eye Clinic and from staff and 
students of Cardiff University. The 60 participants taking part in the clinical trial will 
be stratified according to risk of AMD progression using the AREDS simplified scale 
(Ferris et al 2005) and randomly allocated to receive either light mask or no intervention 
in a 1:1 ratio using computer generated random permuted blocks (both groups will 
continue to receive Ranibizumab injections as required for the fellow eye). It is not 
appropriate in this study to use a sham treatment since a non-illuminated mask may 
have a physiological effect on the retina and patients would be aware that they weren’t 
perceiving light and so would be unmasked to their intervention group. The intervention 
will be the Polyphotonix eye mask (see Section 4.5) that emits a dim green light through 
organic LEDs, illuminating the retina through closed eyelids at night. This is designed 
to reduce the metabolic activity of the retina, thereby reducing the potential risk of 
hypoxia. Participants will wear the mask every night for 12 months. A study flow 
diagram is shown in Figure 57 below. 
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Figure 57. Study flow diagram showing participant timeline 
 
4.7 Trial Objectives   
The primary aim of this trial is to collect preliminary data from people with early AMD 
in one eye and neovascular AMD in the fellow eye, in order to assess the effect of low-
level light therapy at night, compared with no intervention, on the progression of early 
AMD. Secondly, the safety of the intervention will be assessed since this is the first 
trial investigating light therapy in patients with AMD. 
The secondary aims of the study are to: 
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1) Establish the effect of low-level night-time light therapy, compared with no 
treatment control, on secondary outcome measures, including: change in drusen volume 
from baseline in the eye with early AMD; Ranibizumab retreatment rates in the fellow 
eye with nAMD; progression of early AMD on the basis of change in functional 
outcome measures; change in health related QoL (assessed using the EuroQol EQ-5D 
instrument); change in self reported visual function assessed using the 48-item Veterans 
Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48). 
2) Establish the acceptability of low-level night-time light therapy in people with AMD 
by monthly qualitative interviews. 
3) Determine the effect of low-level night-time light therapy on sleep patterns by 
conducting the Pittsburgh Sleep Quality Index (PSQI) questionnaire every month with 
both intervention arms by interview with the study investigator. 
4) Establish the relationship between baseline functional biomarker outcomes and the 
severity of AMD (assessed using simplified AREDS grading scale and initial drusen 
volume). 
5) Evaluate the ability of all clinical tests to act as prognostic biomarkers for AMD 
progression. 
6) Evaluate the ability of all clinical tests to act as predictive biomarkers for low-level 
night-time light therapy in people with AMD. 
7) Compare the sensitivity of all clinical tests to disease progression over 12 months. 
4.8 Eligibility criteria 
Inclusion criteria 
 Between the ages of 55-88 years 
 ETDRS visual acuity 40 letters or better in the test eye  
 Early AMD in the study eye 
 nAMD in the fellow eye, within a month of 3rd Ranibizumab injection (trial 
only) 
 Willing to adhere to allocated treatment for duration of trial 
Exclusion criteria 
 Ocular pathology other than macular disease 
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 Significant systemic disease or medication known to affect visual function 
 Systemic disease that would compromise participation in a 1 year study (trial 
only) 
 Insufficient English language comprehension  
 Cognitive impairment as determined using an abridged Mini Mental State 
Examination (MMSE)  
 Oxygen mask worn at night 
Suspension criteria for the Trial 
 Participant wishes to discontinue the study 
 Serious adverse events (e.g. conversion of nAMD in the test eye) or 
unexpected changes in clinical status 
4.9 Intervention 
Participants will be randomly allocated to either the treatment arm, or a no treatment 
control group. Those allocated to the treatment group will be given a 12 weekly 
disposable light mask (Polyphotonix Medical, UK) that presents organic LED 
illumination (peak output 502 nm) to both eyes, overnight, for 12 weeks. Light masks 
will be replaced every 12 weeks at the participant’s routine appointment at the nAMD 
clinic so that the total duration of mask usage is 12 months.  
The current management of patients with early AMD involves advising on modifying 
their lifestyle, for instance, cessation of smoking and improving diet. The only other 
intervention which is based on evidence from a robust RCT is the provision of a 
nutritional supplement consisting of high dose antioxidants plus zinc. This AREDS 
formula (vitamin C, 500 mg; vitamin E, 400 IU; beta carotene, 15 mg and zinc, 80 mg) 
has been shown to reduce risk of progression from early to advanced AMD by around 
20% over 5 years in people with specific features of AMD (AREDS 2001a). However, 
a recent systematic review by the Cochrane Collaboration indicated that there may be 
an increased risk of mortality in individuals taking vitamin E and beta carotene 
supplementation (Evans and Lawrenson 2012). As this was recently published, it is not 
reflected in the current guidelines for the management of AMD. For this reason, the 
low level light therapy will be compared to a no-treatment control, rather than to the 
AREDS formula as the best current intervention. 
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Participants in both groups will receive routine ophthalmological care for the eye with 
nAMD (i.e. Ranibizumab injections). If the eye with early AMD converts to nAMD, 
they will proceed to Ranibizumab treatment for this eye also, and will be withdrawn 
from the study.  
4.10 Sample Size  
The aim of this Phase I/IIa proof of concept study is to assess the acceptability of night-
time light therapy, and to provide baseline data to enable a larger Phase III randomised 
controlled trial to be carried out. Therefore, it will not be powered to detect small 
changes. The aim is to recruit 60 people, which, allowing for a 15% dropout throughout 
the 12-month period, will leave a final cohort of 51. This will be enough to detect a 
50% reduction in participants showing disease progression at a probability level of 0.2 
with a power of 80%, and a change in the time constant of cone adaptation of 1 minute 
to be detected at a probability level of 0.05 with a power of 80%.  
4.11 Statistical Analysis  
Statistical analysis will be carried out on an intention-to-treat basis. There will be no 
interim analysis, but conversions to nAMD in the eye with early AMD at baseline, and 
ranibizumab retreatments for the fellow eye, will be recorded at each participant visit 
to the nAMD clinic for safety monitoring purposes. This trial will primarily be 
concerned with providing information about the safety of the device in the treatment of 
AMD, and the magnitude of any treatment effect. On this basis, descriptive statistics 
will be carried out to summarise the demographic characteristics of the two groups, as 
well as the proportion of individuals showing disease progression in each group, the 
magnitude of changes in secondary outcome measures, including drusen volume, 
measures of visual function, and the self-report tests, and the fellow eye retreatment 
rates. 
The primary outcome measure will be the proportion of patients demonstrating disease 
progression at 12 months. Comparisons will be performed using stratified Mantel-
Haenszel tests and presented as forest plots. Formal statistical analysis will also include 
linear regression analysis to investigate changes in drusen volume controlling for 
intervention arm, baseline drusen volume and patient characteristics. Analysis of 
covariance (ANCOVA) will be carried out to compare the change in secondary 
outcome measures and the ranibizumab retreatment rates over 12 months between the 
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two intervention arms. Note that all analysis except for the ranibizumab retreatment 
rate pertains to the eye with early AMD. To establish the relationship between baseline 
functional biomarker outcomes and the severity of AMD, a one-way analysis of 
variance (ANOVA) will be conducted to compare the mean results at baseline between 
participants with grades of AMD in each group on the AREDS simplified scale. This 
analysis will take place when the baseline data collection is complete. To assess the 
ability of the clinical tests to act as prognostic and predictive biomarkers, receiver 
operating characteristics curves will be constructed to plot the sensitivity and specificity 
of the baseline measures in predicting outcomes within the control and intervention 
arms, respectively. When the trial is completed, linear regression analysis will be used 
to determine how well the change in the functional measures relate to the change in our 
primary outcome measure (drusen volume), which is a validated biomarker for disease 
progression.  
4.12 Outcome Measures  
This study will include two co-primary outcome measures, one examining structural 
changes and one measuring functional changes. The former will be the proportion of 
people demonstrating disease progression in the eye with early AMD during the 12-
month trial period. This will be based on an increase in drusen volume beyond the test-
retest confidence intervals (Yehoshua et al. 2011a) or the development of advanced 
AMD. The drusen analysis software available for the Cirrus OCT, described in Section 
1.3.5, allows drusen volume to be objectively assessed. No matter what the initial 
drusen volume, approximately 50% of people with AMD will have a significant 
increase in drusen volume over 12 months (Yehoshua et al. 2011a). A recent trial shows 
that about 10% of people will develop advanced AMD within 12 months (Neelam et 
al. 2008). Therefore, it is expected that 60% of participants would have an increase in 
drusen volume or a progression to advanced AMD. The development of the latter would 
be diagnosed by an ophthalmologist at the patient’s monthly Ranibizumab clinic 
appointment. The primary functional outcome measure will be the change in the rate of 
retinal adaptation i.e. the time taken for photoreceptors to regain sensitivity following 
exposure to a bright flash of light.  
Secondary outcome measures include the change in drusen volume over the 12-month 
trial period; the number of Ranibizumab retreatments required during the trial period in 
the fellow eye with wet AMD; changes in chromatic thresholds using the CAD test, 
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changes in visual acuity, psychophysical 14Hz flicker thresholds, self-report outcome 
measures including health related quality-of-life (EQ-5D) and visual function (VFQ-
48), a sleep quality questionnaire (Pittsburgh Sleep Quality Index, PSQI) and a semi-
structured interview (via monthly phone calls) to determine intervention acceptability. 
The primary outcome measures and the first secondary outcome measure (the change 
in drusen volume) will be assessed at baseline and then at monthly intervals using OCT 
images obtained at the regular Ranibizumab follow-up appointments, in order to gain a 
better understanding about the time-course of structural changes as a result of the 
intervention. 
4.13 Safety 
Since low-level light-therapy is non-invasive, the risk of safety issues associated with 
the device is low. It is unlikely that any chemical, electrical or mechanical damage from 
the light-mask would occur, since the components of the light source and battery are 
sealed in a plastic casing. Allergic reaction to the foam that contacts the patient is also 
unlikely, since the plastic is inert. There is a potential for the device to disturb sleep. 
However, two previous trials using light-masks have not reported any adverse effects 
due to sleep disruption (Arden et al. 2010; Arden et al. 2011).  The potential impact of 
device failure is that no light will be emitted and the device will be replaced. Therefore, 
no serious ethical considerations are apparent. 
 
However, as this is the first clinical trial investigating the effect of low-level light 
therapy on AMD, it is important to monitor safety closely. All adverse events (AE) and 
serious adverse events (SAE) will be recorded. The chief investigator of the trial will 
be updated on AEs every month, and SAEs within two working days. Since the trial 
does not involve medicinal product or life-threatening procedure, the risk of a SAE is 
low. However, potential SAEs include an increased rate of developing wet AMD in the 
eye with early AMD and an increased rate of neovascular AMD recurring in the fellow 
eye, resulting in increased Ranibizumab retreatment rates. These SAEs would be 
diagnosed by ophthalmologists at the monthly Ranibizumab clinic and recorded by the 
study investigator by monthly assessment of medical records. In a recent meta-analysis 
of 5 studies investigating the development of wet AMD in the fellow eye, it was 
reported that the cumulative incidence of wet AMD in the 426 patients was 12.2% (CI 
1.7% - 30.6%) (Wong et al. 2008). Therefore, a reasonable upper limit for the number 
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of people likely to convert to wet AMD each month would be n x (30.6% / 12 months), 
where n is the number of people wearing the light mask in the trial. 
 
It is up to the chief investigator to evaluate the nature of the AEs and SAEs for 
seriousness, causality and expectedness. If an SAE occurs that is both related and 
unexpected, the chief investigator will notify the National Research Ethics Service, the 
Trial Steering Committee, and the Device Manufacturer who will in turn notify the 
MHRA within 15 days of being informed of the SAE.  
4.14 Summary 
Age-related macular degeneration (AMD) is the leading cause of blindness among 
older adults in the developed world. The only treatments currently available, such as 
Ranibizumab injections, are for neovascular AMD, which accounts for only 10-15% of 
people with the condition. Hypoxia has been implicated as one of the primary causes 
of AMD, and is most acute at night when the retina is most metabolically active. By 
increasing light levels at night, the metabolic requirements of the retina and hence the 
hypoxia will be significantly reduced. In this chapter, the development of a clinical trial 
protocol has been described which seeks to determine whether low-level night-time 
light therapy in patients with early AMD can prevent the progression of early AMD. 
This will be the first randomised controlled trial of its kind in AMD.  
The intervention is an eye mask which emits a dim green light which illuminates the 
retina through closed eyelids at night. This is designed to reduce the metabolic activity 
of the retina, thereby reducing the potential risk of hypoxia. The retinal illuminance 
required to reduce oxygen demand by 50% in the dark is approximately 70 scotopic 
trolands. There is a concern that this light during the night will disrupt circadian 
rhythms due to a reduction in melatonin secretion. Therefore, the retinal illuminance 
employed by the sleep mask must be less than the threshold that reduces melatonin 
secretion by 50% so as to not significantly disrupt the circadian cycle. A luminance of 
75 photopic cd/m2 (equivalent to a retinal illuminance of 23 scotopic trolands) is 
sufficient to substantially reduce oxygen demand whilst not disrupting circadian 
rhythms, and hence sleep quality.  
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Chapter 5. Discussion and Future Work 
This thesis has presented the development and evaluation of three functional 
biomarkers for the assessment of progression of AMD. It has confirmed that delayed 
dark adaptation is highly diagnostic for early AMD. Three stimuli, evaluating different 
macular locations, were compared, and it was determined that the assessment of foveal 
cone adaptation was optimal when using a 2o radius stimulus (although the diagnostic 
capacity did not differ significantly from that provided by the other stimuli). Cone tau 
using the 2o radius stimulus was able to distinguish patients with early AMD from 
healthy controls with a sensitivity of 90% and a specificity of 100%, and with an inter-
session repeatability of 36.4%. The inter-session repeatability of two further functional 
tests known to be sensitive to early AMD, 14-Hz flicker thresholds and CAD chromatic 
sensitivity, was also established. The most repeatable test was found to be the RG CAD 
test, which performed significantly better than the 14-Hz flicker test. Finally, these 
outcome measures were used in the development of a protocol for a clinical trial 
examining the impact of low-level light therapy, a novel therapeutic intervention, on 
the progression of AMD.  
5.1 Discussion 
Age-related macular degeneration (AMD) is responsible for more than 50% of visual 
impairment registrations in the UK (Bunce et al. 2010) and is the leading cause of 
blindness in the developed world (Resnikoff et al. 2004). For the majority of people 
with AMD, there is no treatment. The remaining 10-15% of people with the advanced, 
neovascular form of the disease are mainly treated with intra-ocular injections of 
Ranibizumab. Follow up for these patients is long term and places a significant burden 
on the NHS. Indeed, advanced AMD currently costs the British economy £1.2B to 
£3.7B p.a (Access Economics 2009; Cruess et al. 2008). Furthermore, the disease is 
associated with depression, falls and social isolation (Dargent-Molina et al. 1996; 
Margrain et al. 2012). Given that the average age of the UK population is predicted to 
increase during the next two decades (Office for National Statistics 2009), this 
significant socioeconomic problem will simply continue to worsen as the incidence of 
AMD increases. Therefore, there is a great need to evaluate potential therapeutic 
interventions that endeavor to treat the disease at an early stage, to prevent sight loss 
from occurring.  
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Early AMD develops slowly over time, and therefore end stage disease is not a suitable 
outcome measure to use in Phase II clinical trials of novel interventions.  Therefore, 
biomarkers must be implemented as surrogate outcome measures, which are both 
sensitive to changes in visual function over time and have a high level of intersession 
repeatability. Visual acuity is the most commonly used psychophysical test of visual 
function in clinical trials. However, VA is relatively unaffected during the early stages 
of AMD, making it insensitive to early changes in disease progression. Furthermore, 
the inherent variability of the test (1.5 logMAR lines) (Siderov and Tiu 1999) will often 
mask the minute changes in VA that occur in early AMD (2 letter loss) (Klein et al 
1995). Therefore, recent cross-sectional studies have evaluated a number of alternative 
functional biomarkers for AMD, including dark adaptation (Gaffney et al. 2011; 
Dimitrov et al. 2011; Dimitrov et al. 2012), temporal sensitivity  (Dimitrov et al. 2011; 
Dimitrov et al. 2012) and colour vision (O’Neill-Biba et al. 2010). 
 
Dark Adaptation 
Dark adaptation describes the recovery of visual sensitivity following exposure to a 
bright light which bleaches a substantial proportion of photopigment (Lamb and Pugh 
2004). There is a growing body of evidence to suggest that dark adaptation is a sensitive 
biomarker in AMD, as discussed in Chapter 1 (Brown and Kitchin 1983; Brown et al. 
1986a; Owsley et al. 2001; Owsley et al. 2007; Dimitrov et al. 2008; Dimitrov et al. 
2011). Indeed, Dimitrov et al. (2011) rated rod recovery during dark adaptation to have 
the greatest diagnostic capacity compared to a battery of other tests including flicker 
sensitivity, photostress recovery and colour vision. However, due to its lengthy 
recording period and relative test difficulty it was deemed to have limited clinical 
applicability. Cone dark adaptation, on the other hand, is able to detect early AMD with 
a shorter test duration (Phipps et al. 2003; Dimitrov et al. 2008; Gaffney et al. 2011). 
 
Gaffney et al. (2011) found that the time constant of cone recovery (cone τ) and the 
time to rod-cone break (RCB) were most diagnostic for early AMD when measured at 
12o from the fovea compared to 0.5o, 2o and 7o retinal eccentricities. However, since 
the stimuli were not area-matched, it was not clear whether the 12o stimulus truly had 
the greatest diagnostic potential or whether it simply had less variability due to the 
larger retinal area stimulated. Therefore, in Chapter 2, the dynamics of dark adaptation 
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were assessed using 3 area-matched stimuli (2o radius spot and 7o and 12o radii annuli) 
in 10 participants with early AMD and 10 age-matched controls. The cone τ and time 
to RCB were highly diagnostic for AMD using all 3 stimuli, yielding areas under the 
ROC curves between 0.830 and 0.940.  No statistically significant differences were 
found in the diagnostic performance between any parameter.  This is contradictory to 
the previous findings of Gaffney et al. (2011), and suggests that the annular stimulus at 
12o was found to be most diagnostic in their study because the larger retinal area 
reduced variability. Therefore, all three stimuli would be suitable to use in the diagnosis 
of AMD.  
 
However, for dark adaptation to be implemented as a biomarker in clinical trials, it is 
necessary to calculate its inter-session repeatability. This will enable clinicians to 
determine whether changes observed over time are due to measurement imprecision or 
disease progression. For this reason, the repeatability of cone τ and time to RCB was 
assessed using the same three stimuli in a cohort of 11 healthy young adults and 10 
healthy older adults. The time constant of cone recovery using the 2o stimulus produced 
the lowest coefficient of repeatability, although this was not significantly different from 
the other stimuli. There was no statistically significant difference in repeatability 
between the 6 parameters investigated (cone τ and time to RCB for 2o spot, 7o and 12o 
radii annuli), with CoRs ranging between 36.4% and 53.3%. Therefore, any of the 3 
stimuli may be used to monitor the progression of AMD and determine the efficacy of 
novel therapeutic interventions.  
 
14-Hz Flicker Test and Colour Assessment and Diagnosis (CAD) Test 
A number of studies have found temporal sensitivity to be reduced in patients with 
AMD (Mayer et al. 1992b; Mayer et al. 1994; Phipps et al. 2003; Phipps et al. 2004; 
Dimitrov et al. 2011; Luu et al. 2013). This is thought to be due to a compromised outer 
retinal oxygen supply in AMD being unable to meet increased metabolic demand 
elicited by flickering stimuli (Kiryu et al. 1995; Riva et al. 2001). The threshold for 
flicker detection has been rated as having the highest potential clinical value in the 
diagnosis and monitoring of AMD as it can be performed quickly, is reproducible and 
diagnostically sensitive (Phipps et al. 2004; Dimitrov et al. 2011). Furthermore, flicker 
threshold has also been shown to increase gradually with disease progression (Dimitrov 
et al. 2012). 
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An increase in chromatic thresholds, especially in the YB domain, has long been 
reported to occur in early AMD. Tritan colour contrast thresholds are abnormal in 
patients with AMD and minimal lens opacities (Arden and Wolf 2004), and they also 
change significantly over time in patients with early AMD compared with age-matched 
controls (Holz et al. 1995). A new computer-based technology, the CAD test, has 
recently been developed which enables the rapid quantification of chromatic thresholds 
(Barbur and Rodriguez-Carmona 2006). Using this test, YB thresholds have been found 
to increase linearly with disease severity (O’Neill-Biba et al. 2010).  
 
In Chapter 3, the coefficient of repeatability of these two candidate functional 
biomarkers was evaluated in 30 healthy adult participants. The most repeatable test was 
found to be the RG CAD threshold test, which performed significant better than the 14-
Hz flicker test. A small learning effect was found for both the 14-Hz flicker and the 
CAD parameters, indicating that the familiarisation trials were not sufficient to saturate 
learning. This observation indicates that a control group is required if these biomarkers 
are to be implemented in clinical trials of new interventions for AMD. The results of 
this study will help clinicians determine if changes over time are due to measurement 
imprecision or disease progression, provided that the experimental conditions and 
psychophysical procedures are kept constant. These, and other candidate biomarkers 
such as cone dark adaptation, must now be assessed in longitudinal studies to validate 
their prognostic and predictive capabilities. 
Clinical Trial Development 
Age-Related Macular Degeneration is characterised by the dysfunction and death of 
photoreceptors in the central retina. There is an increasing amount of evidence to 
implicate hypoxia in its pathogenesis (Feigl 2009; Stefánsson et al. 2011). By 
increasing the light level during the night, the metabolic demands of the outer retina 
could be significantly reduced, thus reducing the oxygen requirements, and potentially 
providing an intervention which would reduce the progression of conditions with a 
hypoxic aetiology, such as AMD and diabetic retinopathy (Arden 2001).  Indeed, a 
recent clinical trial in patients with diabetic macular oedema who wore a low-level light 
mask during the night for 6 months found a reduction in oedema and an improvement 
in functional measures in the treated eye only, which was ascribed to the obviation of 
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hypoxia (Arden et al. 2011). Chapter 4 described the development of a clinical trial 
protocol that seeks to determine whether the same intervention (low level light therapy) 
could prevent the development of AMD.  
A literature review of the effects of background luminance on the rod circulating 
current determined that 50 scotopic Td would provide a 50% reduction in the dark 
current. However, to minimise the effect of the intervention on the night-ime melatonin 
production, a retinal illuminance of 23 scotopic Td (causing a 25% reduction in 
circulating current) was selected for the trial. This chapter also reviewed literature on 
the best way of presenting this retinal illuminance, and determined that a light mask 
strapped to the participant’s head at night would eliminate the problems represented by 
differences in the sleep position of different individuals when attempting to standardise 
the dose of light presented.  
In summary, the main conclusions of this thesis are: 
 Cone dark adaptation is a sensitive functional biomarker for early AMD. 
 Area-matched stimuli of 2o, 7o and 12o radii have equal diagnostic validity and 
inter-session repeatability for the assessment of cone dark adaptation in early 
AMD . 
 The red-green CAD threshold test was significantly more repeatable than the 
14-Hz flicker test. 
 A small, but significant, learning effect exists for both the 14-Hz flicker test and 
the CAD parameters. 
 A low level night time light therapy may be trialled using an eye mask which is 
able to substantially reduce the rod circulating current, but care should be taken 
to ensure that the irradiance does not exceed 5µW/cm2 in order to minimise the 
potential negative effects of melatonin production suppression.  
 
5.2 Further Work 
A primary aim of this thesis was the optimisation of cone dark adaptation protocols for 
the diagnosis of early AMD, and the measurement of the inter-session repeatability of 
three candidate functional biomarkers for AMD: cone dark adaptation; 14-Hz flicker 
and the CAD test. However, there is a lack of studies investigating the predictive value 
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of these tests in identifying persons at risk of disease progression. There is some 
evidence from small cohorts that cone dark adaptation and abnormal flicker sensitivity 
may predict the onset of nAMD (Mayer et al. 1992a; Mayer et al. 1994; Sandberg et al. 
1998). However, further longitudinal studies are required to test this hypothesis. A 
predictive test is valuable as it enables the clinician to build an enhanced risk profile 
for each patient, allowing a suitable monitoring plan to be developed.  
Further longitudinal data is also required to determine the ability of the tests to monitor 
disease progression. Dimitrov et al. (2012) investigated the relationship between visual 
function and fundus appearance by classifying almost 300 participants with AMD into 
12 subgroups based on the International Classification and Grading System. They 
found that both 14-Hz flicker and colour vision declined linearly across the hierarchy 
of fundus changes, whereas dark adaptation appeared to become abnormal early, 
reached a point of poor function and then remained at this low level. This suggests that 
steady-state tests of visual function, namely 14-Hz flicker and colour vision, would 
have a potential value in monitoring disease progression. However, only a prospective 
study that monitors individuals with early AMD over time using these tests can truly 
validate this postulation.   
For this reason, the clinical trial protocol that has been described in Chapter 4 has a 
secondary aim of evaluating the ability of these clinical tests to act as predictive 
biomarkers for low-level light therapy in people with AMD, and to compare the 
sensitivity of these tests to disease progression over the 12-month follow-up period.  
In Chapter 3, it was found that the 14-Hz flicker test was significantly less repeatable 
than the RG CAD test parameter. It is possible that the repeatability of the test could be 
improved by extending the test duration in order to achieve a more reliable final 
threshold. Therefore, the inter-session repeatability should be re-assessed using an 
extended number of trials in the QUEST adaptive procedure to confirm this theory. 
In Chapter 4, the development of a clinical trial protocol was described, which 
commenced in May 2014. Its primary aim is to collect preliminary Phase I/IIa proof of 
concept trial data from a cohort of participants with early AMD in one eye and 
advanced, wet AMD in the fellow eye, in order to assess the effect of low-level night-
time light therapy, compared with no intervention, on disease progression in early 
AMD. Furthermore, the safety of the intervention will be assessed.
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Visual 
Acuity 
 
 
AMD Classification 
 
 
 
Methods 
 
 
Visual Function  
 
 
Results 
(Brown and 
Kitchin 1983) 
Case-control 8 AMD 
(66-83yrs) 
6 Control 
(63-74 yrs) 
20/60 to 
20/400 
20/20 
* 
 
Four LEDs flashed 15o from 
fovea. 
Scotopic sensitivity AMD group had significant reduction in 
scotopic sensitivity for rods and cones 50% had 
increased time constant of recovery for rod 
function compared with controls. 
(Brown et al. 
1986a)  
Case-control 4 AMD 
(67-74 yrs) 
5 Control               
(58-74 yrs)  
20/25 to 
20/40 
20/20 
Drusen ± pig. change (2pts), 
CNV (1pt), GA (1pt) 
Green and red LEDs flashed at 
5, 10, 15 and 25o eccentric to 
fovea after 6 min 1160cd/m2 
pre-adaptation. 
Scotopic and 
photopic sensitivity 
Rod and cone thresholds elevated in AMD, 
(0.5-1.5 log units), so AMD may not be 
confined to macula. Greatest sensitivity loss in 
macular area. 
(Brown et al. 
1986b) 
Case-control 6 AMD                   
(69-78 yrs) 
6 Control              
(63-82 yrs) 
6/7.5 to 
6/95- 
≥6/6 
Drusen ± pig. change  Four LEDs flashed 5, 10, 20 and 
40o eccentricity after 3 min, 
130cd/m2 bleach. 
Cone-mediated DA Thresholds significantly elevated in AMD, 
consistent at all eccentricities. No consistent 
difference between time constants of recovery 
for AMD vs controls. 
(Sunness et al. 
1988) 
Cross sectional 8 AMD                   
(55-86 yrs) 
20/16 to 
20/40 
Drusen only ± pig. change 
(5pts), CNV only in fellow 
eye(2pts), CNV in fellow 
eye + PED in test eye (1pt) 
Fundus camera stimulator 
compared sensitivity between 
drusen and drusen-free areas. 
Scotopic sensitivity No significant difference in retinal sensitivity 
between drusen and non-drusen areas in AMD, 
but marked sensitivity losses were found in 
areas of advanced AMD such as PED. 
(Sunness et al. 
1989) 
Prospective    
(median 45 
months) 
18 AMD                
(57-81 yrs) 
20/16 to 
20/50 
Study eye: drusen Gd0 (no 
drusen>125μm) to Gd6 
(large, confluent drusen)                  
Fellow eye: drusen (7pts), 
CNV (7pts), PED (3pts), 
GA (1pt)   
Tubinger perimeter measured 
absolute sensitivity after 1 hour 
in dark using 1.8o red foveal 
stimulus 
Absolute scotopic 
foveal sensitivity 
Absolute foveal sensitivity predicted the 
development of advanced AMD with 100% 
sensitivity and 92% specificity, and was a better 
predictor than status of fellow eye, initial VA 
and high-risk drusen characteristics. 
(Eisner et al. 1991) Cross sectional 41 AMD 
(≥ 60 yrs) 
≥ 20/25 Fellow eyes of unilateral 
nAMD: 32 high risk, 9 low 
risk  
3o 660nm stimuli after 3 min 
20,000 Td bleach. 
Cone-mediated DA High risk eyes generally had slower rates of DA 
(P<0.001). 30/32 high-risk eyes had slow DA 
and abnormal colour matching. 
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(Eisner et al. 1992) Prospective    
(18 months) 
47 AMD 
(55-86 yrs)  
≥ 20/25 Fellow eyes of unilateral 
nAMD (hyperpig ± drusen 
± atrophy) 
3o, 160ms, 660nm test after 
3min 20,000 Td, 580nm bleach. 
Time constant to recovery 
measured.  
Cone-mediated DA A combination of colour matching and DA was 
most effective at distinguishing the eyes which 
developed nAMD at 18 months.  
(Steinmetz et al. 
1993) 
Case-control 12 AMD                
(54-86 yrs) 
 
* Control  
≥ 6/12 
 
 
* 
Study eye: drusen (50% 
delayed choroidal filling & 
75% hypofluorescent on 
FFA.) 
Fellow eye: 42% drusen 
only, 8% PED, 50% CNV  
Modified HFA measured 
scotopic conditions and DA. In 
DA, 2 min bleach of >95% 
rhodopsin preceded testing on 
HFA.  
Scotopic sensitivity Scotopic thresholds were reduced in 50% AMD 
pts who had poor night vision or central 
scotoma in the dark. DA was delayed, but no 
correlation was found between the quantity of 
drusen and severity of functional defect. 
(Owsley et al. 
2000) 
Case-control 80 AMD                
(59-91 yrs) 
12 Control           
(62-80 yrs) 
≥ 20/60 
 
≥ 20/30 
Early: 5 or more drusen 
>63μm ± hyperpig (71pts) 
Late: CNV (3pts) or GA 
>175μm (6pts)  
Dark and light-adapted static 
threshold were measured at 52 
loci in the central 38° of retina 
using modified HFA. 
Scotopic and 
photopic sensitivity 
Mean dark-adapted sensitivity was significantly 
lower in AMD than in controls.  The greatest 
severity was 2° to 4° from the fovea, and 
decreased with increasing eccentricity. 
(Owsley et al. 
2001) 
Case-control 20 AMD                
(66-88 yrs)  
16 Control           
(62-79 yrs)  
≥ 20/25 
 
* 
Early AMD: one or more 
drusen >63μm ± focal 
hyperpig 
Scotopic sensitivity and rate of 
rod-mediated DA measured at 
12° eccentricity using modified 
HFA after 0.25ms, 7.65 log scot 
Td s-1 (98%) bleach. 
Scotopic sensitivity 
and rod-mediated DA 
Early AMD exhibited deficits in almost all rod-
mediated parameters of DA compared with 
controls.  AMD more likely to fall outside 
normal range for variables representing DA 
kinetics (85%)than for steady-state functions 
like scotopic sensitivity (25%).  
(Haimovici et al. 
2002) 
Case-control 31 AMD            
(mean 71yrs) 
11 Control       
(mean 71yrs)  
≥ 6/9 
 
≥ 6/9 
Study eye: macular drusen 
only 
Fellow eye: Gp I: PED and 
RPE tears (11pts); Gp II: 
CNV (10pts); Gp III: drusen 
only (10pts) 
Modified HFA measured time 
constant to recovery in DA & 
scotopic sensitivity 
Scotopic sensitivity, 
rod- and cone- 
mediated DA 
Scotopic sensitivities were largely normal in all 
groups. Both rod- and cone- DA abnormal, but 
rods were more severely affected. Dysfunction 
was most marked near the fovea and in pts with 
PED/RPE tear in fellow eye. 
(Phipps et al. 2003) Case-control 16 AMD                
(62-78yrs)  
14 Control           
(64-80yrs) 
>6/12 
           
>6/12 
Study eye: five or more soft 
drusen > 63μm ± hyperpig.  
Fellow eye: drusen only 
(11pts), CNV (3pts), PED 
(2pts) 
0.5o foveal stimuli flickering at 
5Hz presented on gamma-
corrected colour TV monitor 
after 40s (>95%)  bleach 
Cone-mediated DA Cone pigment regeneration delayed in most 
AMD eyes and most affected visual function 
compared with steady-state parameters. 
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(Scholl et al. 2004) Cross sectional 7 AMD                   
(68-80 yrs) 
 
20/20 to 
20/40 
Study eye: drusen only 
(3pts); nAMD (2pts); GA 
(2pts). All 7 had increased 
fundus autofluorescence, 
FAF. 
Photopic and scotopic fine 
matrix mapping performed 
using modified HFA. 
Photopic and scotopic 
sensitivity 
Areas of increased FAF had moderate to severe 
scotopic but not photopic sensitivity loss, 
implying that increased FAF in EARLY AMD 
has a functional correlate and predilection to rod 
loss. 
(Jackson et al. 
2006) 
Case-control 19 AMD            
(mean 74 yrs) 
17 Old Control 
(mean 69 yrs) 
12 Young Control 
(mean 23 yrs) 
0.22        (SD 
0.20) 
0.09        (SD 
0.35) 
-0.05       
(SD 0.05) 
Early AMD: soft drusen > 
63μm  ± hyperpig. ± 
hypopig. 
Scotopic Sensitivity Tester-1 
(SST-1) with 0.5s, full-field 
stimulus after 1min, 1000cdm-2 
bleach. 
Rod- mediated DA Significant delay in rod-mediated DA in old vs. 
young controls, but no significant delay in 
AMD vs. old controls.  
(Owsley et al. 
2007) 
Case-control 45 early AMD     
(72.5 yrs, SD 9.0) 
21 inter AMD     
(75.9 yrs, SD 9.4) 
17 late AMD 
(68.8yrs, SD 7.1) 
43 Control    
(68.7yrs, SD 7.0) 
0.16        (SD 
0.14) 
0.19        (SD 
0.15) 
0.30        (SD 
0.22) 
0.10        (SD 
0.12) 
AREDS Study step 2-6 
                                                    
AREDS Study step 7-9 
                                                   
AREDS Study step 10-11 
                                                 
AREDS Study step 1 
A modified HFA tested DA at 
12° eccentricity after 11ms, 
7.65 log scot Td s-1 (98%) 
bleach. 
Cone- and rod-
mediated DA 
AMD pts had significant impairments in rod-
mediated but not cone-mediated DA in the 
parafovea at 12° eccentricity, which were 
increasingly abnormal as disease severity 
increased. 
(Jackson and 
Edwards 2008) 
Case-control 17 AMD            
(mean 75.1 yrs) 
8 Young Control  
(mean 32.6 yrs) 
9 Old Control   
(mean 73.1 yrs) 
0.14        (SD 
0.40) 
0.05        (SD 
0.1) 
0.14         
(SD 0.21) 
AREDS Fundus Grading 
System where 1 is old 
control and 10 is advanced 
AMD 
DA measured at 5o eccentricity 
with AdaptDx. after 0.25ms, 
6.38log scot Td s-1 bleach.  
Rod-mediated DA AMD had significantly slower DA than old 
controls. No difference between young and old 
controls. DA impairment increased with AMD 
severity. 
(Dimitrov et al. 
2008) 
Case-control 27 AMD                 
(67.5 ±5.0 yrs)  
22 Control         
(66.8 , ± 5.9 yrs) 
0.026     (SD 
.078) 
-0.017    
(SD .083) 
Study eye: at least one large 
drusen >125μm within 
inner macula (3000μm 
centred on fovea) ± 
hyperpig. ± hypopig. 
A CRT dark adaptometer 
measured DA with a 4° 
foveated, spot after 11ms, 6.48 
log scot Td s-1 (30% rhodopsin) 
bleach 
Rod- and cone- 
mediated DA 
Slowed cone and rod recovery and a delayed 
RCB were evident in the eyes with AMD. 
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(Gaffney et al. 
2011) 
Case-control 10 AMD             
(mean 68.3 yrs) 
10 Control         
(mean 70 yrs) 
0.09        (SD 
0.11) 
-0.002    
(SD 0.10) 
AREDS Severity Scale: Test 
eye: early AMD (8pts) inter 
AMD (2pts)  
Fellow eye: early AMD 
(5pts), adv. AMD (5pts) 
 
A CRT dark adaptometer 
measured DA using 4 foveal 
annuli (0.5, 2, 7, 12o radius) 
after 80% cone bleach (2min 
5.1log phot. Td). 
Cone- mediated DA Cone-mediated DA significantly impaired in 
early AMD. High diagnostic potential of time 
constant of cone recovery using annular stimuli 
at 12o. 
(Dimitrov et al. 
2011) 
Case-control 221 EARLY AMD           
(72.86 ±9.94 yrs)  
109 Control 
(73.07±10.32 yrs)  
≥20/60 
 
≥20/20 
Study eye: soft (>125μm) or 
reticular drusen ± hyperpig. 
± hypopig. 
Fellow eye:  drusen± pig. 
changes  (129pts), CNV 
(8pts), GA ± CNV (84pts) 
A CRT dark adaptometer 
measured DA with a 4° spot at 
fovea, 3.5 and 10o eccentricity 
after 11ms, 6.48 log scot Td s-1 
(30% rhodopsin) bleach. 
Rod- and cone- 
mediated DA 
Cone recovery rate in DA (62%) and PSR 
(63%) both equally effective. Rod recovery rate 
in DA had greatest diagnostic capacity (87%), 
although a combination of 14Hz flicker and 
PSR (71%) was favoured due to test 
reproducibility and clinical applicability.  
(Clark et al. 2011) Cross sectional 74 Pts                     
(53-95 yrs) 
 
20/16 to 
20/632 
 
G1: <10 small drusen <63 
μm (17pts);                       
G2: ≥10 small drusen or 
<15 inter drusen 63-125 
μm ± hyperpig (18pts).;                      
G3: ≥15 inter drusen or any 
large drusen≥ 125μm 
(20pts);                                
G4: GA (19pts); 
DA measured over 20min for 
500nm target at 5o eccentricity 
using AdaptDx after 0.25ms 
photoflash 6.38log scot Td sec-1 
(82% rhodopsin) bleach. 
Rod-mediated DA In AMD, thinning of retina measured using 
SDOCT is associated with reduced rod-
mediated light sensitivity.  
 
(Dimitrov et al. 
2012) 
Case -control 293 AMD            
(72.64 ± 10.04yrs) 
64 Control       
(69.16 ± 11.35yrs) 
 
20/10 to 
20/60 
≥20/20 
AMD classified into 12 
subgroups using ICGS. 
Hard drusen only (59pts), 
inter drusen (12pts), soft 
drusen >125μm (121pts), 
noncentral GA study eye 
(14pts), late AMD fellow 
eye (87pts)  
2 steady-state (14 Hz flicker 
and isoluminant blue colour and 
2 adaptation tests (PSR and rod 
DA recovery rate).  A CRT dark 
adaptometer measured DA with 
a 2° spot at 3.5o eccentricity 
after 11ms, 6.48 log scot Td s-1 
(30% rhodopsin) bleach.  
Rod-mediated DA Rod-mediated DA significantly abnormal with 
hard and/or intermediate drusen, worse with 
more advanced fundus changes, but limited 
ability to discriminate between these cases. 
Steady state tests and clinical signs showed 
significant concordance with increasing AMD 
severity. 
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(Gaffney et al. 
2013) 
Case-control 10 AMD             
(73.0 ± 7.01yrs) 
10 Control          
(73.3 ± 4.11yrs) 
0.08 ± 0.12 
logMAR 
0.03 ± 0.11 
logMAR 
AREDS Severity Scale: Test 
eye: early AMD (10pts)  
Fellow eye: early AMD 
(2pts), adv. AMD (8pts) 
 
A CRT dark adaptometer 
measured DA using a 12o radius 
annulus after exposure to 3 pre-
adapting light intensities (4.90, 
5.20 and 5.50 log phot.Td).  
Cone- mediated DA Dark adaptation was highly diagnostic for early 
AMD at all pre-adapting bleaching intensities. 
Lower bleaching intensities may be used to 
expedite DA whilst maintaining the integrity of 
the data. 
(Jackson et al. 
2014) 
Case-control 127 AMD         
(mean 73 years) 
21 Control        
(mean 65 years) 
Mean 78 
letters  
Mean 77 
leters 
AREDS Severity Scale:  
41 Early AMD 
72 Intermediate AMD 
14 Advanced AMD 
DA measured at 5o eccentricity 
for up to 6.5 minutes with 
AdaptDx. after 0.8ms, 1.8x104 
scot cd/m2  bleach. 
Rod- and cone- 
mediated DA 
The rapid DA test (≤ 6.5 minutes) had a 
diagnostic sensitivity of 90.6% and a specificity 
of 90.5%, suggesting that it is useful for the 
detection of AMD.  The rapid test duration 
limited its ability to differentiate disease 
severity. 
* Data unavailable. AMD: Age-related macular degeneration. CNV: choroidal neovascularization. nAMD: neovascular AMD. GA: Geographic atrophy. HFA: Humphrey Field Analyzer. PED: 
Pigment epithelial Detachment. RPE: Retinal Pigment Epithelium. VA: Visual Acuity.  ICGS: International Classification and Grading System 
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Study Study 
Design 
Participants Visual 
Acuity 
AMD Classification Light Source Outcome 
Measure  
Results 
(Chilaris 1962) Case report 1 AMD               
(62 years) 
6/10 
                          
10/10 
Early AMD (pigmentary 
changes) 
Fellow eye normal 
Direct ophthalmoscope for 
30s 
VA PSRT was delayed in eye with early 
AMD compared with fellow, normal 
eye. 
(Severin et al. 
1963) 
Case-control 1 AMD                
(57 years) 
57 Controls     (23-
41 years) 
RE: 20/70 
LE: 20/20 
* 
AMD- *                         
Fellow eye normal 
 Zeiss light coagulator 
(242,600 lux) for 150ms   
VA and contrast 
discrimination 
PSRT delayed in eye with AMD and 
moderately prolonged in fellow, normal 
eye compared with controls. 
(Forsius et al. 
1964) 
Case-control * AMD 
402 Controls         
( * ) 
* Dry AMD * 
nAMD  (at least 4 pts) 
Keeler ophthalmoscope 
(2145 lux) for 15s at 30cm 
VA PRST not delayed in dry AMD, 
irrespective of VA. 3 nAMD pts had 
normal PRST. 1 nAMD pt had delayed 
PRST (follow-up 4 years). 
(Glaser et al. 
1977) 
Case-control 29 AMD 
179 Control       
(55 pts ≤30yrs,   
72 pts 31-60yrs, 
52 pts ≥ 61yrs) 
6/6 to 6/12 
 
Submacular drusen (18pts) 
AMD (11pts) 
Penlight (2340 lumens/m2) 
for 10s at 2-3cm 
VA Prolonged PSRT in all AMD pts and 
7/18 patients with drusen. 
(Smiddy and 
Fine 1984) 
Prospective 
(4.3 years) 
71 AMD 20/15 to 
20/100 
Bilateral drusen ± 
pigmentation 
Penlight for 20s at 2 inches VA No correlation between PSRT and VA, 
age or severity of drusen. 
(Wu et al. 1990) Case-control 17 AMD           
(59-79, 72yrs) 
18 Controls      
(18-77, 47yrs) 
20/25 to 
20/70 
20/15 to 
20/40 
Soft/hard drusen only Indirect ophthalmoscope 
(6V), for 10s at 10cm 
VA PSRT significantly longer in AMD 
compared with controls (mean 122.9s 
and 23.2s respectively). PSRT did not 
significantly increase with age or 
worsening VA. 
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(Collins and  
Brown 1989) 
Case-control 21 AMD         
(66.6 years) 
11 Controls  (65.8 
years) 
Pre-AMD: 
≥6/6; AMD: 
≤6/7.5 
Controls: 
≥6/6 
Study eye: hard drusen ± 
pigmentation (10 AMD, 
11 pre-AMD) 
500W floodlight for 10s Contrast 
discrimination 
PSRT significantly longer in both pre-
AMD and AMD compared with 
controls. 
(Cheng and 
Vingrys 1993) 
Case-control 11 AMD 
 
11 Pre-AMD 
 8 Controls       
(60-85 yrs) 
6/7.5 to 6/15 
≥6/7.5 
≥6/6 
Early AMD: confluent 
drusen ± pigmentation 
Pre-AMD: no/hard drusen 
± pigmentation 
QI light (60,000cd/m2) for 
20s at 40cm 
VA AMD had longer PSRT compared with 
pre-AMD and controls. No significant 
difference between PRST of pre-AMD 
and controls. 
(Sandberg and 
Gaudio 1995) 
Cross-
sectional 
133 AMD 
(74.4±0.6 yrs) 
 
≥ 20/60 
Study eye: drusen only 
Fellow eye: nAMD 
Welch Allyn Finnoff ocular 
transilluminator in trial 
frame for 10s at retinal 
illuminace 6logTd (94% 
cone bleach) 
VA Delayed PSRT in 62% of fellow eyes of 
patients with nAMD. PSRT increased 
with decreasing VA and foveal RPE 
atrophy. 
(Sandberg et al. 
1998) 
Prospective 
(4.5 years) 
127 AMD        (58-
89 yrs)  
20/20 to 
20/60 
Study eye: fellow eye of 
unilateral nAMD pts with 
drusen (hard or soft), pig 
changes and RPE atrophy 
Welch Allyn 
transilluminator for 10s 
VA Slow PSRT appears to be an 
independent risk factor for progression 
to nAMD. The relative risk increased by 
30% for every minute of PSRT. 
(Midena et al. 
1997) 
Case-control 47 AMD 
(mean 65yrs) 
36 Controls 
(mean 64yrs) 
≥20/25 Early AMD: soft drusen ≥ 
63μm ± pig. changes ± 
RPE atrophy.  
Bilateral ARM: 34 pts 
Fellow eye nAMD: 13 pts 
Registriert Nyktometer (3 
mins bleach at 2200cd/m2) 
VA PSRT significantly lower in early AMD 
compared to normal eyes but no 
difference in PSRT between bilateral 
AMD and fellow eyes with nAMD. 
 
(Schmitt et al. 
2003) 
Cross-
sectional 
30 AMD 
(73.3±9.7yrs) 
 
≥ 20/80 AMD severity graded 
using AREDS scale (G1: 
1pt; G2: 6pts; G3: 11pts; 
G4: 12pts) 
Eger Macular Stressometer 
(EMS) 
VA No significant difference in PSRT 
between patients with AMD, cataracts, 
glaucoma or diabetic retinopathy, 
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perhaps due to EMS not creating enough 
photostress. 
(Bartlett et al. 
2004) 
Case-control 29 AMD           
(55-82, 70.2yrs) 
49 Controls      
(18-76, 44.6yrs) 
≥ 0.1                     
 
≥ 0.1 
Early AMD: Soft drusen 
and pig. changes (17pts) 
AMD: GA/CNV (12pts) 
EMS  VA The EMS had a sensitivity of 29% in 
early AMD and 50% in late AMD. 
Direct illumination of greater intensity 
and longer duration may reduce 
variability. 
(Wolffsohn et al. 
2006) 
Prospective (1 
year) 
156 AMD     
(78.96 ±6.64yrs) 
0.60 (0.39) 
0.08 (0.39) 
0.07 (0.38) 
nAMD: 90 pts 
GA: 19 pts 
GA + nAMD: 47 pts 
EMS VA PSRT was normal in AMD pts and did 
not correlate with visual function 
measures (contrast sensitivity and VF 
defects) or subjective problems with 
light. PSRT did not predict those whose 
vision decreased over time. 
(Binns and 
Margrain 2007) 
Case-control 31 AMD 
(72.4±8.0yrs) 
27 Controls 
(71.7±7.0yrs) 
0.04 ± 0.07 
0.20 ± 0.15 
Early AMD:  soft drusen ≥ 
63μm ± pig. changes  
 
Bright white background 
(5.6log phot Td) for 2 mins 
(86% cone bleach) 
41Hz and 5Hz 
focal cone ERGs 
Rate of recovery of the ERG photostress 
test was reduced in early AMD, and 
provided a sensitivity and specificity of 
77% and 85% respectively. 
(Dhalla et al. 
2007) 
Case-control 15 AMD            
(65-84 years) 
50 Young 
Controls          
(30-49 years) 
5 Old Controls 
(65-84 years) 
Mild: 
>20/40;  
Moderate: 
20/40 to 
20/200 
Severe: 
<20/200 
Mild AMD: ≤5 drusen 
<64μm 
Moderate AMD: drusen≥ 
63μm ± pig. changes            
                                     
Severe AMD: Foveal GA                         
  
Macular Automated 
Photostress (MAP) test 
Foveal threshold 
using Humphrey 
perimeter 
All 3 AMD groups had decreased foveal 
sensitivity and a delayed recovery time. 
Increasing AMD severity resulted in 
greater depression of foveal threshold 
after photostress of 17%, 22% and 39% 
for mild, moderate and severe AMD.  
* Data unavailable. AMD: Age-related macular degeneration. EMS: Eger Macular Stressometer. nAMD: neovascular AMD. PSRT: Photostress Recovery Time. RPE: Retinal Pigment Epithelium. 
VA: Visual Acuity.  
 
Table 3. Studies Investigating Photostress Recovery and Age-Related Macular Degeneration. 
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Study Study 
Design 
Participants Visual 
Acuity 
AMD Classification Functional Test Results 
(Bowman 1978) Case-Control 15 AMD 
(mean 66.5 years) 
10 Control 
(mean 64 years) 
6/6 -6/12: 
8pts 
6/12-6/30: 
7pts 
* FM 100 Hue AMD patients had a blue-yellow chromatic 
deficiency, which improved when 
illumination was increased. 
(Bowman 1980) Case-Control 15 AMD 
(mean 66.5 yrs) 
10 Control 
(mean 64 yrs) 
6/6 -6/12: 
8pts 
6/12-6/30: 
7pts 
* FM 100 Hue 
Panel D-15 
Colour discrimination deteriorated with 
decreasing luminance in AMD. FM 100 more 
sensitive than Panel D-15 in early AMD. 
(Bowman et al. 
1984) 
Case-Control 10 AMD 
(mean 74.3yrs) 
10 Old Control 
(mean 73.2yrs) 
10 Young Control 
(mean 21.3yrs) 
6/18-6/60 * Panel D-15 
Desaturated D-15 
H- 16 Panel 
With decreasing luminance, colour 
discrimination deteriorated more in AMD 
compared with both age-matched and young 
controls. Desaturated D-15 most sensitive in 
assessing chromatic deficiency. 
(Collins 1986) Case-Control 10AMD 
(mean 67.2yrs) 
11 Pre-AMD 
(mean 66.0yrs) 
11 Control 
(mean 65.8 yrs) 
6/7.5 to 
6/9.5 
≥6/6 
 
≥6/6 
Pre-AMD and AMD: drusen  ± 
pigmentary disturbance at macula 
Desaturated D-15 Colour discrimination equally diminished in 
pre-AMD (VA ≥6/6) and AMD, with a 
tendency towards tritan deficiency. 
 
(Applegate et al. 
1987) 
Prospective 
(>2 years) 
3 AMD (4 eyes) 
(53-73, mean 64yrs) 
≥ 20/25 Bilateral drusen 
Fellow eye CNV: 2pts 
FM 100 Hue 
Panel D-15 
Prior to VA loss, BY sensitivity is 
progressively reduced in AMD. RG sensitivity 
loss occurs later in the disease, when clinically 
manifest signs are seen.  
(Smith et al. 
1988) 
Cross-
Sectional 
10 AMD 
(50-78, mean 61yrs) 
6/6 to 6/18 Sarks Classification: Gd II (3pts); 
Gd III (4pts); Gd IV (3pts) 
Colour matching and Stiles 
Crawford Effect using 
Moreland anomaloscope 
Colour matching abnormalities increased with 
AMD severity. Stiles-Crawford effect 
abnormal in 9/10 eyes. 
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(Atchison and 
Lovie-Kitchin 
1990) 
Case-Control 15 AMD 
(58-68, mean 63.5yrs) 
15 Control 
(59-67, mean 63.3yrs) 
≥6/6 
 
≥6/6 
AMD: Hard drusen ± pig. changes  Desaturated D-15 No significant difference in colour 
discrimination between patients with AMD 
and age-matched controls. 
(Eisner et al. 
1991) 
Cross 
sectional 
41 AMD 
(≥ 60 yrs) 
≥ 20/25 Fellow eyes of unilateral nAMD: 
32 high risk, 9 low risk (hyperpig 
± drusen ± atrophy) 
Farnsworth Panel D-15, 
Rayleigh colour matching  
High-risk eyes (large confluent  drusen + 
hyperpig) had abnormal colour matching and 
failed the D-15 test 
(Eisner et al. 
1992) 
Prospective    
(18 months) 
47 AMD 
(55-86 yrs)  
≥ 20/25 Fellow eyes of unilateral nAMD 
(hyperpig ± drusen ± atrophy) 
Farnsworth Panel D-15, 
Rayleigh colour matching 
A combination of colour matching and dark 
adaptation was most effective at 
distinguishing the eyes which developed CNV 
after 18 months 
(Cheng and 
Vingrys 1993)) 
Case-Control 11 AMD 
 
11 Pre-AMD 
 8  Control 
(60-85 yrs) 
6/7.5 to 6/15 
≥6/7.5 
≥6/6 
Early AMD: confluent drusen ± 
pigmentation 
Pre-AMD: no/hard drusen ± 
pigmentation 
Ishihara Plates 
Panel D-15 
Desaturated panel 
Only AMD pts had YB defects in Panel D-15. 
Desaturated panel produced many false 
positives. Positive correlation between 
confluent drusen and losses in colour 
saturation and hue discrimination. 
(Frennesson et 
al. 1995) 
Case-Control 27 AMD 
(57-80, mean 69.7yrs) 
29 Control 
(51-79, mean 67.7yrs) 
0.96±0.05 
 
0.98±0.04 
AMD: Soft drusen (some 
confluent) ± pig. changes (no pig. 
clumping)  
Fellow eye CNV: 8pts 
Colour contrast sensitivity 
using computer graphics 
technique 
D-15 
Mean colour contrast sensitivity significantly 
lower in early AMD for tritan, protan and 
deutan axis. Correlation between tritan 
threshold and FA.  
D-15 not significantly abnormal in AMD 
group. 
(Holz et al. 1995) Prospective  (2 
years) 
47 AMD 
(55-84, mean 69yrs) 
6/9 Unilateral or bilateral drusen Colour contrast sensitivity 
using computer graphics 
technique 
Tritan thresholds significantly elevated at 
fovea compared with parafovea, and increased 
with disease progression 
(Midena et al. 
1997) 
Case-Control 47 AMD 
(mean 65yrs) 
36 Control 
(mean 64yrs) 
≥20/25 Early AMD: soft drusen ≥ 63μm ± 
pig. changes ± RPE atrophy.  
Bilateral AMD: 34 pts 
Fellow eye nAMD: 13 pts 
FM-100 Hue No colour vision defect was observed in any 
AMD pt using FM-100. 
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(Arden and Wolf 
2004) 
Case-Control 24 AMD 
(mean 76 yrs) 
109 Control 
(57-82, mean 71.5yrs) 
≥ 0.6 
 
* 
Early and late AMD grading 
using Bird’s classification (Bird et 
al. 1995) 
Colour contrast sensitivity 
(Computer graphics system) 
Elevated threshold for tritan optotypes in 
unaffected eyes of AMD patients. Tritan 
thresholds in AMD eyes were correlated with 
disease severity. 
(Feigl et al. 2004)  Prospective  (1 
year) 
13 AMD 
(mean 72yrs) 
13 Control 
(mean 70yrs) 
≥ 6/12 
 
≥ 6/12 
Early AMD: hard/ soft distinct 
and indistinct drusen >63μm ± 
RPE abnormalities 
Desaturated D-15 and Panel 
D-15 
Desaturated CV significantly impaired in 
AMD (mainly Tritan defect) but did not 
change over time. 
(O’Neill-Biba et 
al. 2010) 
Cross-
sectional 
18 AMD pts 
(47-85, mean 68yrs) 
6/4.8 to 6/60 No drusen/small drusen: 2 eyes; 
Extensive small, inter drusen± 
pigmentation: 21 eyes; Large, 
extensive inter drusen, non-central 
GA: 5 eyes; Central GA: 1 eye; 
nAMD: 5 eyes 
CAD test All 18 AMD pts had acquired CV defects. 
Mean YB loss increases linearly with disease 
severity and is greater than RG loss for all 
AMD groups. 
* Data unavailable. AMD: Age-related macular degeneration. FM-100 Hue: Farnsworth Munsell 100 Hue. RG: red-green. YB: yellow-blue. 
 
Table 4. Studies investing colour vision and AMD. 
 
 
 
 
 
 
 
 
 
 
 199 
 
 
 
 
Study Study Design Participants Visual 
Acuit
y 
AMD Classification Methods  Results 
(Brown and 
Lovie-Kitchin 
1987b) 
Case-control 9 AMD                      
(60-85,mean 70.9yrs)  
8 Pre-AMD                
(61-72, mean 65.4yrs) 
10 Control                 
(57-74, mean 65.5yrs) 
≥ 6/30                                 
 
≥ 6/6 
 
≥ 6/6 
AMD: Drusen ± pig. change 
(2pts), GA (3pts), pig. change 
only (3pts), CNV (1pt) 
Pre-AMD: Drusen ± pig. 
change (7pts), pig.change only 
(1pt) 
Temporal modulation 
sensitivity and critical 
flicker frequency 
measured across 
frequencies of 0.5–30Hz. 
Temporal function not significantly 
depressed in patients with drusen and pig. 
changes and normal VA. 
(Applegate et al. 
1987) 
Prospective             
(>2 years) 
3 AMD (4 eyes) 
(53-73, mean 64yrs) 
≥ 20/25 Bilateral drusen 
Fellow eye CNV: 2pts 
Flicker sensitivity  Flicker sensitivity was reduced by 0.5 log 
units in patients with early AMD and 
normal L-M cone sensitivities. 
(Brown and 
Lovie-Kitchen 
1989) 
Case-control 8 AMD                       
(mean 71 years) 
8 Control                   
(mean 69.6 years) 
≥ 6/24 AMD: Hard drusen ± pig. 
change  
Temporal summation 
measured using a red LED 
presented for durations 
between 4 and 1024ms. 
Although patients with AMD had longer 
critical durations than controls, they were 
not statistically significant.  
(Haegerstrom-
Portney and 
Brown 1989) 
Case-control 10 AMD                      
(72 years)  
8 Pre-AMD                 
(67 years) 
9 Control                     
(63 years) 
20/32 
 
20/20-1 
 
20/20 
AMD: Drusen ± pig. change 
(10 pts) 
 
Flicker sensitivity 
measured using a 2o central 
target flickering at 25Hz 
presented on yellow, 
magenta and blue 
adaptation backgrounds. 
S-cone sensitivity depressed in 80% of 
AMD patients only. Both AMD and pre-
AMD patients showed a small reduction 
in M-cone sensitivity, but no significant 
loss in L-cone pathways. 
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(Mayer et al. 
1992a) 
Case-control 13 AMD                    
(71.7 years) 
19 Control                  
(70.3 years) 
≥ 20/30 
 
≥ 20/30 
Test eye: fellow eye of 
unilateral CNV. 
Foveal flicker frequency 
measured at frequencies of 
10 and 14Hz. 
Eyes at risk of developing AMD could be 
distinguished from healthy eyes with 
78% accuracy on the basis of foveal 
flicker sensitivity at 10 and 14Hz. 
(Mayer et al. 
1992b) 
Case-control 13 AMD                    
(60-82, mean 71.7yrs) 
19 Control                  
(65-88, mean 70.3yrs) 
≥ 20/30 
 
≥ 20/30 
 
Test eye: fellow eye of 
unilateral CNV. 
Temporal contrast 
sensitivity measured using 
foveal long-wavelength 
circle flickering between 
1.8 and 50Hz. 
Eyes at risk of developing AMD had less 
sensitivity to flicker contrast, especially 
at a frequency of 14Hz.  
(Mayer et al. 
1994) 
Prospective       (1.5-
4 years) 
16 AMD                   
(71.9 years) 
20 Control                
(70.2 years) 
 
≥ 20/30 
                             
≥ 20/25 
Test eye: fellow eye of 
unilateral CNV. 
Flicker modulation 
sensitivity measured at 2.5 
and 50Hz using a 2.8o, 
660nm stimulus. 
Foveal flicker sensitivity at low- to mid- 
temporal frequencies discriminated pre-
exudative AMD from healthy eyes  
(Phipps et al. 
2004) 
Case-control 25 AMD                      
(69.4 ± 6.2yrs) 
34 Control                   
(68.9 ± 5.4yrs) 
≥ 6/12 
 
≥6/12 
Study eye: greater than 5 soft 
drusen (>63 μm) ± pig. change 
or end-stage CNV in fellow eye 
Static and flickering 
stimuli presented with 
durations of 200ms (static) 
or 800ms (flicker) 
Flickering targets expose functional 
deficits in early AMD better than static 
targets.   
(Dimitrov et al. 
2011) 
Case-control 221 Early AMD           
(72.86 ±9.94 yrs)  
109 Control 
(73.07±10.32 yrs)  
≥20/60 
 
≥20/20 
Study eye: soft (>125μm) or 
reticular drusen ± hyperpig. ± 
hypopig. 
Fellow eye:  drusen± pig. 
changes  (129pts), CNV (8pts), 
GA ± CNV (84pts) 
Flicker thresholds 
measured with a foveal, 2o 
Gaussian blob at temporal 
frequencies of 4 and 14Hz. 
A combination of 14Hz flicker and PSR 
(71%) was favoured due to test 
reproducibility and clinical applicability. 
(Dimitrov et al. 
2012) 
Case -control 293 AMD               
(72.64 ± 10.04yrs) 
64 Control              
(69.16 ± 11.35yrs) 
20/10 to 
20/60 
≥20/20 
AMD classified into 12 
subgroups using ICGS. Hard 
drusen only (59pts), inter 
drusen (12pts), soft drusen 
>125μm (121pts), noncentral 
GA study eye (14pts), late 
Flicker thresholds 
measured with a foveal, 2o 
Gaussian blob at a 
temporal frequency of 
14Hz. 
14Hz flicker thresholds declined 
gradually across the spectrum of early 
AMD fundus changes.  
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 AMD fellow eye (87pts)  
(Luu et al. 2012) Prospective         (24 
months) 
127 AMD  
24 Control        (72.6 ± 
6.9yrs) 
 
≥ 0.29 
≥ 0.0 
AMD graded using ICGS: 88 
progressed within early AMD 
and were excluded; 18 had non-
progressed early AMD; 16 
developed GA; 5 developed 
CNV. 
Flicker perimetry 
performed with an 
automated perimeter (M-
700; Medmont 
International Pty Ltd) 
within the central 6o from 
fixation. 
Eyes that went on to develop GA or CNV 
had significantly reduced mean flicker 
sensitivity before clinical detection of 
GA or CNV compared with control eyes. 
The rate of change of  flicker sensitivity 
was increased in eyes with GA but not in 
eyes with CNV. 
(Luu et al. 2013) Case-control 279 AMD         (66.6 
years) 
24 Controls  (65.8 
years) 
Pre-
AMD: 
≥6/6; 
AMD: 
≤6/7.5 
Controls: 
≥6/6 
AMD classified into 10 
subgroups using ICGS 
Static and flicker 
perimetry performed with 
an automated perimeter 
(M-700; Medmont 
International Pty Ltd) 
within the central 6o from 
fixation. 
Static and flicker perimetry both show 
trends of reduced sensitivity with disease 
progression. 
* Data unavailable. AMD: Age-related macular degeneration. CNV: choroidal neovascularization. nAMD: neovascular AMD. GA: Geographic atrophy. RPE: Retinal                                       
Pigment Epithelium. VA: Visual Acuity.  ICGS: International Classification and Grading System 
 
Table 5. Studies investing temporal sensitivity and AMD.
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Appendix II. Matlab Code for Dark Adaptation 
 
%DARK ADAPTATION EXPERIMENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                       
% First written 3/3/090 
% This version written 6/12/100 
  
% This version is specific to the 12deg annulus used in the Bleaching 
study 
% To use other sizes need to alter code in line 15                                                               
back to >9*17.5 
  
clear all 
  
 % Input co ordinates and sizes for cross and spot 
   HorizontalLocation = input('Horizontal location in degrees? '); 
   VerticalLocation = input('Vertical location in degrees? '); 
   SpotSize = input('Spot size in degrees?')*17.5; % size of spot in 
pixels 
   RingThickness = input('Ring thickness in degrees?')*35; % thickness 
of ring in pixels 
   if SpotSize < 9*17.5; OutsideLineSize=100; InsideLineSize=100; end 
   if SpotSize > 20*17.5; OutsideLineSize=0; InsideLineSize=200; end 
   if SpotSize == 14*17.5; OutsideLineSize=0; InsideLineSize=100; end 
   LineThickness = 50; % this it the thickness of the fixation cross 
   LineSize = SpotSize+OutsideLineSize; % this is the length of the 
cross line in pixels 
   InnerLineSize = SpotSize-InsideLineSize; 
   % NOTE assumes a 55 cm viewing distance! 
    
KbName('UnifyKeyNames'); 
% The Try, Catch, End commands will respond to bugs / problems 
try 
    % First set up all the parameters 
    whichScreen = 0; 
    window = Screen(whichScreen, 'OpenWindow'); 
    white = WhiteIndex(window); % pixel value for white 
    black = BlackIndex(window); % pixel value for black 
    gray = (white+black)/2; 
 203 
    inc = white-gray; 
    
    % And, set the parameters of the spot, 1st and 3rd numbers give 
the horizontal position 
    % the 2nd and 4th give the vertical, the spot is streched inbetween. 
    % SpotSize = 35/2; % This is the size of the spot in pixels 
    offsetCenteredspotRect = [640-SpotSize  512-SpotSize  640+SpotSize  
512+SpotSize]; % size and position of spot on screen 
    offsetCenteredspotRect2 = [640-SpotSize+RingThickness  512-
SpotSize+RingThickness  640+SpotSize-RingThickness  512+SpotSize-
RingThickness]; 
    SurroundRectInner = [640-SpotSize-10  512-SpotSize-10  
640+SpotSize+10  512+SpotSize+10]; % size and position of anulus 
    SurroundRectOuter = [496 368 784 656]; 
     
    % Set up the sounds for correct and incorrect responses and to 
indicate 
    % that a new neutral density filter is required 
    correctSound = sin(2*pi*100*[0:0.00125:2.0]); 
    incorrectSound = sin(2*pi*40*[0:0.00125:2.0]); 
    NewFilterSound = sin (2*pi*200*[0:0.00125:10.0]); 
     
    % Intial psychophysical increment step size 
    incrementStep = 0.4;% good parameter =12 if not bleached 
    SpotLuminance = 2.0;% good parameter = 5 if not bleached 
     
    % Set up various flags  
    response = 0; 
    responseCounter = 0; 
    reversalCounter = 1;%this counts reversals but is reset after each 
threshold 
    DarkAdptCounter = 0; % counts the number of times a dark adptn 
threshold is recorded. 
    presentationCounter=1; %counts all presentations, used in Humphrey 
version 
    dataCounter=1;%this is the reversal counter, it counts all 
reversals 
    thresholdCounter = 1;% this counter is for the Humphrey version 
i.e. it counts the no. of threshold points 
 204 
    AdjustmentFilter1 = 1.2;% this is the optical density of the first 
ND filter 
    AdjustmentFilter2 = 0;% this is the optical density of the secondt 
ND filter - which is not yet in place!!! 
    % Clear arrays that contain data 
    SecondNDFIlterFlag = 0; % this line is used as a flag to stop the 
luminance being raised if the spot luminance hits it's lowest level a 
second time i.e. after the 2.1 ND filter has been added 
    resultTime = 1; 
    resultThreshold = 1; 
    BreakFlag=0; 
     
    % Set keys up. 
    rightKey = KbName('RightArrow'); 
    leftKey = KbName('LeftArrow'); 
    escapeKey = KbName('ESCAPE'); 
     
    % This screen can be used to write instructions 
    Screen(window, 'FillRect', 0);     
    Screen('DrawText', window, 'DARK ADAPTATION VERSION 6/5/10', 300, 
200, white); 
    Screen('DrawText', window, 'Hit any key to start experiment', 300, 
400, white); 
    Screen(window, 'Flip'); 
    Kbwait;% duration of instruction presentation 
     
    % Set up the timer. 
    startTime = now; 
    durationInSeconds = 1500; 
    durationEachThreshold = 1; 
    numberOfSecondsRemaining = durationInSeconds;  
    SecondsRemaining = durationEachThreshold; 
     
    % Calibration variables 
    MinScreenLum = 0.12; % Keep: contrast = 100 & brightness = 63 
    GammaFunc = 2.15; 
    MaxScreenLum = 122.5; 
  
    % Now start the experiment loop. 
    fprintf('Experiment started'), 
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    StartExptSecs = GetSecs; % this times the whole dark adaptation 
expt 
     
 while GetSecs - StartExptSecs < durationInSeconds% Keep experiment 
running  
                
            % Set up flags etc to re enter the threshold loop 
            stopRule = 1;%keeps loop running till stop rules met, then 
=0 
  
      while stopRule > 0 % Keep looking for threshold i.e. expt 
running. 
  
            GammaCorrectSpotLum = 255*(((10^SpotLuminance)-
MinScreenLum)/MaxScreenLum)^(1/GammaFunc) 
            %This calculates the grey scale required for desired 
luminance 
            %SpotLuminance raised to power of 10 to 'un-log' the number 
  
            Screen('DrawText', window, ['GammaCorr: ' 
num2str(SpotLuminance,4)], 970, 940, [0,0,240]); 
                if InnerLineSize <0 % this line stops the central cross 
going ' funny' if we are presenting a small spot. 
                    InnerLineSize = 0; 
                end 
            Screen('DrawLine', window, [GammaCorrectSpotLum*7 
GammaCorrectSpotLum*7 GammaCorrectSpotLum*7], 
640+(HorizontalLocation*35), 512-(VerticalLocation*35)-LineSize, 
640+(HorizontalLocation*35), 512-
(VerticalLocation*35)+LineSize,LineThickness); % presents peripheral 
fixation markers 
            Screen('DrawLine', window, [GammaCorrectSpotLum*7 
GammaCorrectSpotLum*7 GammaCorrectSpotLum*7], 
640+(HorizontalLocation*35)-LineSize, 512-(VerticalLocation*35), 
640+(HorizontalLocation*35)+LineSize, 512-
(VerticalLocation*35),LineThickness); 
            Screen('FillOval', window, [0 0 0], SurroundRectInner); % 
draws invisible spot i.e. surround 
            Screen('FillOval', window, [GammaCorrectSpotLum 
GammaCorrectSpotLum 0], offsetCenteredspotRect); % draws white spot 
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            Screen('FillOval', window, [0 0 0], 
offsetCenteredspotRect2); % draws black spot 
            Screen('DrawLine', window, [GammaCorrectSpotLum*7 
GammaCorrectSpotLum*7 GammaCorrectSpotLum*7], 
640+(HorizontalLocation*35), 512-(VerticalLocation*35)-InnerLineSize, 
640+(HorizontalLocation*35), 512-
(VerticalLocation*35)+InnerLineSize,LineThickness); % presents 
peripheral fixation markers 
            Screen('DrawLine', window, [GammaCorrectSpotLum*7 
GammaCorrectSpotLum*7 GammaCorrectSpotLum*7], 
640+(HorizontalLocation*35)-InnerLineSize, 512-(VerticalLocation*35), 
640+(HorizontalLocation*35)+InnerLineSize, 512-
(VerticalLocation*35),LineThickness); 
            Screen(window, 'Flip'); % presents test 
            WaitSecs (0.2); % presentation time 
                   
            %Remove stimulus 
            %Screen('DrawText', window, sprintf('%i seconds 
remaining...', numberOfSecondsRemaining), 20, 60, white); 
            Screen('DrawText', window, ['GammaCorr: ' 
num2str(SpotLuminance,4)], 970, 940, [0,0,240]); 
            Screen('DrawLine', window, [GammaCorrectSpotLum*7 
GammaCorrectSpotLum*7 GammaCorrectSpotLum*7], 
640+(HorizontalLocation*35), 512-(VerticalLocation*35)-LineSize, 
640+(HorizontalLocation*35), 512-
(VerticalLocation*35)+LineSize,LineThickness); 
            Screen('DrawLine', window, [GammaCorrectSpotLum*7 
GammaCorrectSpotLum*7 GammaCorrectSpotLum*7], 
640+(HorizontalLocation*35)-LineSize, 512-(VerticalLocation*35), 
640+(HorizontalLocation*35)+LineSize, 512-
(VerticalLocation*35),LineThickness); 
            Screen('FillOval', window, [0 0 0], SurroundRectInner); % 
draws large spot i.e. surround 
            Screen('DrawLine', window, [GammaCorrectSpotLum*7 
GammaCorrectSpotLum*7 GammaCorrectSpotLum*7], 
640+(HorizontalLocation*35), 512-(VerticalLocation*35)-InnerLineSize, 
640+(HorizontalLocation*35), 512-
(VerticalLocation*35)+InnerLineSize,LineThickness); % presents 
peripheral fixation markers 
            Screen('DrawLine', window, [GammaCorrectSpotLum*7 
GammaCorrectSpotLum*7 GammaCorrectSpotLum*7], 
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640+(HorizontalLocation*35)-InnerLineSize, 512-(VerticalLocation*35), 
640+(HorizontalLocation*35)+InnerLineSize, 512-
(VerticalLocation*35),LineThickness); 
            Screen(window, 'Flip'); % blanks out test 
            ResponseSecs = GetSecs;% gets the time the stimulus was 
flipped out 
             
            % Wait for a response 
            while 1 
                [ keyIsDown, timeSecs, keyCode ] = KbCheck; 
                if keyIsDown 
                     
                     if keyCode(escapeKey)% this small loop helps stop 
the programme after the ESC key is pushed. 
                        BreakFlag=1; 
                        break 
                     end 
                    %fprintf('"%s" typed at time %.3f seconds\n', 
KbName(keyCode), timeSecs - ResponseSecs); 
                    if (timeSecs - ResponseSecs)<0.6; 
                        response = 1; %this means the response was 
correct 
                        %responseCounter = responseCounter + 1; 
                        sound(correctSound) 
                    else 
                        response = -1; %this means the response was 
incorrect (in this case too slow) 
                        %responseCounter = responseCounter - 1; 
                        sound (incorrectSound) 
                        break 
                    end 
         
                    while KbCheck; end % this avoids KbCheck reporting 
multiple events 
                    break 
                end 
  
                % Now, if no button push + long wait, time is up! 
                SecsNow = GetSecs; 
                timeSincePresentation = (SecsNow - ResponseSecs); 
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                if timeSincePresentation > 1; 
                    response = -1; %this means the response was 
incorrect (in this case completely missed) 
                    %responseCounter = responseCounter - 1; 
                    break 
                end 
            end % waiting for repsonse or time up 
  
            if BreakFlag==1% this small loop helps stop the programme 
after the ESC key is pushed. 
            break 
            end 
             
            %Now record each presentation. 
             presentationTime(presentationCounter)= (GetSecs - 
StartExptSecs); 
            presentationThreshold(presentationCounter)= 
SpotLuminance-AdjustmentFilter1-AdjustmentFilter2; 
            presentationCounter = presentationCounter + 1; 
             
  %Now adjust next stimulus increment on the basis of the response 
            if response > 0;% that is, correct 
                 
                 if incrementStep > 0.0; % that is, threshold was 
raised up on the last step, this must be a threshold 
                 resultTime (thresholdCounter) = (GetSecs - 
StartExptSecs); 
                 resultThreshold (thresholdCounter) = SpotLuminance-
AdjustmentFilter1-AdjustmentFilter2; 
                 thresholdCounter = thresholdCounter + 1; 
                 stopRule = -1; % this should make the programme 
realise that a threshold has been recorded 
                 end 
                  
              incrementStep = -0.3;% now ensure that the next step is 
down 0.3 log units 
              WaitSecs (0.5 + rand(1.5)) 
            end 
             
            if response < 0;% that is, incorrect 
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                %sound(incorrectSound) 
                incrementStep = 0.1; 
                WaitSecs (rand(1.0)) 
            end 
             
            % Now alter stimulus for next presentation 
            %if thisFlag == 1; 
                SpotLuminance = SpotLuminance + incrementStep;   
                if SpotLuminance > 2 
                SpotLuminance = 2; 
                end 
                 
                % Now reset the stimulus intensity when the minimum 
                % luminance is reached 
                if SpotLuminance < -0.9; 
                   SecondNDFIlterFlag = SecondNDFIlterFlag + 1; %This 
is the counter that determines which adjustments are made for a ND 
filter put on the screen 
                   sound (NewFilterSound) % makes a beep to tell the 
investigator to insert a new filter 
                   if SecondNDFIlterFlag == 1 % This is the 1st loop 
i.e. the 1st time the subject reaches -1log cd/m2 
                        AdjustmentFilter2 = 2.1; 
                        LineThickness = 10; 
                        WaitSecs (5.0) 
                        SpotLuminance = 1.1; % resets the stimulus 
intensity to the maximum brightness 
                   end 
                   if SecondNDFIlterFlag == 2 % This is the 2nd loop 
i.e. the 2nd time the subject reaches -1log cd/m2 
                      AdjustmentFilter2 = 3.6; 
                      WaitSecs (5.0) 
                      SpotLuminance = 0.5; % increases spot lum by 0.6 
ND 
                   end    
                end 
               
      end % this ends the search for a threshold 
      beep 
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      if BreakFlag==1 % this small loop helps stop the programme after 
the ESC key is pushed. 
          break 
      end    
       
 end % Now go back and collect data for the next threshold point 
  
% Now display the results 
        presentationTime = presentationTime (:);% converts row of 
presentation time into column 
        presentationThreshold = presentationThreshold (:); %converts 
row of presentation threshold to column 
        plot(presentationTime, presentationThreshold,'b*')%this 
should plot every presentation 
        xlabel('Time(s)') 
        ylabel('Log Threshold') 
        AXIS ([0 300 -1.5 2.5]) 
        hold on 
         
        resultTime = resultTime(:);% This changes format to column 
vectors 
        resultThreshold = resultThreshold(:); 
        plot(resultTime, resultThreshold,':ko')% this should plot the 
thresholds 
         
   % Now fit the final exponential curve 
        Starting = [1.2,5,40];  
        options=optimset('Display','off');% if set 'off' to 'iter' 
will see iterations 
        %logFOCThreshold=log10(FOCThresholdNotLog); 
        
Estimates=fminsearch(@myfitExp,Starting,options,resultTime,resultThre
shold); 
        fT = Estimates(1) 
        iT = Estimates(2) 
        Tau =Estimates(3) 
        % Now plot this curve 
        ExpFitTime =0:2.0:300;% now create some x-axis data at 1.0 
steps 
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        ExpFitThreshold = Estimates(1)+((Estimates(2)-
Estimates(1))*exp(-ExpFitTime./Estimates(3))); 
        plot(ExpFitTime, ExpFitThreshold,'r-','LineWidth',2) 
  
  
  
   Screen('CloseAll'); 
     
   %Now output all the data to Excel spreadsheet 
    presentationData = [presentationTime, presentationThreshold] 
    thresholdData = [resultTime, resultThreshold] 
    ExpFitTime=ExpFitTime(:); 
    ExpFitThreshold=ExpFitThreshold(:); 
    curveFit = [ExpFitTime, ExpFitThreshold] 
    xlswrite('d:\projects 2012\TopographyDAresults.xls', 
presentationData,'Model','A14'); 
    xlswrite('d:\projects 2012\TopographyDAresults.xls', 
thresholdData,'Model','D14'); 
catch 
    Screen('CloseAll'); 
    rethrow(lasterror); 
    psychrethrow(psychlasterror); 
end 
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Appendix III. Gamma correction and Matlab code for 14-Hz 
flicker test 
 
Gamma Correction 
 
 
 
 
 
Matlab Code  
% 14 Hz FLICKER THRESHOLD: YES/NO, QUEST 
% 
% This programme uses a YES/NO, QUEST driven staircase to determine 
contrast  
% thresholds for a flickering gaussian blob.  
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% The code is adapted from Gaboiumdemo, kbDemo and QuestDemo. 
% Ver. 1: Tom Margrain on 28-11-12. This was a 2 IFC version. 
% Issues: the frame refresh rate is 60Hz on the laptop but for some 
reason 
% it reduces significantly from time to time; I guess other programmes 
% running the background are stealing resources. If this happens the 
% stimulus will be flickering more slowly than expected. The main 
problem 
% seems to be for the first presentation, after that things are 
generally 
% better. 
% Ver. 8 - Fully working 2 IFC programme. Only altered to Ver. 9 
because 2 
% IFC may be tricky for patients 
% Ver. 9 - Here the programme is altered from 2 IFC to a Yes/No 
% Ver. 10 - Now pushing the response key during the presentation should 
% work too + keep track of false positives + improve the 'feel' by 
altering 
% the timing of presentations 
% Ver. 11 - implements a 'simple gamma correction' using code from the 
online 
% AdditiveBlendingForLinearSuperpositionTutorial. The important lines 
of 
% code that were not used before include  
% PsychImaging('AddTask', 'General', 'EnablePseudoGrayOutput') - this 
line 
% lets us call up all screen output in the range 0-1 (0-100%) rather 
than 
% grey scale.  
% PsychImaging('AddTask', 'FinalFormatting', 
'DisplayColourCorrection', 'SimpleGamma'); 
% This line sets up simple gamma correction in the video output 
'pipeline' 
% PsychColourCorrection('SetEncodingGamma', win, gamma); So, all 
output is 
% gamma corrected automatically. 
% This version also allows the 'blob' to occupy a 0-1 range rather 
than 
% 0-0.5 (line 130). It also changes the slightly misleading variable 
% "contrast" to the more accurate "luminance" i.e. the output is 
threshold 
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% luminance (lines 167, 173). The final output (threshold) is log 
luminance  
% as a fraction of the max screen luminance in cd/m2. 
% This version saved as Trial14Hz Gaussian blob set for 2 degrees at 
1.4m 
% viewing distance. 
  
% INSTRUCTIONS 
% 1)This programme needs to write to an Excel file. 
% 2)Tell subject the expt last 3.5 minutes (40 trials). 
% 3)The task is to push any button when a flickering stimulus is seen. 
  
  
% First, set up all the relevant parameters 
clear all 
trialsDesired = 40; % number of times a choise is offered 
wrongRight={'wrong','right'}; % this is used at the end of each trail 
to identify the response 
stimFreq = 14; % temporal frequency of flickering gabor in Hz 
KbName('UnifyKeyNames'); 
escapeKey = KbName('ESCAPE'); 
format compact 
avgfps = []; 
contrastPresent = []; 
falsePositive = 0; % used to count false positive responses 
%contrast = 1; 
% PTB-3 correctly installed and functional? Abort otherwise. 
AssertOpenGL; 
  
% This programme uses Psychophysics QUEST routines to determine 
threshold 
% to get these to work it is necessary to provide information about 
the 
% threshold we are looking for in particular an initial guess at the 
% treshold and the standard deviation 
% Provide our prior knowledge to QuestCreate, and receive the data 
struct "q". 
participant=[]; 
while isempty(participant) 
    participant=input('Subjects name please: ', 's'); 
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end 
tGuess=[]; 
while isempty(tGuess) 
    tGuess=input('Estimate threshold (e.g. -1): '); 
end 
tGuessSd=[]; 
while isempty(tGuessSd) 
    tGuessSd=input('Estimate the standard deviation of your guess, 
above, (e.g. 2): '); 
end 
pThreshold=0.82; 
beta=3.5;delta=0.01;gamma=0.5;% These values may not be right for yes 
/no!! 
% beta controls the steepness of the psychometric function. Typically 
3.5. 
% delta is the fraction of trials on which the observer presses blindly. 
Typically 0.01. 
% gamma is the fraction of trials that will generate response 1 when 
intensity==-inf. 
q=QuestCreate(tGuess,tGuessSd,pThreshold,beta,delta,gamma); 
q.normalizePdf=1; % This adds a few ms per call to QuestUpdate, but 
otherwise the pdf will underflow after about 1000 trials. 
  
% Use try and catch to rescue code from a crash 
try 
  
% Select screen with maximum id for output window: 
screenid = max(Screen('Screens')); 
  
% Open a fullscreen, onscreen window with gray background. Enable 32bpc 
% floating point framebuffer via imaging pipeline on it, if this is 
possible 
% on your hardware while alpha-blending is enabled. Otherwise use a 
16bpc 
% precision framebuffer together with alpha-blending. We need alpha-
blending 
% here to superimpose the gabor blob on the background. The programme 
will 
% abort if your graphics hardware is not capable of any of this. 
PsychImaging('PrepareConfiguration'); 
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%PsychImaging('AddTask', 'General', 'FloatingPoint16Bit'); 
PsychImaging('AddTask', 'General', 'FloatingPoint32BitIfPossible'); 
% Enable bitstealing aka PseudoGray shader: This line is needed so 
that 
% subsequent screen output is in the range 0-1 i.e. up to 100% of 
screen output. No need to call grey levels.  
% It also increase the number of grey scales that can be generated 
PsychImaging('AddTask', 'General', 'EnablePseudoGrayOutput'); 
% Sets up the final video output pipeline to include gamma correction 
PsychImaging('AddTask', 'FinalFormatting', 'DisplayColourCorrection', 
'SimpleGamma'); 
% Finally open a window according to the specs given with above 
% PsychImaging calls, clear it to a background colour of 0.5 aka 50% 
% luminance: 
[win, winRect]=PsychImaging('OpenWindow',screenid, 0.5); 
% This wait allow you to see the 'gamma correction' kick in! First its 
not 
% there, then,.. 
WaitSecs (0.5); 
% OK, now apply the gamma correction to all outputs to the screen, so 
% easy! The default value here is gamma = 2 but need to determine 
exactly 
% what it is for your screen 
gamma = 1 / 2.196152819; 
PsychColourCorrection('SetEncodingGamma', win, gamma); 
  
WaitSecs (1); 
  
% Enable alpha-blending, set it to a blend equation useable for linear 
% superposition with alpha-weighted source. This allows to linearly 
% superimpose gabor patches in the mathematically correct manner, 
should 
% they overlap. Alpha-weighted source means: The 'globalAlpha' 
parameter in 
% the 'DrawTextures' can be used to modulate the intensity of each 
pixel of 
% the drawn patch before it is superimposed to the framebuffer image, 
ie., 
% it allows to specify a global per-patch contrast value: 
Screen('BlendFunction', win, GL_SRC_ALPHA, GL_ONE); 
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% Query frame duration: We use it later on to time 'Flips' properly 
for an 
% animation with constant framerate: 
ifi = Screen('GetFlipInterval', win); 
  
% Create a gabor patch: This is 184x184 pixel matrix that has periperal 
values 
% around zero and a central value of 1. The gray scale range of the 
monitor 
% is 1 at the centre of the gabor. 
[x,y] = meshgrid(-184:184, -184:184); 
whiteBlob = (exp(-((x/92).^2)-((y/92).^2))); 
  
  
% Create blob movie, first determine frame rate 
rate = 1/ifi; 
  
% Determine number of frames avaliable for a given stimulus frequency 
framesAvaliable = rate/stimFreq; 
  
% Determine the step size to get through 360 degrees (1 cycle) in the 
% number of frames valiable 
step = 360/framesAvaliable; 
  
% Set up degrees, start a zero and increment in the loop according to 
the 
% step size 
x=-180; 
  
% Get the time at the very start to record the total experimental time 
exptStart = Screen('Flip', win); 
  
% Introduce experiment wait for signal to start 
%Screen('FrameRect', win ,[0,128,0], [540,300,740,500],1); 
Priority(2);% Uprate the priority for Matlab i.e. try to keep Windows 
out! 
Screen('DrawText', win, 'PUSH THE BUTTON WHEN YOU SEE THE BLOB', 350, 
383, [1,1,1]); 
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Screen ('Flip', win); 
WaitSecs (4); 
Screen('HideCursorHelper', win); 
Screen ('Flip', win); % Flipping removes the text from the screen 
  
% NOW WE CAN IMPLEMENT THE MAIN EXPT LOOP 
for k=1:trialsDesired; 
  
    % First pick up the threshold recommened by QUEST 
    tTest=QuestQuantile(q); % Recommended by Pelli (1987). 
  
    % Unlog tTest, this controls the luminance of the stimulus 
    luminance = 10^tTest; 
  
    % Generate the textures to be displayed during each frame, assume 
60Hz so 
    % going from 1 to 120 will be a 2s presentation 
    for i=1:120; 
        %Need to change contrast to a fraction 
        Blob = whiteBlob * (luminance) * sind(x); 
        gabortex(i)=Screen('MakeTexture', win, Blob, [], [], 2); 
        x=x+step; 
    end; 
  
    % Wait a random period of time before giving the presentation 
    randomdelay = rand*6; 
    StartSecs = GetSecs; 
    timeNow=0; 
    while timeNow <randomdelay   
        SecsNow = GetSecs; 
        timeNow = (SecsNow - StartSecs); 
        [ keyIsDown, timeSecs, keyCode ] = KbCheck; % this command 
checks the keyboard for an input 
        if keyIsDown % if a key is pushed this is what to do 
            falsePositive = falsePositive+1;% counts the incorrect 
responses  
            Beeper(400)  
            while KbCheck; end % this avoids KbCheck reporting multiple 
events 
        end 
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    end 
            
     
    % Clear the screen and wait a bit 
    Screen ('Flip', win); 
    %Screen('FrameRect', win, [200,200,200], [540,300,740,500]); 
     
    response = 0; % This flag holds a record of if the stimulus is 
seen or not, 0=not seen 
    count = 0; % This is needed to count the number of presentations 
    vbl = Screen('Flip', win); 
    tstart = vbl; % records the time the main presentation loop started 
    %lastTime=vbl; 
    for i=1:120; 
        Screen('DrawText', win, 1,0 ,0, [200,200,0]);    
        Screen('DrawTexture', win, gabortex(i),[],[],45); 
        % Check the frame presentation time, does it always match the 
        % frame referesh rate? 
        vbl = Screen('Flip', win, vbl + ifi/2); 
        %frametime(i)=vbl-lastTime;% puts frame time (ms) into an 
array 
        lastTime = vbl; 
        count = count+1; %Will count up to 120 
        % check for keyboard response during presentation 
        [ keyIsDown, timeSecs, keyCode ] = KbCheck; % this command 
checks the keyboard for an input 
        if keyIsDown % if a key is pushed this is what to do 
            response=1;% flags a correct response  
            break % breaks out of the presentation loop 
        end 
    end; 
     
    % Clear the screen of any residual gabor and get time stamp 
    tend = Screen ('Flip', win); % records the time the presentation 
stopped 
     
    % Check frames per second for this trial, store result in array 
avgfps 
    avgfps(k) = count / (tend - tstart); 
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    % Now get the participants response 
    ResponseSecs = GetSecs;% gets the time the stimulus was flipped 
out 
             
    % Wait for a response for three seconds, if in the 1st second = 
correct 
    while 1 
        [ keyIsDown, timeSecs, keyCode ] = KbCheck; % this command 
checks the keyboard for an input 
        if keyIsDown % This bit of code is only executed if a button 
is pushed 
            %fprintf('"%s" typed at time %.3f seconds\n', 
KbName(keyCode), timeSecs - ResponseSecs); 
            if (timeSecs - ResponseSecs)<1; % checks that response was 
within 1s of stimulus offset 
                response = 1; %this 'flag' means the response was 
correct 
                Beeper (1000) % make a 'beep' sound 
                 
            else 
                response = 0; %this means the response was incorrect 
(in this case too slow) 
                Beeper (600) 
                falsePositive = falsePositive+1;% counts the incorrect 
responses 
                break 
            end 
  
            while KbCheck; end % this avoids KbCheck reporting multiple 
events 
            break 
        end 
  
        % Now, if no button push + long wait, time is up! 
        SecsNow = GetSecs; 
        timeSincePresentation = (SecsNow - ResponseSecs); 
        if timeSincePresentation > 4; % If no response within 1s of 
stimulus, its missed, get out of loop 
            break 
        end % waiting for repsonse or time up 
 221 
    end 
  
    % Print the results for this particular trial 
    fprintf('Trial %3d at %5.2f is 
%s\n',k,tTest,char(wrongRight(response+1))); 
    LuminancePresent(k)=tTest; 
  
    % Now update the QUEST routines with the last threshold value (this 
is all 
    % in logs) and let it know if the participant responded correctly 
(1) or 
    % incorrectly (0) 
    q=QuestUpdate(q,tTest,response); % Add the new datum (actual test 
intensity and observer response) to the database. 
  
    % Close all the windows that were opened for this presentation 
    Screen ('Close'); 
  
    % Now go back for the next trial 
end 
  
% Display cursor again now its all over 
Priority(0);% Resest normal priority 
Screen('ShowCursorHelper', win); 
  
% Ask Quest for the final estimate of threshold. 
t=QuestMean(q);     % Recommended by Pelli (1989) and King-Smith et 
al. (1994). Still our favorite. 
sd=QuestSd(q); 
  
fprintf('Final threshold estimate (mean±sd) is %.2f ± %.2f\n',t,sd); 
  
% Determine total experimental time and print this out 
exptEnd = Screen('Flip', win); 
exptTotal = exptEnd - exptStart 
  
% Print out the frame per sec for each trial 
%avgfps; 
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% Print out the number of false positives 
falsePositive 
  
% Close onscreen window, release all ressources: 
Screen('CloseAll'); 
  
% The presentation rate has been a problem / variable so, these lines 
are 
% used to plot frame time. 
figure(1) 
k=1:trialsDesired; 
plot (k,avgfps) 
xlabel ('Trial') 
ylabel ('Frames / sec') 
  
% Plot the stimuli presented 
figure(2) 
k=1:trialsDesired; 
plot (k,LuminancePresent, 'ob') 
xlabel ('Trial') 
ylabel ('Log luminance') 
  
% Dump all the key data to Excel 
LuminancePresent = LuminancePresent(:); % This (:) changes the vector 
from a row to a column 
trialNumber = k(:); 
today = now; % this is a weird number that represents the current date 
and time, Excel understands! 
name ={participant}; 
xlswrite('c:\Users\CAD User\Documents\Excel\14Hz Flicker Data.xls', 
today,'Sheet1','B3'); 
xlswrite('c:\Users\CAD User\Documents\Excel\14Hz Flicker Data.xls', 
today,'Sheet1','B4'); 
xlswrite('c:\Users\CAD User\Documents\Excel\14Hz Flicker Data.xls', 
name,'Sheet1','B5'); 
xlswrite('c:\Users\CAD User\Documents\Excel\14Hz Flicker Data.xls', 
exptTotal,'Sheet1','E3'); 
xlswrite('c:\Users\CAD User\Documents\Excel\14Hz Flicker Data.xls', 
trialNumber,'Sheet1','A8'); 
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xlswrite('c:\Users\CAD User\Documents\Excel\14Hz Flicker Data.xls', 
LuminancePresent,'Sheet1','B8'); 
xlswrite('c:\Users\CAD User\Documents\Excel\14Hz Flicker Data.xls', 
t,'Sheet1','E4'); 
xlswrite('c:\Users\CAD User\Documents\Excel\14Hz Flicker Data.xls', 
sd,'Sheet1','E5'); 
xlswrite('c:\Users\CAD User\Documents\Excel\14Hz Flicker Data.xls', 
falsePositive,'Sheet1','E6'); 
  
% All done, phew! 
catch % The following code is run if the experiment crashes  
    Screen('CloseAll'); 
    rethrow(lasterror); 
    psychrethrow(psychlasterror);  
end 
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PURPOSE 
To evaluate the inter-session repeatability of the Colour Assessment and Diagnosis 
(CAD) test and a novel 14-Hz flicker test in a population of healthy participants in order 
to provide benchmark data for their use as functional biomarkers for age-related 
macular degeneration (AMD). 
METHODS 
Visual function was assessed using both techniques in 30 healthy adults (mean age 36.3 
± 14.1 years) on 2 separate days. Inter-session repeatability of RG and YB CAD 
thresholds and 14-Hz flicker thresholds was assessed by determining their coefficient 
of repeatability (CoR). 
RESULTS 
The CoR was calculated to be 0.39 CAD units (17.0%) for RG thresholds, 0.43 CAD 
units (31.1%) for YB thresholds and 0.015 (53.4%) for 14-Hz flicker contrast 
thresholds. On average, thresholds improved by 4.72% (RG), 6.33% (YB) and 13.3% 
(14-Hz flicker) between visits 1 and 2, suggesting a small but consistent learning effect. 
The CoR for all parameters was relatively small compared to the mean thresholds 
obtained (RG: mean 2.27 ± 4.58, CoR 0.39; YB: mean 1.37 ± 0.55, CoR 0.43; 14-Hz 
flicker: mean 0.028 ± 0.01, CoR 0.015). 
CONCLUSIONS 
This study has described the repeatability of the CAD and 14-Hz flicker tests. The data 
can help clinicians decide if the results from repeated measures are of clinical 
significance. Despite pre-test training, there was some evidence of a learning effect. 
Therefore, clinical trials using these techniques should ensure training is sufficient to 
minimize these effects. 
 
KEY WORDS: repeatability, age-related macular degeneration, biomarkers, colour 
vision, flicker 
 
 
 
 
 
Age-related macular degeneration (AMD) is a disorder of the central retina that is 
characterized by progressive dysfunction and death of photoreceptor cells. It is thought 
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that 7.2 million people in the United States suffer from some form of AMD1, whilst 
56% of registrations as sight impaired in the United Kingdom are attributable to the 
condition2, and over 50% of people aged over 65 in Europe are believed to have signs 
of AMD3. On a personal level, the condition is associated with an increased risk of falls, 
depression, and increased difficulty carrying out daily tasks4-6. The economic costs are 
also substantial, for example, AMD is estimated to cost the US economy $30 billion 
per annum7.  Whilst anti vascular endothelial growth factor (anti VEGF) treatment 
provides a means of treating neovascular AMD (nAMD), it is both expensive and 
invasive. Giving up smoking, adopting healthy diets and consuming antioxidants can 
reduce AMD progression, but a treatment for early AMD and geographic atrophy is 
absent. It is not, therefore, surprising that a substantial research effort is being directed 
towards the development of new treatments for AMD.  
 
Early AMD develops very slowly over time8 and, therefore, it is not practicable to use 
end stage disease as an outcome measure for Phase II trials of new interventions. This 
necessitates the identification of biomarkers which may be used as surrogate outcome 
measures in clinical trials. The key requirements of these biomarkers are (i) that they 
must be sensitive to disease progression, and (ii) they must have a high level of inter-
session repeatability. The development of tests sensitive to early AMD, and to disease 
progression is also a necessity in the early diagnosis and monitoring of patients with 
AMD in a primary care setting.   
 
The standard psychophysical test of visual function used in clinical trials and in 
optometric practice is visual acuity. However, the high contrast visual acuity test does 
not meet either criterion for an optimal biomarker 9,10. Whilst VA is substantially 
reduced by advanced AMD, during the earlier stages of the disease process it remains 
relatively unaffected9. This may be partially attributable to the relative sparing of the 
fovea in early stage disease11, but is also likely to be due to the inherent variability in 
the test results (the between session coefficient of repeatability is around 0.15 logMAR 
/ 1.5 lines for a standard logMAR test10). Hence, recent cross-sectional studies have 
evaluated a range of alternative functional biomarkers for AMD12-16. 
 
Numerous studies have found that temporal sensitivity is adversely affected by 
AMD14,15,17-24, to a greater extent than the generalized loss which occurs due to normal 
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aging25. This is thought to be due to the compromised outer retinal oxygen supply in 
AMD being unable to meet the increased metabolic demand elicited by flickering 
stimuli26,27. Flicker frequencies of above 10Hz have been shown to increase the 
difference in oxygen tension between retinal arterial and venous blood substantially 
more than lower frequencies28. This indicates that the metabolic activity of the retinal 
tissue is upregulated in response to this high temporal frequency stimulation. Given the 
recent evidence to suggest that early functional changes in AMD are initiated by 
chronic retinal ischemia29, a functional test which causes a greater demand on the retinal 
oxygen metabolism is more likely to detect the ischemic deficits in early AMD. 
The threshold for flicker detection is a desirable test to use when monitoring functional 
changes in AMD as it can be performed quickly, is reproducible and diagnostically 
sensitive14,22. For this reason, Dimitrov et al. rated 14-Hz flicker threshold measurement 
as having the greatest potential clinical value out of a battery of functional tests in the 
diagnosis and monitoring of AMD14. Furthermore, flicker threshold has also been 
shown to increase gradually with disease progression15.  
 
An increase in chromatic thresholds, especially in the yellow-blue (YB or tritan) 
domain, is another functional change which has long been reported to occur in the early 
stages of AMD12,30-36. Tritan colour contrast thresholds are abnormal in patients with 
AMD and minimal lens opacities36, and they also change significantly over time in 
patients with early AMD compared with age-matched controls35. However, for 
chromatic sensitivity to be employed as a functional biomarker of AMD, a means of 
accurately quantifying chromatic thresholds is required, which falls beyond the remit 
of standard clinical colour vision tests. A computer-based technology, known as the 
Colour Assessment and Diagnosis (CAD) test, has been developed which implements 
dynamic luminance contrast noise, in order to isolate red-green (RG) and YB 
thresholds37-39. This allows a rapid quantification of thresholds along 16 different 
directions in colour space40. Using the CAD test, YB thresholds in patients with AMD 
have been shown to increase linearly with disease severity12. O’Neill-Biba et al. 
reported evidence of an elevation in threshold, even when the retina appeared normal, 
in individuals whose fellow eye demonstrated signs of advanced AMD, indicating that 
impaired colour vision may be an early functional indicator of retinal dysfunction in 
AMD12. Barbur et al. evaluated an approach to maximizing the diagnostic sensitivity 
of the test through the calculation of an index representing chromatic threshold as a 
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function of light level in the low photopic, high mesopic range41. This resulted in a 
reduction in the substantial between subject variability in chromatic thresholds 
conferred by individual differences in factors such as media opacity, pupil diameter and 
macular pigment optical density, and removed the effect of age on colour vision in 
healthy individuals. However, to date, no data have been published regarding the 
between session variability of the CAD test.   
 
It is clear that both the 14-Hz flicker and CAD chromatic sensitivity tests may be useful 
as functional biomarkers in future clinical trials, fulfilling the first requirement of 
showing a sensitivity to increased severity of funduscopic changes associated with 
AMD12,14,15. Repeatability data have recently been published for the assessment of cone 
dark adaptation42, another potentially important biomarker for early AMD13-16,33,43-47. 
However, there is currently little published data regarding the inter-session repeatability 
of the flicker and chromatic threshold assessment techniques. This is crucial in 
determining the minimum change in each parameter which may be considered to be 
clinically significant – an important issue when powering trials and interpreting 
outcomes, as well as in the clinical management of patients with early AMD.  
 
The aim of this study was to assess the inter-session repeatability of the colour 
assessment and diagnosis (CAD) test and the 14-Hz flicker test in a population of 
healthy participants. 
 
METHODS 
Participants 
Adults with limited experience in psychophysical experiments were recruited to the 
study from the staff and students at the School of Optometry and Vision Sciences, 
Cardiff University. Thirty healthy adults (13 female), aged 22-72 years (mean 36.3 ± 
14.1 years) took part in the study. This study was powered to detect within subject 
standard deviation to within 25% of the true population value48. All participants had 
corrected visual acuity of 20/20 or better (logMAR 0.0) in their test eye, age-normal 
lens clarity and a normal retinal appearance with no history of any ocular or systemic 
disease known to affect visual function. All participants had a LOCS score of 0 for all 
parameters, apart from RE, who had NO2 and NC2 (LOCS III)49. As a random sample 
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of the population was desired, subjects were not excluded on the basis of having a 
colour vision defect. The School’s Research Ethics Committee approved the study and 
all procedures were carried out in accordance with the tenets of the Declaration of 
Helsinki. All participants provided written consent to taking part in the study, having 
received an information sheet prior to their appointment and having had the opportunity 
to ask any questions. 
 
Experimental procedure 
All participants attended the laboratory on two separate days within a period of two 
weeks. Screening data were obtained at the beginning of the first session to ensure that 
eligibility criteria were met. This included patient ocular and medical history, logMAR 
visual acuity (ETDRS chart), and fundus imaging (Optical Coherence Tomography and 
fundus photography; Topcon 3D OCT 1000). Lens clarity was assessed using a slit 
lamp biomicroscope, and graded according to the LOCS III system for nuclear 
opalescence (NO), nuclear colour (NC), cortical opacity (C) and posterior subcapsular 
opacity (P)49. 
 
Stimuli for both psychophysical tests were presented on a calibrated, high-resolution 
24” widescreen LCD monitor (NEC MultiSync PA241W) with a frame rate of 60Hz, 
as depicted in Figure 1. The luminance of the monitor was ϒ-corrected50. In a dimly 
illuminated room, participants were positioned 1.4 m away from the monitor, and any 
required refractive correction, appropriate for the viewing distance, was provided. The 
test eye was the eye with better visual acuity or, in the case of equal acuity, the right 
eye was selected. The fellow eye was occluded. The test order was randomized between 
subjects, but kept the same on both visits for each subject. 
 
14-Hz flicker sensitivity 
Flicker thresholds were determined using the well-established Bayesian adaptive 
psychometric method known as QUEST51,52. In this method, the strength of each 
successive stimulus presentation is set to match the current most probable estimate of 
threshold. In practice, QUEST was implemented in Matlab (The Math Works Inc.) 
using routines available within Psychophysics Toolbox to drive a yes / no adaptive 
staircase53. The results from a practice run that included 10 trials were used as the 
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starting point for a final threshold estimate that converged after 40 trials. False positive 
responses were deemed to be responses that occurred more than 1s after stimulus offset. 
 
Subjects were asked to fixate the center of the screen where the test stimulus, a 4o 
foveated Gaussian blob at a temporal frequency of 14Hz, was presented to the fovea 
for a duration of 2 seconds. The flickering stimulus was generated by modulating a 
luminance increment following a sinusoidal temporal profile. The mean luminance of 
the monitor was 51 cd/m2 and the chromaticity co-ordinates were 0.305, 0.323. To 
ensure that participants could not anticipate the next presentation, the inter stimulus 
interval was varied randomly between 4 and 10 seconds. The participants received 
verbal instructions on how to perform the test before undertaking the familiarization 
trial. Their task was to press a button on a keypad as soon as they perceived a flickering 
stimulus in the center of the monitor. If more than one false positive response was made, 
the practice trial was repeated until they were able to complete the familiarization trial 
with a maximum of 1 false positive response. 
 
Colour Contrast Sensitivity 
Colour contrast sensitivity was assessed using the CAD test (v2.2.4, City Occupational 
Ltd). RG and YB colour detection thresholds were measured by employing coloured 
stimuli moving against an achromatic background. The background (chromaticity co-
ordinates 0.305, 0.323; mean luminance 26 cd/m2) comprised a checkerboard of 15x15 
squares (total 3.3 degrees diameter), which fluctuated randomly in luminance above 
and below the average background level in order to generate dynamic luminance 
contrast noise. The check luminance was distributed with equal probability within +/- 
55% of background luminance. This noise masked the detection of residual luminance 
contrast cues in the isoluminant coloured stimulus. The colour-defined stimulus 
comprised a checkerboard of 5 × 5 squares (total 1.1° diameter) moving diagonally 
across the checkerboard, in one of four directions. The stimulus duration was 600ms. 
A four-alternative forced choice procedure was used, whereby the participant was 
required to press a button indicating the direction of movement. Displacement 
thresholds were measured in 16 directions in colour space (6 red, 6 green, 2 blue, 2 
yellow), with colour directions selected to correspond to the red / green colour 
confusion lines (140 to 175 degrees) and the S-cone isolating axes (58 to 68 degrees). 
Threshold was determined using a two-down, one-up staircase in which colour intensity 
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was reduced by an initial step size of 0.006 CD units until the coloured stimulus could 
not be distinguished from the background by the observer. This staircase procedure was 
repeated for nine reversals, at each of which the step size was reduced by 0.001 CD 
units until a final step size of 0.002 CD units was attained. Thresholds were obtained 
by averaging the chromatic distance in the CIE colour space during the last four 
staircase reversals.  
 
The participant’s task was to press one of four buttons on a keypad to indicate the 
perceived direction of motion of the coloured stimulus. Each stimulus presentation was 
followed by an audible ‘bleep’ to indicate when to respond. A response was required, 
even if the participant was uncertain of the direction of movement. Any trial could be 
presented for a second time at the participant’s request. A familiarization trial lasting 
approximately 1 minute was performed prior to commencing the main trial. 100% 
correct response was required in the learning test to ensure that the subject understood 
the requirements of the test. The ‘definitive’ CAD program was then implemented and 
RG and YB thresholds were measured over a of 12 to 15 minute period. 
 
Statistical Analysis 
Flicker thresholds were transformed into Weber contrast values by dividing pedestal 
luminance (I - Ib) by the average luminance (Ib).  The repeatability of the colour and 
flicker thresholds was assessed using established statistical techniques55. The 
coefficient of repeatability (CoR) was calculated by multiplying the standard deviation 
of the differences between the two visits by 1.96. Confidence intervals for the CoR 
were calculated according to the method described by Bland and Altman55.  
 
RESULTS 
Chromatic sensitivity and flicker thresholds were successfully obtained from all 30 
participants on two separate days. Data from the 2 visits were generally collected on 
successive days but always within two weeks. None of the participants required 
additional practice sessions for either test, which minimized potential inter-individual 
differences in any learning effect. An example of the flicker data obtained on both visits 
from a typical participant (AB) is shown in Figure 2. In each plot, the solid horizontal 
line represents the final threshold and the dashed horizontal lines denote the 95% 
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confidence intervals. Sample CAD results from the same observer are shown in Figure 
3. 
 
Only 1 subject (TM) with a congenital protanopic deficiency had a RG CAD threshold 
outside of the age-corrected statistically determined normal limits56. Similarly, only 1 
subject (RE) had YB thresholds outside of the normal range. The lens opacities of this 
72-year old participant had been graded as NO2 and NC2, so this YB defect is most 
likely due to the early stages of nuclear cataract. Both of these participants, whilst 
falling outside of the published limits of normality56, showed repeatable results.  
 
The difference in RG thresholds recorded at the first and second visits is plotted as a 
function of the mean RG threshold for all 30 participants in the Bland and Altman plots 
shown in Figure 4a, whereas Figure 4b shows the Bland Altman plot for RG thresholds 
with the protanopic individual’s data point removed to aid visualization of the spread 
of the other data. Similar plots for all 30 individuals are shown for YB and 14-Hz flicker 
thresholds in Figure 4 c and d.  
 
In each graph, the solid horizontal line depicts the bias, i.e. the mean difference between 
the two visits, and the dashed horizontal lines represent the 95% limits of agreement, 
i.e. the mean difference ± the coefficient of repeatability (CoR). These plots describe 
the between session repeatability for all 3 measures. There was no evidence of a 
systematic change in repeatability with increasing thresholds (i.e. no heteroscadicity). 
The bias line crosses the y-axis slightly above 0 in all cases. Relative to visit 1, 
thresholds improved by 4.72%, 6.33% and 13.3% for RG, YB and 14-Hz Flicker 
respectively, indicating the presence of a possible small learning effect.  
 
The mean RG, YB chromatic thresholds and 14-Hz flicker thresholds for visits one and 
two are shown in Table 1, along with the CoR for each test. The expression of the CoR 
as a percentage of the group averaged test result (at visits 1 and 2) allows a direct 
comparison of the repeatability of parameters with different units. Although the RG 
thresholds were more repeatable than the YB thresholds, the difference in the CoR was 
not significant (95% confidence intervals did not overlap). There was also no 
significant difference in repeatability between the YB CAD thresholds and 14-Hz 
flicker. However, the CoR for the RG CAD thresholds was significantly better than that 
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of the 14-Hz flicker (see Table 1). Scatter plots showing the effect of age on the between 
visit variability are shown in Figure 5. There was no evidence of any systematic effect 
of age on variability for any parameter. 
 
DISCUSSION 
In order to monitor the progression of AMD and determine the efficacy of novel 
therapies, functional biomarkers must be identified that are reliable, repeatable and 
clinically applicable. This will allow candidate treatments to be assessed with 
maximum efficiency by minimizing the sample size and follow-up duration required to 
achieve a useful end point. The development of functional tests sensitive to subtle 
changes in AMD status is also important in the clinical diagnosis and management of 
the condition in clinical settings. Visual acuity, despite the common acknowledgement 
that it is a poor assay of early AMD, is still the standard functional vision test amongst 
both clinicians and researchers. It is therefore necessary that new functional tests are 
developed that are as quick to perform and have the same ease of use as VA, but with 
improved sensitivity to disease progression and better inter-session repeatability. Two 
such tests that have been shown to be sensitive to disease severity in AMD are the 14-
Hz flicker and CAD chromatic sensitivity test14,15. The flicker test employs a stimulus 
which is bigger (4 degrees diameter) than the stimulus presented in the CAD test (1.1 
degree diameter). However, the CAD stimulus moves out from a central fixation 
position to a location extending to 2.3 degrees into the parafovea. Hence both stimuli 
are assessing a region of the macula extending to around 2 degrees from fixation. This 
targets the parafoveal region in which functional deficits have been identified early in 
the AMD disease process43.  
 
The coefficient of repeatability (CoR) is an important statistical technique due to its 
potential to describe the smallest change that can be deemed clinically significant 55. 
This is helpful in identifying those individuals who have shown a “clinically significant 
decline” in performance, and can therefore be used to determine the optimal sample 
size for a trial, i.e. it can be powered to detect a certain percentage who show this level 
of functional decline. The most repeatable test was found to be the RG CAD threshold 
test. This performed significantly better than the 14-Hz flicker test which produced the 
least repeatable results.  
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The Bland Altman plots all showed a mean difference between visits that was slightly 
above zero, suggesting a small learning effect for both the 14-Hz flicker test and the 
CAD parameters. This was confirmed by a post hoc paired samples t-test (p < 0.05) for 
all tests. This learning effect may have been limited by the familiarization trials which 
were carried out for the two techniques before both visits. If more than 1 false positive 
occurred on the 14-Hz flicker practice trial lasting 1 minute or if the subject did not 
score 100% in the CAD practice trial which also took 1 minute to complete, they were 
made to repeat it until they achieved the required standard and were deemed competent 
in task performance. However, the familiarization trials were clearly not sufficient to 
saturate learning.  
 
A limitation of the study is that different repeatability values will need to be established 
if the tests are applied under different experimental conditions. A change in stimulus 
size, eccentricity, temporal frequency, retinal illuminance, or a change in the 
psychophysical procedure used, are all likely to affect the measured variability of the 
techniques. For example, in their recent evaluation of the effect of retinal illuminance 
on chromatic thresholds, Barbur et al. hypothesized that the assessment of colour vision 
at mesopic levels may increase the diagnostic sensitivity of the test, through the 
exacerbation of the effect of disease-related hypoxia 41. Their ‘healthy retina index’ 
(HRindex) is a measure of the effect of retinal illuminance on chromatic thresholds. 
Additional repeatability data will be required to evaluate the clinical interpretation of 
mesopic chromatic thresholds and the HRindex. Inter-session repeatability is also likely 
to be influenced by the characteristics of the patient population. Hence, a further 
potential limitation of the repeatability data reported in this study is that the participant 
cohort was recruited from a University environment, and may not be generalizable to 
the population of patients with age-related macular degeneration. However, the age-
range of participants extended to 72 years, and only 3 of the participants had previously 
taken part in psychophysical experiments hence, the group may be considered to be 
broadly representative of naïve participants in a clinical environment. Furthermore, we 
found no evidence of an effect of age on the between session variability, suggesting 
that the findings of this study will be broadly applicable across age groups. 
 
One limitation of the yes / no adaptive staircase procedure used in the flicker sensitivity 
test is that results are dependent on stimulus strength and an individual’s response 
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criterion i.e. their willingness to guess. Response criterion can vary between and within 
individuals. We attempted to minimize within subject changes in response criteria by 
providing identical instructions at each visit. However, we cannot rule out the 
possibility that the systematic difference between visits (i.e. the bias) was due to a 
change in response criterion. Many things, including instructions, can induce the 
observer to raise or lower his or her criterion, causing threshold to shift up or down. 
This unknown internal criterion of the observer typically differs among observers and 
may vary across populations and over time. The four alternative forced choice paradigm 
employed by the CAD test negates the effect of inter-individual differences in the 
response criterion. 
 
The published limits of normality for the CAD test are based on data collected from 
250 colour normal participants56. The majority of participants in this study produced 
thresholds which fell within these limits, apart from one protanope (TM), and one older 
participant with significant nuclear lens opacities (RE). Excluding these 2 participants, 
the mean (SD) RG thresholds for visit 1 were 1.45 (0.29) and for YB 1.34 (0.37). The 
RG threshold is very similar to that reported by O’Neill-Biba et al12 but the YB value 
is somewhat lower than that reported previously 1.6 (0.15). Control participants in the 
O’Neill-Biba study were on average 20 years older than those studied here and 
increasing lens opacification may therefore, explain the difference. Barbur et al 
reported that chromatic thresholds, uncorrected for differences in media absorption and 
pupil diameter, increase significantly with increasing age in the healthy population41. 
 
In summary, this study has described the inter session repeatability of two tests that 
may be used in the diagnosis and monitoring of AMD. Both colour vision and flicker 
sensitivity tests have been shown to have excellent diagnostic capacity12,14,15,17-24,30-36. 
The results of this study will help clinicians to determine if changes observed over time 
are due to measurement imprecision or disease progression, provided that the 
experimental conditions and psychophysical procedures are kept constant. The 
observation that a small but significant learning effect exists highlights the need for 
control groups in clinical trials of new AMD therapies. These and other candidate 
biomarkers must now be validated in longitudinal studies to confirm their prognostic 
and predictive capabilities.  
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FIGURES 
Figure 1. Images showing the appearance of the moving coloured stimulus used in the CAD 
test [1] (left panel) and the flickering stimulus (right panel) used to determine flicker 
thresholds. 
 
 
Figure 2. 14-Hz Flicker data for participant AB at visit 1 (left panel) and visit 2 (right 
panel), shown with the threshold in decibels. The dashed lines represent the 95% 
confidence intervals, with the solid line depicting the final threshold. 
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Figure 3. CAD data for participant AB at visit 1 (left panel) and visit 2 (right panel). 
The dotted black ellipse is based on the median RG and YB thresholds from 250 
observers, with the grey shaded area representing the 95% limits of variability of these 
observers. The green, red and blue bands display the deuteranopic, protanopic and 
tritanopic confusion lines, respectively. The coloured symbols show the data measured 
for participant AB. 
 
 
Figure 4. Bland Altman plots for RG chromatic thresholds (A), RG chromatic 
thresholds excluding participant TM (B), YB chromatic thresholds (C) and 14-Hz 
flicker thresholds (D). The difference between the measurements from visit 1 to visit 2 
is plotted as a function of the mean value for all 30 participants, and is shown with the 
bias (solid line) and 95% limits of agreement (dashed lines). 
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Figure 5. Scatter plots demonstrating the relationship between age and between visit 
threshold variation for RG chromatic thresholds (A), YB chromatic thresholds (B) and 
14-Hz flicker thresholds (C). Note the lack of a systematic relationship with age for any 
parameter.  
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Table 1. Mean (± standard deviation) and coefficient of repeatability of all three 
parameters assessed at visit one and visit two. 
 
 Mean (± standard deviation) CoR (95% 
CI) 
CoR as % of 
mean 
threshold 
(95% CI) Visit 1 Visit 2 
RG Threshold 2.33 (± 4.58) 2.22 (± 4.58) 0.39 (± 0.13) 17.1 (± 5.6%) 
YB Threshold 1.42 (± 0.56) 1.33 (± 0.56) 0.43 (± 0.14) 31.1            
(± 10.2%) 
14-Hz Flicker 
Threshold 
0.030 (± 0.01) 0.026 (± 
0.009) 
0.015 (± 
0.005) 
53.4             
(± 17.6%) 
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Abstract  
Background 
Age-related macular degeneration (AMD) is the leading cause of blindness among 
older adults in the developed world. The only treatments currently available, such as 
Ranibizumab injections, are for neovascular AMD, which accounts for only 10-15% of 
people with the condition. Hypoxia has been implicated as one of the primary causes 
of AMD, and is most acute at night when the retina is most metabolically active. By 
increasing light levels at night, the metabolic requirements of the retina and hence the 
hypoxia will be considerably reduced. This trial seeks to determine if wearing a light 
mask that emits a dim, green light during the night can prevent the progression of early 
AMD. 
Methods/Design 
ALight is a phase I/IIa, multicentre, randomised controlled trial. Sixty participants (55-
88 years) with early AMD in one eye and neovascular AMD (nAMD) in the fellow eye 
will be recruited from nAMD clinics. They will be randomised (in the ratio 1:1), to 
either receive the intervention or to be in the untreated, control group, stratified 
according to risk of disease progression. An additional 40 participants with healthy 
retinal appearance, or early AMD only will be recruited for a baseline cross-sectional 
analysis. The intervention is an eye mask which emits a dim green light which 
illuminates the retina through closed eyelids at night. This is designed to reduce the 
metabolic activity of the retina, thereby reducing the potential risk of hypoxia. 
Participants will wear the mask every night for 12 months. Ophthalmologists carrying 
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out monthly assessments will be masked to the treatment group, but participants will 
not be masked. The primary outcome measure is the proportion of people who show 
disease progression during the trial period in the eye with early AMD. A co-primary 
outcome measure is the rate of retinal adaptation. As this is a trial of a CE marked 
device for an off-label indication, a further main aim of this trial is to assess safety of 
the mask in the cohort of participants with AMD. 
Trial Status 
The present protocol aims to establish the therapeutic benefit of low-level light therapy 
on disease progression in AMD. Recruitment will begin in April 2014 and continue 
until February 2015. Data collection will take place from June 2014 to April 2016. 
Trial Registration: Current Controlled Trials: ISRCTN82148651 
Protocol : Version 14; 11th September 2013 
Sponsor Contact Details:  
Dr K Pittard Davies 
Cardiff University Research, Innovation and Enterprise Services 
Cardiff University 
7th Floor, 30-36 Newport Rd 
Cardiff CF24 0DE 
Keywords 
Age-related macular degeneration, randomised controlled trial, Light Mask, Hypoxia, 
Biomarker 
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Background 
Age-related macular degeneration (AMD) is the leading cause of blindness in the 
developed world [1] and is responsible for 50% of visual impairment registrations in 
the UK [2]. For the majority of people with AMD, there is no treatment. The remaining 
10-15% of people with the advanced, neovascular form of the disease (nAMD) are 
mainly treated with intra-ocular injections of Ranibizumab, an anti-vascular endothelial 
growth factor (VEGF) agent [3]. Follow up for these patients is long term and places a 
significant burden on the NHS. Indeed, advanced AMD currently costs the British 
economy £1.2B to £3.7B p.a [2, 4, 5]. Furthermore, the disease is associated with 
depression, falls and social isolation [6, 7]. Given this significant socioeconomic 
problem, there is a great need to evaluate potential therapeutic interventions which 
attempt to treat the disease at an early stage, to prevent vision loss from occurring. 
Age-Related Macular Degeneration is characterised by the dysfunction and death of 
photoreceptors in the central retina. There is an increasing amount of evidence to 
suggest that hypoxia plays a major role in its pathogenesis [8, 9]. This has been 
attributed to factors including a disruption of choroidal circulation [10-13], and 
thickening and deposition of drusen at Bruch’s membrane [9, 14]. The latter increases 
the distance over which oxygen must travel to reach the retinal pigment epithelium 
(RPE) from the choroidal circulation. Disease-related changes to Bruch’s membrane 
also impair the diffusion of nutrients, which consequently exacerbates choroidal 
perfusion abnormalities, promoting further hypoxia [8, 15].  
Even in the healthy retina, intra retinal oxygen profiles obtained from animals show 
that the oxygen tension at the proximal side of the photoreceptor inner segments is close 
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to zero in darkness [16, 17]. This is attributable to the metabolic demand of the ‘dark 
current’ in the approximately 120 million rods [18]. When this limited supply of oxygen 
to the outer retina is further compromised by the changes to the choroidal circulation 
and Bruch’s membrane, which occur in AMD, hypoxia may result. This hypoxia could 
be the precursor for increased VEGF production and apoptosis [19, 20].  
The fragile balance between metabolic demand and oxygenation is exemplified 
functionally by the adverse effects of hypoxia on colour vision [21-23], dark adaptation 
[21, 23-25], mesopic sensitivity [26] and the electroretinogram [12, 27-29]. To date, 
there is no direct evidence of the effect of hypoxia on visual function in AMD. 
However, there is evidence that scotopic threshold elevation and prolonged ERG 
implicit times are associated with areas of reduced choroidal blood flow in AMD [30, 
31] and pilot data from our lab show a transient reduction in scotopic thresholds in an 
individual with early AMD whilst inhaling oxygen. 
Environmental manipulation of light levels can substantially reduce the metabolic 
demands of the outer retina thereby reducing the need for oxygen, and potentially 
providing an intervention which would delay the progression of conditions with a 
hypoxic aetiology [32].  A pilot study by Arden et al. (2010) found no adverse effects 
from the provision of low-level night lighting over the course of 12 months in 
individuals with diabetic retinopathy [33]. Furthermore, a recent clinical trial in patients 
with diabetic macular oedema who wore a low-level light mask during the night for 6 
months reported a reduction in oedema and an improvement in functional measures, 
which was attributed to the obviation of night time hypoxia [34]. In this trial, we will 
be using the same intervention (low level light therapy) to determine its ability to 
prevent the development of AMD. 
Methods/Design 
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Trial objectives 
The primary aim of this study is to collect preliminary Phase I/IIa proof of concept trial 
data from people with early Age-Related Macular Degeneration (AMD) in one eye and 
advanced neovascular AMD (nAMD) in the fellow eye, recruited from a hospital 
nAMD clinic, in order to assess the impact of low-level night-time light therapy, 
compared with no intervention, on disease progression in the eye with early AMD. A 
further main aim of this trial is to assess safety of the mask in the cohort of participants 
with AMD.  
The secondary aims of the study are to:  
1) Establish the effect of low-level night-time light therapy, compared with no 
treatment control, on secondary outcome measures, including: change in drusen volume 
from baseline in the eye with early AMD; Ranibizumab retreatment rates in the fellow 
eye with nAMD; progression of early AMD on the basis of change in functional 
outcome measures; change in health related QoL (assessed using the EuroQol EQ-5D 
instrument); change in self reported visual function assessed using the 48-item Veterans 
Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48). 
2) Establish the acceptability of low-level night-time light therapy in people with AMD 
by monthly qualitative interviews. 
3) Determine the effect of low-level night-time light therapy on sleep patterns by 
conducting the Pittsburgh Sleep Quality Index (PSQI) questionnaire every month with 
both intervention arms by interview with the study investigator. 
4) Establish the relationship between baseline functional biomarker outcomes and the 
severity of AMD (assessed using simplified AREDS grading scale and initial drusen 
volume). 
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5) Evaluate the ability of all clinical tests to act as prognostic biomarkers for AMD 
progression. 
6) Evaluate the ability of all clinical tests to act as predictive biomarkers for low-level 
night-time light therapy in people with AMD. 
7) Compare the sensitivity of all clinical tests to disease progression over 12 months. 
Study Design and Setting 
ALight is a Phase I/IIa prospective proof of concept randomised controlled trial, 
consisting of two parallel groups. Trial recruitment and data collection will take place 
at the Medical Retina Clinic, Bristol Eye Hospital. Additional cross-sectional data will 
be collected from people with healthy eyes, or only early signs of AMD at Cardiff 
University School of Optometry and Vision Sciences.  
Eligibility criteria 
Inclusion criteria 
 Between the ages of 55-88 years 
 ETDRS visual acuity 40 letters or better in the test eye  
 Early AMD in the study eye 
 nAMD in the fellow eye, within a month of 3rd Ranibizumab injection (trial 
only) 
 Willing to adhere to allocated treatment for duration of trial 
Exclusion criteria 
 Ocular pathology other than macular disease 
 Significant systemic disease or medication known to affect visual function 
 Systemic disease that would compromise participation in a 1 year study (trial 
 253 
only) 
 Insufficient English language comprehension  
 Cognitive impairment as determined using an abridged Mini Mental State 
Examination (MMSE) [7] 
 Oxygen mask worn at night 
Suspension criteria for the Trial 
 Participant wishes to discontinue the study 
 Serious adverse events (e.g. conversion of nAMD in the test eye) or 
unexpected changes in clinical status 
Interventions 
Participants allocated to the treatment group will be given a 12 weekly disposable light 
mask (Polyphotonix Medical, UK) that presents organic light emitting diode (OLED) 
illumination (peak output 502 nm) to both eyes, overnight, for  12 weeks. Light masks 
will be replaced every 12 weeks at the participant’s routine appointment at the nAMD 
clinic so that the total duration of mask usage is 12 months.  
The mask provides a luminance of 75 photopic cd/m2. When adjusted for the spectral 
sensitivity of rod photoreceptors, this equates to 186 scotopic cd/m2 [35]. Light 
transmission by the human eyelid has been found to range between 0.3%-2% for light 
in the region of 500-505nm [36-38]. Under these conditions, pupil diameter in people 
in the age group 60-85 years is approximately 4mm [39]. This will result in a retinal 
illuminance in the order of 23 scotopic Td (assuming an eyelid transmission of 1%).  
The masks will be pre-programmed to function only between specific hours i.e. 8pm to 
8am, to prevent misuse. Outside of these hours they will not illuminate if worn. The 
mask is activated when a touch sensor on the device is gently covered with a finger for 
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3 seconds. It will deactivate if not worn continuously for the first 15 minutes, and after 
that, the light will remain on for the remainder of the 8 hour period.  
Treatment acceptability will be evaluated during a monthly interview with the study 
investigator. Compliance data will be obtained at the monthly visit from the treatment 
group i) through evaluation of a diary of mask usage, ii) objectively through data 
collected on a chip in the mask itself (based on a sensor which logs when the mask is 
in contact with the face). This provides precise data on the hours the mask is worn each 
night by each participant. As each mask is programmed with the unique participant 
identification code, compliance data stored on-chip will be non-identifiable except via 
the password protected electronic database. 
The current management of patients with early AMD involves advising on lifestyle 
factors, such as stopping smoking and improving diet. The only other intervention 
which is based on evidence from a robust RCT is the provision of a nutritional 
supplement consisting of high dose antioxidants plus zinc. This AREDS formula 
(vitamin C, 500 mg; vitamin E, 400 IU; beta carotene, 15 mg and zinc, 80 mg) has been 
shown to reduce risk of progression from early to advanced AMD by around 20% over 
5 years in people with specific features of AMD [40].  However, a recent systematic 
review by the Cochrane Collaboration indicated that there may be an increased risk of 
mortality in individuals taking vitamin E and beta carotene supplementation [41]. As 
this is a recently published document, it is not reflected in the current guidelines for the 
management of AMD. For this reason, the low level light therapy will be compared to 
a no-treatment control, rather than to the AREDS formula as the best current 
intervention. 
Participants in both groups will receive routine ophthalmological care for the eye with 
nAMD (i.e. Ranibizumab injections). If the eye with early AMD converts to nAMD, 
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they will proceed to Ranibizumab treatment for this eye also, and will be withdrawn 
from the study.  
Outcome Measures 
This study includes two co-primary outcome measures, one reflecting structural status, 
and one functional status.  
i) The proportion of people who show ‘disease progression’ in the eye with early AMD 
during the 12 months of the study based on an increase in drusen volume beyond test-
retest repeatability limits or a progression to advanced AMD. Software available for 
the Cirrus Optical Coherence Tomography (OCT) system allows automated assessment 
of drusen volume. Irrespective of initial drusen volume, approximately 50% of people 
with AMD show a significant increase in drusen volume over the 12 month study period 
i.e. beyond test-retest 95% confidence intervals (Yehoshua et al. 2011). Conversion to 
advanced disease will also be considered to be an indicator of disease progression in 
this analysis. Data from a trial on a similar group indicates about 10% of people meeting 
our inclusion criteria will develop advanced AMD within 12 months (Neelam et al. 
2009). Hence 60% of participants might be expected to show progression based on 
increased drusen volume or progression to late AMD. The development of advanced 
AMD will be determined on the basis of ophthalmologist diagnosis at the monthly 
follow-up appointments at the nAMD clinic.  
ii) The rate of retinal adaptation (time taken for photoreceptors to recover their 
sensitivity after being exposed to a bright adapting light). 
Secondary outcome measures include: the change in drusen volume over the 12 month 
follow-up period; the number of Ranibizumab retreatments required during the year in 
the fellow eye with nAMD (assessed through review of medical records at the end of 
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12 months); changes in visual function including chromatic thresholds, visual acuity 
and psychophysical 14 Hz flicker thresholds; self-report outcome measures including 
health related quality-of-life (EQ-5D) and visual function (VFQ-48) [42];  a sleep 
quality questionnaire (Pittsburgh Sleep Quality Index, PSQI) and a semi structured 
interview (conducted monthly by interview) to determine intervention acceptability. 
To obtain detailed information about the time-course of any therapeutic action, the 
primary and the first of the secondary outcome measures (based on drusen volume) will 
be assessed at baseline and then at monthly intervals (using OCT images obtained at 
the regular nAMD clinic follow up appointments). 
Participant Timeline 
The study flow diagram (Figure 1) outlines the appointment schedule. In brief, potential 
participants are identified at their first visit to the nAMD clinic. At the second visit (1 
month later), informed consent will be obtained, and screening tests and baseline 
questionnaires will be carried out. At the third monthly visit, baseline functional tests 
will be carried out, and participants will be randomly assigned to either the treatment 
or intervention group. Participants in both intervention groups will attend a short, 
monthly follow-up appointment following their routine appointment at the nAMD 
clinic throughout the year. Final outcome data will be collected from control and 
intervention groups at a 12 month follow up appointment, scheduled to follow a regular 
visit to the nAMD clinic.  
Participants in the cross-sectional baseline study will attend Cardiff University for one 
visit only.  
Recruitment 
Sixty participants will be recruited to the trial. Ophthalmologists will identify potential 
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trial participants who are attending for their first appointment at the nAMD clinic at 
Bristol Eye Hospital, and will provide them with an information sheet and ask for their 
permission to be contacted by the study investigators. The potential participants will be 
contacted at least 2 days after their receipt of the information sheet, and invited to meet 
the study investigator at their next visit to the nAMD clinic (approximately 1 month 
later) to discuss the trial, provide consent if they choose to participate, and carry out 
some basic screening tests. Participants will be informed after this screening visit 
whether they are eligible to take part in the study. Due to the low number of patients 
required to participate in the study it is planned for the trial and data collection to take 
place principally at a single NHS centre i.e. Bristol Eye Hospital. If needed, additional 
participants will be recruited from supplementary recruitment centres to ensure that 
targets are met. 
Forty control participants and participants with grade 1 AMD (AREDS simplified scale 
[43] for the baseline cross-sectional analysis will be recruited by local Optometrists in 
Bristol and Cardiff, from a database of elderly volunteers, from Bristol Eye Hospital, 
from the list of research volunteers at the Cardiff University Eye Clinic and from staff 
and students of Cardiff University.  
Randomisation 
Participants will be stratified according to risk of AMD progression (using the AREDS 
simplified scale [43]), and randomly allocated to receive either light mask or no 
intervention in a 1:1 ratio using computer generated random permuted blocks (both 
groups will continue to receive Ranibizumab injections as required for the fellow eye). 
The study investigator will be provided with three piles of envelopes by the chief 
investigator in order to randomise the participant to either the intervention or control 
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arm of the study. Each pile relates to a different stratum of randomisation i.e. grade 2, 
3 or 4 of AMD, according to the AREDS simplified scale. The envelopes in each pile 
will be numbered, and will contain the randomisation allocation for each participant. 
Masking 
It is not appropriate in this study to use a sham treatment since a non-illuminated mask 
may have a physiological effect on the retina and patients would be aware that they 
weren’t perceiving light and so would be unmasked to their intervention group. The 
study investigator who collects the outcome data will also be providing the masks and 
instructions on its usage; hence, will not be masked to the intervention group. However, 
the potential for experimenter bias is limited as the primary outcome measure, disease 
progression, is an objective measurement carried out by automated computer software. 
The Ophthalmologists who are seeing the participants for their regular Ranibizumab 
injections will be masked, which will prevent any bias in their retreatment decisions for 
the fellow eye. 
Data Collection Methods 
Screening Visit 
Following a discussion of the study, and the obtaining of informed consent, the study 
investigator will question the participant regarding their ocular and medical history. 
Retinal photographs will be taken if they have not already been acquired, and repeated 
if image quality is insufficient to allow evaluation. OCT and fundus photographs will 
be assessed to check for eligibility. Van Herick angle of drainage will be measured, and 
media clarity will be assessed for each eye and the lens graded according to the LOCS 
III grading scale[44]. Visual acuity will be assessed in each eye using the Early 
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Treatment of Diabetic Retinopathy Study (EDTRS) chart, following a brief refraction, 
if necessary. An abridged version of the MMSE test will be used to assess for cognitive 
impairment (5 mins;[7]). 
Those still deemed eligible for inclusion in the study will also undertake several 
questionnaires, completed through verbal interview with the investigator: Visual 
function (VA LV VFQ-48) [42]; Health related quality-of-life (EQ-5D); Pittsburgh 
Sleep Quality Index (PSQI) [45]; Smoking history (pack years); Vitamin 
supplementation; Ethnic origin. 
Baseline Assessment 
Optical coherence tomography images and fundus photographs obtained during the 
participant’s routine visit to the Ranibizumab clinic will be obtained and analysed to 
assess drusen volume and AMD grade, according to AREDS simplified scale [43]. If 
the images are of insufficient quality, additional images will be captured.   
EDTRS visual acuity will be assessed in each eye. Chromatic thresholds will be 
measured for the eye with early AMD using the Colour Assessment and Diagnosis 
(CAD) test [46] (City Occupational Ltd). Contrast thresholds to a 14 Hz flickering 
stimulus will be measured for the eye with early AMD using the procedure outlined by 
[47]. The rate of parafoveal cone dark adaptation will be determined for the eye with 
early AMD using a psychophysical procedure described previously [48]. Thresholds 
will be determined using a psychophysical method, based on a ‘3 down, 1 up’ staircase 
paradigm [48]. A Maxwellian View optical system will be used to light adapt 
photoreceptors in the central 43.6º of the test eye (the output of a white LED will be 
modified by a Lee filter, HT015, to provide a retinal illuminance of 5.20 log phot Td.s-
1, providing a bleach of 85% cone photopigment and 74% rhodopsin). All light levels 
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fall within the safety guidelines set out in British Standard BS EN 15004-2 (2007). 
There will be an initial training phase, of around 5 minutes, then the adapting light will 
be presented, and finally recovery of visual thresholds will be monitored for 25 minutes 
after exposure to the adapting light. 
Those individuals who are assigned to the treatment group will then be given a light 
mask, and provided with written and oral instructions on its use. There will also be a 
reprise of the key information provided in the participant information letter about 
follow-up appointments. Participants will be given written copies to take home of the 
PSQI questionnaire that will be used in the monthly interview. 
Monthly Assessment  
The investigator will access the OCT images and medical records of all participants 
after they have attended the Ranibizumab clinic for each monthly follow up 
appointment. This will allow measurement of drusen volume on a monthly basis, which 
will allow the final analysis to include an assessment of the time course of any 
therapeutic action. Additionally, reviewing medical records will facilitate monitoring 
of the conversion rate to advanced AMD in the control and intervention groups in the 
eye with early AMD at baseline, and of Ranibizumab retreatment rates in the eye with 
nAMD, for adverse event reporting purposes. 
Participants in both intervention groups will attend a short, monthly follow-up 
appointment following their routine Ranibizumab clinic appointment, during which 
both groups will undertake the PSQI sleep quality questionnaire. In addition, the 
treatment group will bring their mask along to each monthly visit to allow objective 
compliance data (nightly hours of use) to be exported from the device, retraining in 
mask use if required, functionality of the mask to be checked, masks to be replaced 
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every 12 weeks, and a semi-structured interview to be carried out to determine the 
acceptability of the intervention. These data will be used to address secondary 
objectives 2 and 3. 
Final 12 month visit  
This visit will be the same as the baseline visit with the addition of a final semi-
structured interview assessing the acceptability of the intervention, and the 
questionnaires (PSQI, VA LV VFQ-48, Euroqol). 
Baseline cross-sectional study 
The 40 participants recruited only to the cross-sectional part of the study will undergo 
the tests outlined in the baseline assessment visit of the trial.  
Statistical Methods 
It should be noted that, as a Phase I/IIa proof of concept study, this research is designed 
to assess the acceptability of this therapy for the participants, and to provide preliminary 
data to support a larger Phase III randomised controlled trial (RCT) in the future, and 
so is not powered to detect small effect sizes. In order to maximise retention, all follow 
up visits will be timed to coincide with scheduled appointments at the nAMD clinic. 
We will aim to recruit 60 people, which, allowing for 15% dropout through the year, 
will leave a final cohort of 51. This will be sufficient to detect a 50% reduction in people 
showing progression at a probability level of 0.2, with a power of 80%, and a change 
in the time constant of cone adaptation of 1 minute to be detected at a probability level 
of 0.05, with a power of 80%. The additional 40 participants enrolled into the cross-
sectional part of the study will allow a total cohort of n=100 to address secondary aim 
4. 
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Analysis will be carried out on an intention to treat basis. There will be no interim 
analysis, but conversions to nAMD in the eye with early AMD at baseline, and 
Ranibizumab retreatments for the fellow eye, will be recorded at each participant visit 
to the nAMD clinic for safety monitoring purposes.  
This trial will primarily be concerned with providing information about the safety of 
the device in the treatment of AMD, and the magnitude of any treatment effect. On this 
basis, descriptive statistics will be carried out to summarise the demographic 
characteristics of the two groups, as well as the proportion of individuals showing 
disease progression in each group, the magnitude of changes in secondary outcome 
measures including drusen volume, measures of visual function, and the self-report 
tests, and the fellow eye retreatment rates.  
The primary outcome measure will be the proportion of patients demonstrating disease 
progression at 12 months. Comparisons will be performed using stratified Mantel-
Haenszel tests and presented as Forest plots. 
Formal statistical analysis will also include linear regression analysis to investigate 
changes in drusen volume controlling for intervention arm, baseline drusen volume and 
patient characteristics (such as age, vitamin supplement intake, and history of smoking). 
Analysis of covariance (ANCOVA) will be carried out to compare the change in 
secondary outcome measures (e.g. drusen volume, functional tests, self-report 
measures) and the Ranibizumab retreatment rates over 12 months between the two 
intervention arms, controlling for the characteristics listed above. Note that all analysis 
except for the Ranibizumab retreatment rate pertains to the eye with early AMD. This 
will address secondary aim 1. To meet our fourth secondary aim, which is to establish 
the relationship between baseline functional biomarker outcomes and the severity of 
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AMD, we will carry out a one way analysis of variance (ANOVA) to compare the mean 
results at baseline between participants with grades of AMD in each group on the 
AREDS simplified scale. This analysis will take place when the baseline data collection 
is complete. To assess the ability of the clinical tests to act as prognostic and predictive 
biomarkers, Receiver Operating Characteristics (ROC) curves will be constructed to 
plot the sensitivity and specificity of the baseline measures in predicting outcomes 
within the control and intervention arms, respectively. This will address secondary aims 
5 and 6.  When the trial is completed, linear regression analysis will be carried out to 
determine how well the change in the functional measures relate to the change in our 
primary outcome measure (drusen volume), which is a validated biomarker for disease 
progression. This will address the seventh secondary aim. 
Trial Management 
The Chief Investigator has ultimate responsibility for the trial management, assisted by 
the Trial Management Group. Any important protocol modifications will be 
communicated to all relevant parties (investigators, research ethics committee, NIHR 
CRN Portfolio, trial registry, journals, NHS Research and Development, Device 
Manufacturer, funding body) by the Chief Investigator.  
A Trial Steering Committee has been established which will also act as a Data 
Monitoring Committee. In addition to annual meetings, they will be issued with 
information about any adverse events throughout the course of the study, so that they 
can decide whether it is appropriate for the study to be terminated. A 3 monthly 
newsletter will be issued to all investigators and the steering committee, updating on 
recruitment and other issues, throughout the trial.  
Safety Monitoring 
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All Adverse Events (AEs) and Serious Adverse Events (SAEs) will be recorded. The 
chief investigator (AB) will be provided with an update of AEs every month and all 
SAEs within two working days. This trial does not involve a medicinal product or life-
threatening procedure. Hence, the risk of a SAE is low. However, one potential SAE is 
an increased rate of progression to nAMD in the eye with early AMD at baseline. 
Although this is at odds with the literature it is not an impossible outcome. Another 
potential SAE would be an increased rate of recurrence of nAMD in the fellow eye 
(resulting in increased Ranibizumab retreatment rates). Conversion to nAMD and 
Ranibizumab retreatment requirement in the fellow eye will be determined by 
ophthalmologists at the monthly Ranibizumab clinic, and recorded by the study 
investigator through assessment of medical records after each monthly Ranibizumab 
appointment. 
Wong et al (2008) carried out a meta-analysis of studies which had looked at the 
progression to choroidal neovascularization in the fellow eye when free of advanced 
disease at study inception. They reported that the cumulative 1 year incidence of nAMD 
in the 426 patients enrolled in the 5 studies which evaluated this outcome was 12.2% 
(CI 1.7%–30.6%). Therefore, we have placed an upper limit on the number of people 
expected to convert to nAMD per month of; n x (30.6% / 12 months), where n is the 
number of people in the trial who are using the light therapy light mask.  
The chief investigator will assess the nature of the AEs and SAEs for seriousness, 
causality and expectedness. Following the initial report, follow up data may be 
requested by the chief investigator. Where the SAE is both related and unexpected the 
chief investigator will notify the Device Manufacturer, who will notify the MHRA, the 
National Research Ethics Service North West and the Trial Steering Committee within 
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15 days of receiving notification of the SAE.  
Data Management 
Any trial data will be recorded on spreadsheets using the numerical identifier for each 
patient. This data will be non-identifiable. All paper records will also use the unique 
numerical identifier, which will be non-identifiable. The only identifiable personal data 
will be the paper and electronic copies of the patient database. The paper copy will not 
be transferred between Cardiff and Bristol Eye Hospital, and will be kept in a locked 
filing cabinet at all times. The electronic database will be stored on a secure, Cardiff 
University computer drive, which is accessible from Bristol and Cardiff via a password 
protected connection. The study database will be checked for integrity every month by 
the chief investigator. At the end of the trial, the data will belong to Cardiff University. 
At this time, Polyphotonix Medical Ltd (the manufacturer) will have access to the 
results. Anonymised data will be available for verification at any time by the funding 
body, the College of Optometrists, on request. Neither the College of Optometrists, nor 
Polyphotonix Medical Ltd. will influence the data collection or analysis. All data will 
be kept for 15 years in line with Cardiff University’s Research Governance Framework 
Regulations for clinical research.  
 
Dissemination 
A summary of the trial protocol is available to the public through the ISCTRN database. 
Any interested individuals may contact the Chief Investigator for further information. 
Results will be published in peer reviewed journals and at International Conferences. 
The Chief Investigator has ultimate responsibility for the scientific content of any 
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publications.  Dissemination of results to trial participants will take place through a 
summary of findings newsletter sent at the end of the trial to those individuals who 
indicate a desire to receive an update. Dissemination to the wider community of people 
with AMD will take place through publication in the Macular Society’s ‘Digest’ 
members’ magazine, and through presentations at events such as the Macular Society 
‘Top Doctors’ conference. Neither the funding body (the College of Optometrists), the 
light mask manufacturer (Polyphotonix Medical Ltd), or the Sponsor (Cardiff 
University) will influence the presentation or the publication of the research. 
Ethical Considerations 
The study has been approved by the National Research Ethics Service North West, and 
is registered with the International Standardised Clinical Trials Register. A notice of no 
objection has been obtained from the Medicines and Healthcare Regulatory Agency 
(MHRA). The trial will be conducted in adherence with the Declaration of Helsinki and 
the Good Clinical Practice guidelines. The Chief Investigator and the research team 
will preserve the confidentiality of participants in accordance with the Data Protection 
Act 1998. 
Audits & inspections 
The trial is liable to inspection by the College of Optometrists as the funding 
organisation. The study may also be liable to inspection and audit by Cardiff University 
under their remit as Sponsor. 
Discussion 
In this article, we present a clinical trial protocol to evaluate the effect of low-level 
night-time light therapy in patients with early AMD. To our knowledge, this is the first 
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randomised controlled trial of its kind in AMD. This study will provide the foundation 
for future large-scale clinical trials. With the prediction of longer life expectancy in the 
future, the prevalence of AMD and its associated social and economic problems will 
continue to increase unless a treatment is developed that will stop its progression.  
Trial status 
Patient recruitment to begin 1st April 2014. 
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AMD: Age-Related Macular Degeneration; nAMD: Neovascular Age-Related Macular 
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Figure Legend  
Figure 1. Study flow diagram showing participant timeline. 
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